National Clinical Guideline Centre

Appendix I

Pressure ulcer prevention and management

Forest plots

•

•

Commissioned by the National Institute for Health and Care Excellence











Disclaimer

Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer.

Copyright

National Clinical Guideline Centre 2014.

Funding

National Institute for Health and Care Excellence 2014

National Clinical Guideline Centre 2014.

Appendix I: Forest plots

I.1 Pressure ulcer prevention

I.1.1 Risk assessment – clinical effectiveness

Figure 1: Braden scale implementation and training versus clinical judgement – all stages

	Braden	scale	Clinical judg	ement		Risk Ratio		Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	l	M-H, Fix	ed, 95% CI
Saleh 2009	16	74	16	106	100.0%	1.43 [0.77, 2.68]		_	
Total (95% CI)		74		106	100.0%	1.43 [0.77, 2.68]		•	•
Total events	16		16						
Heterogeneity: Not ap Test for overall effect:	•	9 = 0.26)						0.1 Braden scale	1 1 Favour clini

Figure 2: Braden scale implementation and training versus training only – all stages

	Braden s	scale	Training	only		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
Saleh 2009	16	74	17	76	100.0%	0.97 [0.53, 1.77]] -
Total (95% CI)		74		76	100.0%	0.97 [0.53, 1.77]	•
Total events	16		17				
Heterogeneity: Not appropriate the Test for overall effect:	•	' = 0.91)					0.01 0.1 1 10 100 Favours Braden scale Favours training only

Figure 3: Braden training but no implementation versus clinical judgement - all stages

	Training	only	Clinical judg	jement		Risk Ratio		Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	l M	-H, Fixed, 95%	CI	
Saleh 2009	17	76	16	106	100.0%	1.48 [0.80, 2.74]		-		
Total (95% CI)		76		106	100.0%	1.48 [0.80, 2.74]		•		
Total events	17		16							
Heterogeneity: Not ap Test for overall effect:	•	= 0.21)					0.01 0.1 Favour trainir	1 ng only Favour	10 clinical ju	100 udgement

Figure 4: Waterlow scale versus clinical judgement – all stages




Figure 5: Ramstadius scale versus clinical judgement – all stages

	Ramstadius	scale	Clinical judg	ement		Risk Ratio			Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M	-H, Fixe	ed, 95% CI		
Webster 2011	22	410	28	410	100.0%	0.79 [0.46, 1.35]			-	_		
Total (95% CI)		410		410	100.0%	0.79 [0.46, 1.35]						
Total events	22		28									
Heterogeneity: Not ap Test for overall effect:	•	.38)					0.01 Favour R	0.1 lamstadius	scale	l Favour cli	10 nical jud	100 gement

Figure 6: Waterlow scale versus Ramstadius scale – all stages

	Waterlow	scale	Ramstadius	scale		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fix	ed, 95% CI	
Webster 2011	31	411	22	410	100.0%	1.41 [0.83, 2.39]	-		
Total (95% CI)		411		410	100.0%	1.41 [0.83, 2.39]		•	
Total events	31		22						
Heterogeneity: Not ap Test for overall effect:		= 0.21)					0.01 0.1 Favours Waterlow scale	1 10 Favours Ramst	100 tadius scale


Figure 7: Waterlow scale versus clinical judgement – stage 2

	Waterlow	scale	Clinical judg	ement		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Webster 2011	10	411	8	410	100.0%	1.25 [0.50, 3.13]	_
Total (95% CI)		411		410	100.0%	1.25 [0.50, 3.13]	•
Total events	10		8				
Heterogeneity: Not ap Test for overall effect:	•	= 0.64)					0.01 0.1 1 10 100 Favour Waterlow scale Favour clinical judgement

Figure 8: Ramstadius scale versus clinical judgement – stage 2

	Ramstadius	scale	Clinical judg	ement		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H, Fix	ed, 95% CI		
Webster 2011	4	410	8	410	100.0%	0.50 [0.15, 1.65]					
Total (95% CI)		410		410	100.0%	0.50 [0.15, 1.65]			-		
Total events	4		8								
Heterogeneity: Not ap Test for overall effect:	•	0.25)					0.01 (Favour Rams	l).1 andius scale	1 Favour clini	10 cal judge	100 ement

Figure 9: Waterlow scale versus Ramstadius scale – stage 2



I.1.2 Skin Assessment - clinical effectiveness

Figure 10: Skin assessment with transparent disk (NBE) versus skin assessment with transparent disk and Braden scale (control) – for PU (grades 2-4) development

	NBE	E	Contr	ol	Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95%
Vanderwee 2007	56	826	53	791	100.0%	1.01 [0.70, 1.45]	-
Total (95% CI)		826		791	100.0%	1.01 [0.70, 1.45]	•
Total events	56		53				
Heterogeneity: Not app Test for overall effect: 2		P = 0.9	5)				0.1 0.2 0.5 1 2 Favours NBE Favou

Figure 11: Skin assessment with transparent disk (NBE) versus skin assessment with transparent disk and Braden scale (control) – number of people receiving preventative treatment

	NBE	Ξ.	Contr	ol		Risk Ratio	Risk Ratio		
Study or Subgroup	Events Total		Events Total		Weight M-H, Fixed, 95% C		M-H, Fixed, 95%		
Vanderwee 2007	128	826	251	791	100.0%	0.49 [0.40, 0.59]			
Total (95% CI)		826		791	100.0%	0.49 [0.40, 0.59]	•		
Total events	128		251						
Heterogeneity: Not app Test for overall effect: 2		0.1 0.2 0.5 1 2 Favours NBE Favou							


Figure 12: Skin assessment with transparent disk (NBE) versus skin assessment with transparent disk and Braden scale (control) – number of people with a pressure ulcer (2-4) who did not receive preventative treatment (false negatives)

	NBE		Conti	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Vanderwee 2007	30	826	10	791	100.0%	2.87 [1.41, 5.84]	
Total (95% CI)		826		791	100.0%	2.87 [1.41, 5.84]	•
Total events	30		10				
Heterogeneity: Not as	oplicable						01.02 05 1 2 5
Test for overall effect:	Z= 2.92	(P = 0.0)	004)				0.1 0.2 0.5 1 2 5 Favours NBE Favours Braden

Figure 13: Unadjusted odds ratios for the two risk assessment strategies


Study or Subgroup	Positive or Events	n test Total	Negative Events		Odds Ratio M-H, Fixed, 95% CI		Ratio ed, 95% CI
4.1.1 NBE alone							
Vanderwee 2007	26	128	30	698	5.68 [3.23, 9.99]		-
4.1.2 NBE plus Brader	1						
Vanderwee 2007	43	251	10	540	10.96 [5.41, 22.21]		-
						0.01 0.1	10 10
						Protective factor	Prognostic facto

Figure 14: Sensitivity and specificity of the two risk assessment strategies



I.1.3 Repositioning

Figure 15: Repositioning (Frequent turning or the use of pressure reducing mattress) versus no repositioning (standard care without turning): all grades of pressure ulcers



Test for subgroup differences: $Chi^2 = 6.20$, df = 3 (P = 0.10), $I^2 = 51.6\%$

Figure 16: Repositioning (Frequent turning or the use of pressure reducing mattress) versus no repositioning (standard care without turning): Grades 2+ pressure ulcers




Figure 17: Different frequencies of repositioning – 2-hour turning on a standard institutional mattress versus 3-hour turning on a standard institutional mattress: all grades of pressure ulcers




Figure 18: Different frequencies of repositioning – 2-hour turning on a standard institutional mattress versus 3-hour turning scheme: incidence of pressure ulcers (Grade II and higher).




Figure 19: Different frequencies of repositioning – 2-hour turning on a standard institutional mattress versus 4-hour turning scheme + pressure reducing mattress: all grades of pressure ulcers



Figure 20: Different frequencies of repositioning – 2-hour turning on a standard institutional mattress versus 4-hour turning scheme + pressure reducing mattress: incidence of pressure ulcers (Grade II and higher).




Figure 21: Different frequencies of repositioning – 2-hour turning on a standard institutional mattress versus 6-hour turning scheme + pressure reducing mattress: all grades of pressure ulcers




Figure 22: Different frequencies of repositioning – 2-hour turning on a standard institutional mattress versus 6-hour turning scheme + pressure reducing mattress: incidence of pressure ulcers (Grade II and higher).




Figure 23: Kinetic treatment table vs standard care: incidence of pressure ulcers (all grades)

	KTT	•	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Gentilello 1988	8	27	10	38	94.3%	1.13 [0.51, 2.48]	
Summer 1989	1	43	0	43	5.7%	3.00 [0.13, 71.65]	-
Total (95% CI)		70		81	100.0%	1.23 [0.57, 2.65]	
Total events	9		10				
Heterogeneity: Chi2 = 0	0.35, df =	1 (P = 0).55); l ² =	0%			0.1 0.2 0.5 1 2 5 10
Test for overall effect:	Z = 0.54 (P = 0.59	9)				Favours KTT Favours Std

Figure 24: Different frequencies of repositioning – 3-hour turning on a standard institutional mattress versus 4-hour turning scheme + pressure reducing mattress: all grades of pressure ulcers




Figure 25: Different frequencies of repositioning – 3-hour turning on a standard institutional mattress versus 4-hour turning scheme + pressure reducing mattress: incidence of pressure ulcers (Grade II and higher).



Figure 26: Different frequencies of repositioning – 3-hour turning on a standard institutional mattress versus 6-hour turning scheme + pressure reducing mattress: all grades of pressure ulcers





Figure 27: Different frequencies of repositioning – 3-hour turning on a standard institutional mattress versus 6-hour turning scheme + pressure reducing mattress: incidence of pressure ulcers (Grade II and higher).



Test for subgroup differences: Not applicable

Figure 28: Different frequencies of repositioning – 4-hour turning scheme + pressure reducing mattress versus 6-hour turning scheme + pressure reducing mattress: all grades of pressure ulcers




Figure 29: Different frequencies of repositioning – 4-hour turning scheme + pressure reducing mattress versus 6-hour turning scheme + pressure reducing mattress: incidence of pressure ulcers (Grade II and higher).




Figure 30: Different frequencies of repositioning - unscheduled small shifts in body position versus 2-hrly turning: incidence of pressure ulcers (Grade II and higher).




Figure 31: Different frequencies of repositioning - turning 2-h in a lateral and 4-h in a supine position versus repositioning 4-hrly: incidence of pressure ulcers (Grade II and higher).





Figure 32: Different positions for repositioning – 30° tilt position versus 90° lateral and supine position: incidence of pressure ulcer (Grade I – IV).

	30 degree tilt pos	90 degree po	sitions		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI	
2.3.1 30 degree tilt - all	stages (cluster)						<u></u>	
Moore 2011 Subtotal (95% CI)	3	99 99	13	114 114	100.0% 100.0 %	0.27 [0.08, 0.91] 0.27 [0.08, 0.91]		
Total events	3		13					
Heterogeneity: Not appli	icable							
Test for overall effect: Z	= 2.12 (P = 0.03)							
2.3.2 30 degree tilt - er	ythema (non-clus	ter)						
Young 2004 Subtotal (95% CI)	3	23 23	2	23 23	100.0% 100.0%	1.50 [0.28, 8.16] 1.50 [0.28, 8.16]		
Total events	3		2					
Heterogeneity: Not appli	icable							
Test for overall effect: Z	= 0.47 (P = 0.64)							
	, ,							
							0.01 0.1 1 10	100
							Favours 30 degree tilt Favours 90	

Figure 33: Different positions for repositioning – semi recumbent position (45° position of the head and back) versus standard care (supine position): incidence of pressure ulcer (Grade I-IV).

	Semi recumbent	Supine po	sition		Risk Ratio		Ri	sk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI	M-H, F	ixed, 95%	CI	
van Nieuwenhoven 2006	31	112	30	109	100.0%	1.01 [0.66, 1.54]]		-		
Total (95% CI)		112		109	100.0%	1.01 [0.66, 1.54]			*		
Total events	31		30								
Heterogeneity: Not applicabl Test for overall effect: $Z = 0$.							0.05 Favour	0.2 ecumbent p	1 ot Favours	5 s supine p	20 position

Figure 34: Critically ill infants and children: different positions for repositioning – prone positioning versus control supine positioning. Pressure ulcer (Grade II and higher)



I.1.4 Skin massage

Figure 35: Incidence of pressure ulcers for comparison: massage with petroleum jelly +position change versus position change only

	Massage No massage				Risk Ratio	Risk Ratio	
Study or Subgroup	Events 1	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Duimel-Peeters, 2007	13	31	7	18	100.0%	1.08 [0.53, 2.20]	-
Total (95% CI)		31		18	100.0%	1.08 [0.53, 2.20]	*
Total events Heterogeneity: Not appl Test for overall effect: Z		0.84)	7				0.01 0.1 1 10 100 Favours massage Favours no massage

Figure 36: Incidence of pressure ulcers for comparison: massage with DMSO cream + position change versus position change only

	Massage					Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fi	xed, 95% C	1	
Duimel-Peeters, 2007	18	29	7	18	100.0%	1.60 [0.84, 3.04]					
Total (95% CI)		29		18	100.0%	1.60 [0.84, 3.04]			•		
Total events	18		7								
Heterogeneity: Not appl	licable						0.01	0.1	1	+	100
Test for overall effect: Z	= 1.42 (P	= 0.16))				0.01 Fav	ours massage	Favours	10 no ma	100 assage

Figure 37: Incidence of pressure ulcers for comparison: massage with DMSO cream + position change versus massage with indifferent cream + position change

	DMS					Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Duimel-Peeters, 2007	18	29	13	31	100.0%	1.48 [0.90, 2.45]	=
Total (95% CI)		29		31	100.0%	1.48 [0.90, 2.45]	◆
Total events Heterogeneity: Not appl	18		13				
Test for overall effect: Z		= 0.13)					0.01 0.1 1 10 100 Favours DMSO Favours petroleum

I.1.5 Nutritional supplementation and hydration strategies

Figure 38: Incidence of pressure ulcers - Protein, fat, carbohydrate, minerals and vitamins supplement and standard diet versus standard diet



Figure 39: Incidence of all pressure ulcers - High protein enriched with arginine zinc and antioxidants supplement and standard diet versus standard diet

	Suppler	nent	Standard h	ospital		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Houwing, 2003	27	51	30	52	100.0%	0.92 [0.65, 1.30]	=
Total (95% CI)		51		52	100.0%	0.92 [0.65, 1.30]	•
Total events	27		30				
Heterogeneity: Not app Test for overall effect:		P = 0.63)				0.01 0.1 1 10 100 Favours supplement Favours standard hospital

Figure 40: Incidence of stage II pressure ulcers - High protein enriched with arginine zinc and antioxidants supplement and standard diet versus standard diet




Figure 41: Incidence of pressure ulcers - Protein, carbohydrate, lipid, calcium, vitamin A, vitamin D, vitamins E, B1, B2, B6, B12, C, nicotinamide, folate, calcium pantothenate, biotin, and minerals supplement and standard diet versus standard diet

	Suppler	nent	Standard hospit	al diet		Peto Odds Ratio	Peto O
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fi
Delmi, 1990	0	25	2	27	100.0%	0.14 [0.01, 2.31]	
Total (95% CI)		25		27	100.0%	0.14 [0.01, 2.31]	
Total events	0		2				
Heterogeneity: Not ap	plicable					H	
Test for overall effect:	Z = 1.37 (F	P = 0.17)			Fav	ours experimental

Figure 42: Incidence of pressure ulcers –Standard hospital diet plus nutritional supplements (360mL at 6.27kJ/mL and 62.5g/L in protein) vs standard hospital diet

	Suppler	upplement Normal hospital				Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	l	M-H, Fixe	ed, 95% CI		
Dennis, 2005	15	2016	26	2007	100.0%	0.57 [0.31, 1.08]		-	t		
Total (95% CI)		2016		2007	100.0%	0.57 [0.31, 1.08]		•	-		
Total events	15		26								
Heterogeneity: Not app	olicable						0.01	0.1	<u> </u>	10	100
Test for overall effect:	Z = 1.72 (F	P = 0.09)					supplement	Favours n		

Figure 43: Length of time in hospital –Standard hospital diet plus nutritional supplements (360mL at 6.27kJ/mL and 62.5g/L in protein) vs standard hospital diet

Supplement				Norma	l hosp	oital		Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 95%	CI	
Dennis, 2005	34	48	2016	32	46	2007	100.0%	2.00 [-0.91, 4.91]					
Total (95% CI)			2016			2007	100.0%	2.00 [-0.91, 4.91]			•		
Heterogeneity: Not ap Test for overall effect:		(P = 0	0.18)						-100 Favo	-50 ours suppleme	0 ent Favo	50 urs normal	100 hospital

Figure 44: Incidence of grade 2-4 pressure ulcers - Tube fed energy, protein versus standard diet

	Suppler	nent	Standard hosp	ital diet		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fix	ed, 95% CI		
Hartgrink, 1998	25	48	30	53	100.0%	0.92 [0.64, 1.32]					
Total (95% CI)		48		53	100.0%	0.92 [0.64, 1.32]		•			
Total events	25		30								
Heterogeneity: Not ap Test for overall effect:		P = 0.65)					D.1 supplement	1 1 Favours sta	l 0 andard h	100 nospital

Figure 45: Incidence of all pressure ulcers - Tube fed energy, protein versus standard diet

	Suppler	nent	Standard hosp	ital diet		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	l	M-H, Fi	xed, 95% CI		
Hartgrink, 1998	30	48	37	53	100.0%	0.90 [0.68, 1.19]					
Total (95% CI)		48		53	100.0%	0.90 [0.68, 1.19]		•	•		
Total events	30		37								
Heterogeneity: Not ap Test for overall effect:		P = 0.44)				0.01 Fav	0.1 /ours supplement		0 andar	100 rd hospital

Figure 46: Incidence of pressure ulcers –Disease-specific (reduced-carbohydrate, modified-fat formula vs standard high-carbohydrate formula




Figure 47: Incidence of all pressure ulcers – Macronutrient diet plus lipids, gamma-linolenic acid, vitamins A,C and E vs macronutrient diet ready to feed, high fat, low carbohydrate, enteral formula

	Lipids and macron	Lipids and macronutrients				Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Theilla, 2007	8	46	10	49	100.0%	0.85 [0.37, 1.97]	-
Total (95% CI)		46		49	100.0%	0.85 [0.37, 1.97]	•
Total events	8		10				
Heterogeneity: Not ap Test for overall effect:	•						0.01 0.1 1 10 100 Favours Lipids + macro Favours Macronutrients

Figure 48: Incidence of grade 2-4 pressure ulcers – Macronutrient diet plus lipids, gamma-linolenic acid, vitamins A,C and E vs macronutrient diet ready to feed, high fat, low carbohydrate, enteral formula

Lipids and macronu		ıtrients	Macronut	rients		Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fix	ed, 95%	CI	
Theilla, 2007	4	46	6	49	100.0%	0.71 [0.21, 2.36]					
Total (95% CI)		46		49	100.0%	0.71 [0.21, 2.36]		-			
Total events	4		6								
Heterogeneity: Not appropriate the Test for overall effect:							0.01 Favours I	0.1 ipids & macro	1 Favou	10	100

Figure 49: Incidence of pressure ulcers -Protein-enriched meals vs normal postoperative care

	Protein-enriched	meals	Normal postoperative care		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI	
Oloffson, 2007	7	83	14	74	100.0%	0.45 [0.19, 1.04]	-	
Total (95% CI)		83		74	100.0%	0.45 [0.19, 1.04]	•	
Total events Heterogeneity: Not ap	7 plicable		14					100
Test for overall effect:	Z = 1.86 (P = 0.06)					Fa	0.01 0.1 1 10 vours protein-enriched Favours norma	100 al

Figure 50: Time in hospital –Protein-enriched meals vs normal postoperative care

	Protein-ei	nriched m	neals	Normal pos	stoperative	care		Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I	IV,	Fixed, 9	5% CI	
Oloffson, 2007	27.4	14.9	83	39.8	41.9	74	100.0%	-12.40 [-22.47, -2.33]					
Total (95% CI)			83			74	100.0%	-12.40 [-22.47, -2.33]			◆		
Heterogeneity: Not app Test for overall effect:		0.02)						Fa	-100 vours pro	-50 otein-enric	0 hed Fa	50 avours norma	100 al

Figure 51: Incidence of pressure ulcers –Standard hospital diet plus nutritional supplement vs standard hospital diet

	Oral supplement		Standard hospital		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events Total		Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Bourdel-M 2000	118	295	181	377	64.7%	0.83 [0.70, 0.99]	
Delmi, 1990	0	25	2	27	1.0%	0.22 [0.01, 4.28]	-
Dennis, 2005	15	2016	26	2007	10.6%	0.57 [0.31, 1.08]	
Hartgrink, 1998	25	48	30	53	11.6%	0.92 [0.64, 1.32]	
Houwing, 2003	27	51	30	52	12.1%	0.92 [0.65, 1.30]	+
Total (95% CI)		2435		2516	100.0%	0.82 [0.71, 0.95]	♦
Total events	185		269				
Heterogeneity: Chi2 = 1	2.81, df = 4 (P	= 0.59);	$I^2 = 0\%$				
Test for overall effect:	Z = 2.73 (P = 0	0.006)					6.01 0.1 1 10 100 Favours oral supplement Favours standard hospital


Figure 52: Incidence of pressure ulcers –Standard hospital diet plus nutritional supplement vs standard hospital diet

	Suppleme	nt/diet	standard ho	ospital		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Bourdel-M 2000	118	295	181	377	61.0%	0.83 [0.70, 0.99]	
Delmi, 1990	0	25	2	27	0.9%	0.22 [0.01, 4.28]	
Dennis, 2005	15	2016	26	2007	10.0%	0.57 [0.31, 1.08]	
Hartgrink, 1998	25	48	30	53	11.0%	0.92 [0.64, 1.32]	-+
Houwing, 2003	27	51	30	52	11.4%	0.92 [0.65, 1.30]	-
Oloffson, 2007	7	83	14	74	5.7%	0.45 [0.19, 1.04]	
Total (95% CI)		2518		2590	100.0%	0.80 [0.69, 0.92]	♦
Total events	192		283				
Heterogeneity: Chi2 =	5.02, df = 5 (F)	P = 0.41	; I ² = 0%				
Test for overall effect:	Z = 3.13 (P =	0.002)					0.01 0.1 1 10 100 Favours supplement/diet Favours standard hospital

I.1.6 Pressure redistributing devices

I.1.6.1 Constant low-pressure supports (CLP) vs standard foam mattresses (SFM)

Figure 53: Incidence of pressure ulcers – grades 2+ pressure ulcers



3.1 Cubed foam mattress lofman 1994 6 17 14 19 100.0% 0.48 [0.24, 0.96] without al (95% CI) 17 19 100.0% 0.48 [0.24, 0.96] without al (95% CI) 17 19 100.0% 0.48 [0.24, 0.96] without al (95% CI) 17 19 100.0% 0.48 [0.24, 0.96] without al (95% CI) 18 14 leterogeneity: Not applicable est for overall effect: Z = 2.07 (P = 0.04) 3.2 Bead-filled mattress 2 1 43 100.0% 0.32 [0.14, 0.76] without al (95% CI) 32 43 100.0% 0.32 [0.14, 0.76] without al (95% CI) 18 2 1 leterogeneity: Not applicable est for overall effect: Z = 2.59 (P = 0.010) 3.3 Water-filled mattress 15 21 let 100.0% 0.35 [0.15, 0.79] without al (95% CI) 155 161 100.0% 0.35 [0.15, 0.79] without al (95% CI) 155 161 100.0% 0.36 [0.22, 0.59] without al (95% CI) 571 73 100.0% 0.36 [0.22, 0.59] without (95% CI) 571 73 100.0% 0.36 [0.22, 0.59] without (95% CI) 571 73 100.0% 0.36 [0.22, 0.59] without (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] without (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] without (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] without (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] without (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] without (95% CI) 90 80 100.0% 0.78 [0.55, 1.11] without (95% CI) 562 66 604 100.0% 0.78 [0.55, 1.11] without (95% CI) 562 66 604 100.0% 0.78 [0.55, 1.11] without (95% CI) 562 66 604 100.0% 0.78 [0.55, 1.11] without (95% CI) 562 66 604 100.0% 0.78 [0.55, 1.11] without (95% CI) 562 66 604 100.0% 0.78 [0.55, 1.11] without (95% CI) 562 66 604 100.0% 0.78 [0.55, 1.11]	Risk Ratio		Risk Ratio			SFM	CLP	Favours	
### Rectangle of Process of Proce	M-H, Fixed, 95% C	% CI	M-H, Fixed, 95% C	Weight	Total	Events	Total		Study or Subgroup
Subtotal (95% CI) 17 19 100.0% 0.48 [0.24, 0.96] oral events 6 14 deterogeneity: Not applicable electrogeneity: Not applicab								ttress	.3.1 Cubed foam ma
Reterogeneity: Not applicable rest for overall effect: Z = 2.07 (P = 0.04) 3.2 Bead-filled mattress Soldstone 1982 5 32 21 43 100.0% 0.32 [0.14, 0.76] ordal events 5 21 reterogeneity: Not applicable rest for overall effect: Z = 2.59 (P = 0.010) 3.3 Water-filled mattress Andersen 1982 7 155 21 161 100.0% 0.35 [0.15, 0.79] ordal events 7 21 reterogeneity: Not applicable rest for overall effect: Z = 2.52 (P = 0.01) 3.4 Alternative foam Collier 1996 0 130 0 9 Not estimable rest for overall effect: Z = 2.52 (P = 0.01) 3.4 Alternative foam Collier 1996 0 130 0 9 Not estimable rest for overall effect: Z = 2.52 (P = 0.01) 3.5 Alternative foam Collier 1996 0 130 0 9 Not estimable rest for overall effect: Z = 4.03 (P < 0.0001) 3.5 Softform mattress Gray 1994 42 441 17 64 100.0% 0.36 [0.22, 0.59] Fotal events 42 17 Reterogeneity: Not applicable rest for overall effect: Z = 4.03 (P < 0.0001) 3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Solubtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Fotal events 6 27 Reterogeneity: Not applicable rest for overall effect: Z = 3.82 (P = 0.0001) 3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Fotal events 48 66 reterogeneity: Not applicable rest for overall effect: Z = 3.82 (P = 0.0001)		-				14		6	lofman 1994 Subtotal (95% CI)
Subtotal (95% CI) 32 43 100.0% 0.32 [0.14, 0.76] Fotal events 5 21 Felterogeneity: Not applicable Fest for overall effect: Z = 2.59 (P = 0.010) 1.3.3 Water-filled mattress Andersen 1982 7 155 21 161 100.0% 0.35 [0.15, 0.79] Fotal events 7 21 Felterogeneity: Not applicable Fest for overall effect: Z = 2.52 (P = 0.01) 1.3.4 Alternative foam Collier 1996 0 130 0 9 Not estimable Santy 1994 42 441 17 64 100.0% 0.36 [0.22, 0.59] Fotal events 42 17 Felterogeneity: Not applicable Fest for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Fotal events 6 27 Felterogeneity: Not applicable Fest for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Fotal events 48 66 Felterogeneity: Not applicable Fest for overall effect: Z = 3.82 (P = 0.0001)						14	= 0.04)	olicable	
Solidstone 1982 5 32 21 43 100.0% 0.32 [0.14, 0.76] Subtotal (95% CI) 32 1 43 100.0% 0.32 [0.14, 0.76] Subtotal (95% CI) 32 1 100.0% 0.32 [0.14, 0.76] Subtotal (95% CI) 5 21 1 100.0% 0.35 [0.15, 0.79] Subtotal (95% CI) 155 161 100.0% 0.35 [0.15, 0.79] Subtotal (95% CI) 155 161 100.0% 0.35 [0.15, 0.79] Subtotal (95% CI) 155 161 100.0% 0.35 [0.15, 0.79] Subtotal (95% CI) 155 161 100.0% 0.36 [0.22, 0.59] Subtotal (95% CI) 150 100.0% 0.36 [0.22, 0.59] Subtotal (95% CI) 100.0% 0.20 [0.09, 0.45] Sub								ress	.3.2 Bead-filled matt
Total events 5 21 Heterogeneity: Not applicable Fest for overall effect: Z = 2.59 (P = 0.010) 1.3.3 Water-filled mattress Andersen 1982 7 155 21 161 100.0% 0.35 [0.15, 0.79] Subtotal (95% CI) 155 161 100.0% 0.35 [0.15, 0.79] Fotal events 7 21 Heterogeneity: Not applicable Fest for overall effect: Z = 2.52 (P = 0.01) 1.3.4 Alternative foam Collier 1996 0 130 0 9 Not estimable Santy 1994 42 441 17 64 100.0% 0.36 [0.22, 0.59] Subtotal (95% CI) 571 73 100.0% 0.36 [0.22, 0.59] Fotal events 42 17 Heterogeneity: Not applicable Fest for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Fotal events 6 27 Heterogeneity: Not applicable Fest for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Fotal events 48 66 Heterogeneity: Not applicable						21	_		Goldstone 1982
Andersen 1982 7 155 21 161 100.0% 0.35 [0.15, 0.79] Subtotal (95% CI) 155 161 100.0% 0.35 [0.15, 0.79] Fotal events 7 21 Heterogeneity: Not applicable Fest for overall effect: Z = 2.52 (P = 0.01) I.3.4 Alternative foam Collier 1996 0 130 0 9 Not estimable Santy 1994 42 441 17 64 100.0% 0.36 [0.22, 0.59] Subtotal (95% CI) 571 73 100.0% 0.36 [0.22, 0.59] Fotal events 42 17 Heterogeneity: Not applicable Fest for overall effect: Z = 4.03 (P < 0.0001) I.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Fotal events 6 27 Heterogeneity: Not applicable Fest for overall effect: Z = 3.82 (P = 0.0001) I.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Fotal events 48 66 Heterogeneity: Not applicable		-	. , .			21		5	Total events
Subtotal (95% CI) Total events 7 21 Heterogeneity: Not applicable Test for overall effect: Z = 2.52 (P = 0.01) 1.3.4 Alternative foam Collier 1996 Santy 1994 42 441 17 64 100.0% 0.36 [0.22, 0.59] Total events 42 17 Heterogeneity: Not applicable Test for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 Subtotal (95% CI) 73 100.0% 0.20 [0.09, 0.45] Total events 6 27 Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Total events 48 Heterogeneity: Not applicable Total events 48 66 Heterogeneity: Not applicable)	= 0.010		
Subtotal (95% CI) Total events 7 21 Heterogeneity: Not applicable Test for overall effect: Z = 2.52 (P = 0.01) 1.3.4 Alternative foam Collier 1996 Santy 1994 42 441 17 64 100.0% 0.36 [0.22, 0.59] Total events 42 17 Heterogeneity: Not applicable Test for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Total events 6 27 Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Total events 48 Heterogeneity: Not applicable Total events 48 66 Heterogeneity: Not applicable		.=						tress	1.3.3 Water-filled mat
Heterogeneity: Not applicable Test for overall effect: Z = 2.52 (P = 0.01) 1.3.4 Alternative foam Collier 1996						21		7	
Test for overall effect: Z = 2.52 (P = 0.01) 1.3.4 Alternative foam Collier 1996						21		=	Total events Heterogeneity: Not apr
Collier 1996 0 130 0 9 Not estimable Santy 1994 42 441 17 64 100.0% 0.36 [0.22, 0.59] Subtotal (95% CI) 571 73 100.0% 0.36 [0.22, 0.59] Total events 42 17 Heterogeneity: Not applicable Test for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Total events 6 27 Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Total events 48 66 Heterogeneity: Not applicable							= 0.01)		
Santy 1994 42 441 17 64 100.0% 0.36 [0.22, 0.59] Subtotal (95% CI) 571 73 100.0% 0.36 [0.22, 0.59] Total events 42 17 Heterogeneity: Not applicable Test for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Total events 6 27 Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Total events 48 66 Heterogeneity: Not applicable								ı	1.3.4 Alternative foam
Subtotal (95% CI) 571 73 100.0% 0.36 [0.22, 0.59] Total events 42 17 Heterogeneity: Not applicable Test for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Total events 6 27 Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Total events 48 66 Heterogeneity: Not applicable		ble	Not estimable		9	0	130	0	Collier 1996
Total events 42 17 Heterogeneity: Not applicable Test for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Total events 6 27 Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Total events 48 66 Heterogeneity: Not applicable		-			-	17		42	,
Heterogeneity: Not applicable Test for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Total events 6 27 Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Total events 48 66 Heterogeneity: Not applicable		59]	0.36 [0.22, 0.59]	100.0%	73		571		,
Test for overall effect: Z = 4.03 (P < 0.0001) 1.3.5 Softform mattress Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Total events 6 27 Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Total events 48 66 Heterogeneity: Not applicable						17			
Gray 1994 6 90 27 80 100.0% 0.20 [0.09, 0.45] Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Fotal events 6 27 Heterogeneity: Not applicable Fest for overall effect: Z = 3.82 (P = 0.0001) I.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Fotal events 48 66 Heterogeneity: Not applicable						1)	< 0.000		
Subtotal (95% CI) 90 80 100.0% 0.20 [0.09, 0.45] Total events 6 27 Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Total events 48 66 Heterogeneity: Not applicable								ss	1.3.5 Softform mattre
Heterogeneity: Not applicable Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11]	_					27		6	Gray 1994 Subtotal (95% CI)
Test for overall effect: Z = 3.82 (P = 0.0001) 1.3.6 Hi-spec foam mattress/cushion Russell 2003						27		6	Total events
Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Total events 48 66 Heterogeneity: Not applicable						1)	= 0.000		
Russell 2003 48 562 66 604 100.0% 0.78 [0.55, 1.11] Subtotal (95% CI) 562 604 100.0% 0.78 [0.55, 1.11] Total events 48 66 Heterogeneity: Not applicable							shion	attress/cus	1.3.6 Hi-spec foam ma
Total events 48 66 Heterogeneity: Not applicable	-	11]	0.78 [0.55, 1.11]	100.0%	604	66			•
Heterogeneity: Not applicable	•	-					562		, ,
9 , 11						66		_	
<u> </u>							= 0.17)		
I I									
0.1 0.2	0.5 1 2 ours CLP Favours								

Figure 55: Patient acceptability – very uncomfortable

	Softform mattress		Std Fo	am		Peto Odds Ratio		lds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
Gray 1994	0	90	0	80		Not estimable				
Total (95% CI)		90		80		Not estimable				
Total events	0		0							
Heterogeneity: Not ap Test for overall effect:							0.01 0 Favours	1 0.1 softform	1 10 Favours fo	100 am

Figure 56: Patient acceptability - uncomfortable

	Softform mat	tress	Std Fo	am		Peto Odds Ratio	Peto Od	ds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI	
Gray 1994	0	90	2	80	100.0%	0.12 [0.01, 1.91]	+		
Total (95% CI)		90		80	100.0%	0.12 [0.01, 1.91]			
Total events	0		2						
Heterogeneity: Not app							0.01 0.1	 1 10	100
Test for overall effect:	Z = 1.50 (P = 0)	.13)					Favours softform	Favours foam	

Figure 57: Patient acceptability - adequate

Study or Subgroup	Softfor Events		Std Fo Events		Weight	Risk Ratio M-H, Fixed, 95% C	_	Ratio ed, 95% CI
Gray 1994	6	90	44	80	100.0%	0.12 [0.05, 0.27]	-	
Total (95% CI)		90		80	100.0%	0.12 [0.05, 0.27]	•	
Total events Heterogeneity: Not app Test for overall effect:		P < 0.0	44 0001)				0.01 0.1 Favours foam	1 10 100 Favours softform

Figure 58: Patient acceptability - comfortable




Figure 59: Patient acceptability – very comfortable




Figure 60: Patient acceptability - comfort

	CLP			SFM			Mean Difference			M	ean Di	fference	е	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		I۱	/, Fixed	d, 95% (CI	
Russell 2003	2.33	0.98	323	2.46	1.01	383	100.0%	-0.13 [-0.28, 0.02]						
Total (95% CI)			323			383	100.0%	-0.13 [-0.28, 0.02]						
Heterogeneity: Not app Test for overall effect:		(P = 0	0.08)						-100	-50 Favour	s CLP) Favoui	50 rs SFM	100 Л

1.1.6.2 Constant low pressure (ISO) vs constant low pressure (MSO) and alternating pressure (LALDM)

Figure 61: Incidence of pressure ulcers – all grades of pressure ulcers

	ISO		MSO and L	.ALDM	Risk Ratio			Risk			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	ed, 95% CI		
Vermette, 2012	2	55	6	55	100.0%	0.33 [0.07, 1.58]					
Total (95% CI)		55		55	100.0%	0.33 [0.07, 1.58]			-		
Total events	2		6								
Heterogeneity: Not app							0.01	0.1	 1 10	100	J
Test for overall effect:	Z = 1.38 (P = 0.1	7)					Favours ISO	Favours N	ISO and L	_A

Figure 62: Comfort - all grades of pressure ulcers

	ISO		MSO and L	.ALDM		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Vermette, 2012	29	34	27	30	100.0%	0.95 [0.79, 1.14]	-
Total (95% CI)		34		30	100.0%	0.95 [0.79, 1.14]	+
Total events	29		27				
Heterogeneity: Not ap	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.57 (P = 0.5	7)			Favou	irs MSO and LALDM Favours ISO

I.1.6.3 Alternative foam mattress vs standard foam mattress

Figure 63: Incidence of pressure ulcers – all grades of pressure ulcers (studies pooled)




Figure 64: Incidence of pressure ulcers – all grades of pressure ulcers (UK studies pooled)

	Alternative	foam	Std Fo	am		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% CI
Collier 1996	0	130	0	9		Not estimable	
Gray 1994	6	90	27	80	27.5%	0.20 [0.09, 0.45]	←
Russell 2003	48	562	66	604	37.6%	0.78 [0.55, 1.11]	 +
Santy 1994	42	441	17	64	34.8%	0.36 [0.22, 0.59]	
Total (95% CI)		1223		757	100.0%	0.41 [0.19, 0.87]	
Total events	96		110				
Heterogeneity: Tau ² =	0.37; Chi ² = 1	2.41, df =	= 2 (P = 0	.002);	$I^2 = 84\%$		0.1 0.2 0.5 1 2 5 10
Test for overall effect:	Z = 2.31 (P =	0.02)				F	0.1 0.2 0.5 1 2 5 10 Favours Alternative Favours SFM

Figure 65: Incidence of pressure ulcers – grades 2+ pressure ulcers (studies pooled)

	Experime	ental	Std Fo	am		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI
Gray 1994	6	90	27	80	70.0%	0.20 [0.09, 0.45]	_	
Hofman 1994	4	17	13	19	30.0%	0.34 [0.14, 0.85]	_	
Total (95% CI)		107		99	100.0%	0.24 [0.13, 0.45]	•	
Total events	10		40					
Heterogeneity: Chi ² = 0	0.80, df = 1	(P = 0.3)	$(37); I^2 = 0$	%			0.01 0.1	1 10 100
Test for overall effect:	Z = 4.50 (P	< 0.000	001)				vours experimental	Favours control

I.1.6.4 Comparisons between alternative foam supports

Figure 66: Incidence of pressure ulcers – all grades of pressure ulcers


•			_	•	
Foam	1	Foam	2	Risk Ratio	Risk Ratio
Events	Total	Events	Total	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
vs stand	ard fo	am			
42	441	17	64	0.36 [0.22, 0.59]	
nattress v	s Iris f	oam ove	erlay		
5	20	12	20	0.42 [0.18, 0.96]	-
nvoluted	foam				
12	39	21	45	0.66 [0.37, 1.16]	++
ess vs Tr	ansfo	amwave	mattres	ss	
1	50	1	50	1.00 [0.06, 15.55]	—
					0.1 0.2 0.5 1 2 5 10 Favours Foam 1 Favours Foam 2
	Events vs stand 42 nattress v 5 novoluted 12 ress vs Tr	vs standard for 42 441 nattress vs Iris f 5 20 novoluted foam 12 39 ress vs Transfor	Events Total Events vs standard foam 42 441 17 nattress vs Iris foam ove 5 20 12 novoluted foam 12 39 21 ress vs Transfoamwave	Events Total Events Total vs standard foam 42 441 17 64 nattress vs Iris foam overlay 5 20 12 20 envoluted foam 12 39 21 45 ress vs Transfoamwave mattress	Events Total Events Total M-H, Fixed, 95% C vs standard foam 42 441 17 64 0.36 [0.22, 0.59] nattress vs Iris foam overlay 5 20 12 20 0.42 [0.18, 0.96] envoluted foam 12 39 21 45 0.66 [0.37, 1.16] ress vs Transfoamwave mattress

Figure 67: Incidence of pressure ulcers – grades 2+ pressure ulcers

	Maxifloat foam o	verlay	Iris foam o	verlay		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
Vyhlidal 1997	3	20	8	20	100.0%	0.38 [0.12, 1.21]	—
Total (95% CI)		20		20	100.0%	0.38 [0.12, 1.21]	
Total events	3		8				
Heterogeneity: Not app Test for overall effect:							0.01 0.1 1 10 100 Favours maxifloat Favours iris

I.1.6.5 Comparisons between CLP supports

Figure 68: Incidence of pressure ulcers - all grades of pressure ulcers



⁽²⁾ This study evaluates all patients with pressure ulcers regardless of grade

⁽³⁾ This study evaluates all patients with pressure ulcers regardless of grade

Figure 69: Incidence of pressure ulcers – grade 2+ pressure ulcers




Figure 70: Patient acceptability – very uncomfortable

SOFFLEX ROHO Odds Ratio **Odds Ratio Total Weight** M-H, Fixed, 95% CI M-H, Fixed, 95% CI Study or Subgroup **Events** Total **Events** Cooper 1998 43 Not estimable Total (95% CI) 43 Not estimable 41 Total events 0 0 Heterogeneity: Not applicable 0.01 100 0.1 10 Test for overall effect: Not applicable Favours experimental Favours control

Figure 71: Patient acceptability – uncomfortable

	SOFFL	EX	ROH	0		Peto Odds Ratio	Peto Ode	ds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l Peto, Fixe	ed, 95% CI
Cooper 1998	0	41	5	43	100.0%	0.13 [0.02, 0.77]		
Total (95% CI)		41		43	100.0%	0.13 [0.02, 0.77]		
Total events	0		5					
Heterogeneity: Not app	olicable						0.01 0.1 1	10 10
Test for overall effect:	Z = 2.24 (I	P = 0.03	3)				Favours SOFFLEX	

Figure 72: Patient acceptability – adequate

	SOFFL	EX	ROH	0		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Cooper 1998	4	41	4	43	100.0%	1.05 [0.28, 3.92]	_
Total (95% CI)		41		43	100.0%	1.05 [0.28, 3.92]	*
Total events	4		4				
Heterogeneity: Not app Test for overall effect: 2		P = 0.9	4)				0.01 0.1 1 10 100 Favours ROHO Favours SOFFLEX

Figure 73: Patient acceptability – comfortable

	SOFFL	.EX	ROH	0		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Cooper 1998	24	41	24	43	100.0%	1.05 [0.72, 1.52]	
Total (95% CI)		41		43	100.0%	1.05 [0.72, 1.52]	*
Total events	24		24				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.25 (1	P = 0.80	0)				0.01 0.1 1 10 100 Favours ROHO Favours SOFFLEX

Figure 74: Patient acceptability - very comfortable

	SOFFL	EX.	ROH	0		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Cooper 1998	13	41	10	43	100.0%	1.36 [0.67, 2.76]	-
Total (95% CI)		41		43	100.0%	1.36 [0.67, 2.76]	•
Total events	13		10				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.86 (F	P = 0.39	9)				Favours ROHO Favours SOFFLEX

I.1.6.6 Alternating-pressure vs standard foam mattress

Figure 75: Incidence of pressure ulcers – all grades of pressure ulcers

Study or Subgroup	Alternating Pre	ssure Total	SFM Events	-	Weight	Risk Ratio M-H, Fixed, 95% Cl	Risk Ratio M-H, Fixed, 95% CI
Andersen 1982	7	166	21	161	61.4%	0.32 [0.14, 0.74]	
Sanada 2003	6	55	10	27	38.6%	0.29 [0.12, 0.73]	
Total (95% CI)		221		188	100.0%	0.31 [0.17, 0.58]	•
Total events	13		31				
Heterogeneity: Chi ² = 0 Test for overall effect:	,	,,	0%				0.1 0.2 0.5 1 2 5 10 Favours AP Favours SFM

Figure 76: Incidence of pressure ulcers – grades 2+ pressure ulcers

	Alternating Pres	sure	SFM	1		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Sanada 2003	5	55	6	27	100.0%	0.41 [0.14, 1.22]	-
Total (95% CI)		55		27	100.0%	0.41 [0.14, 1.22]	•
Total events	5		6				
Heterogeneity: Not app Test for overall effect:							0.01 0.1 1 10 100 Favours AP Favours SFM

I.1.7 Alternating-pressure vs constant low-pressure

Figure 77: Incidence of pressure ulcers – all grades of pressure ulcers and conditions




Figure 78: Incidence of pressure ulcers - with and without neurological conditions





Figure 79: Incidence of pressure ulcers – grade 2+ pressure ulcers

	AP		CLF	•		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Cavicchioli 2007	1	69	1	71	1.5%	1.03 [0.07, 16.13]	
Gebhardt 1996	0	23	8	20	14.0%	0.05 [0.00, 0.84]	-
Malbrain, 2010	0	8	1	8	2.3%	0.33 [0.02, 7.14]	-
Price 1999	1	40	2	40	3.1%	0.50 [0.05, 5.30]	
Stapleton 1986	11	32	26	68	25.6%	0.90 [0.51, 1.58]	-
Vanderwee 2005	34	222	35	225	53.5%	0.98 [0.64, 1.52]	†
Total (95% CI)		394		432	100.0%	0.80 [0.58, 1.11]	•
Total events	47		73				
Heterogeneity: Chi ² = 5	5.22, df = \$	5 (P = 0)).39); I ² =	4%			0.01 0.1 1 10 100
Test for overall effect: 2	Z = 1.31 (I	P = 0.19	9)				Favours AP Favours CLP

Figure 80: Drop-out due to discomfort

	AP		CLF)		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
6.4.1 AP vs Silicore							<u>L</u>
Conine 1990	19	93	17	94	100.0%	1.13 [0.63, 2.03]	-
Subtotal (95% CI)		93		94	100.0%	1.13 [0.63, 2.03]	•
Total events	19		17				
Heterogeneity: Not app	olicable						
Test for overall effect:	Z = 0.41 (F	P = 0.68	3)				
Total (95% CI)		93		94	100.0%	1.13 [0.63, 2.03]	•
Total events	19		17				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.41 (F	P = 0.68	3)				Favours AP Favours CLP
Test for subgroup diffe	rences: No	ot appli	cable				1 avouis / ii avouis OLi

Figure 81: Comfort rating at 14 days



I.1.7.1 Alternating-pressure and constant low-pressure in ICU/post-ICU

Figure 82: Incidence of pressure ulcers – standard foam mattress in ICU/standard foam mattress post-ICU versus alternating pressure (NIMBUS) in ICU/Standard foam mattress post-ICU

	Standard ICU/SFM p	ost-ICU	AP ICU/SFM p	ost-ICU		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fix	ed, 95% CI	
Laurent 1998	14	80	10	80	100.0%	1.40 [0.66, 2.96]	-	-	
Total (95% CI)		80		80	100.0%	1.40 [0.66, 2.96]		•	
Total events	14		10						
Heterogeneity: Not ap Test for overall effect:	•					Favoi	0.01 0.1 urs standard ICU	1 10 AP ICU	100

Figure 83: Incidence of pressure ulcers - Standard foam mattress in ICU/standard foam mattress post-ICU versus standard foam mattress ICU/constant low pressure mattress (TEMPUR) post-ICU

	Standard ICU/SFM p	ost-ICU	Standard ICU/Temp	our CLP		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Laurent 1998	14	80	11	75	100.0%	1.19 [0.58, 2.46]	
Total (95% CI)		80		75	100.0%	1.19 [0.58, 2.46]	*
Total events	14		11				
Heterogeneity: Not ap	•						0.01 0.1 1 10 100
Test for overall effect:	$\angle = 0.48 \ (P = 0.63)$						Favours SFM post-ICU Favours CLP post-ICU

Figure 84: Incidence of pressure ulcers – alternating-pressure mattress (NIMBUS in ICU/standard foam mattress post-ICU versus standard foam mattress ICU/constant low-pressure mattress (TEMPUR) post-ICU

	Nimbus AP ICU/SFM	I post-IC	Standard ICU/CLP post-ICU			Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	ed, 95% CI	
Laurent 1998	10	80	11	75	100.0%	0.85 [0.38, 1.89]		_	_	
Total (95% CI)		80		75	100.0%	0.85 [0.38, 1.89]		<		
Total events	10		11							
Heterogeneity: Not app Test for overall effect: 2								0.1 irs AP ICU	1 10 Favours sta	100 andard IC

Figure 85: Incidence of pressure ulcers – standard foam mattress in ICU/standard foam mattress post-ICU versus alternating-pressure mattress (NIMBUS) in ICU/constant low-pressure mattress (TEMPUR) post-ICU

	Standard ICU/SFM	post-ICU	AP ICU/CLP p	ost-ICU		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Laurent 1998	14	80	10	77	100.0%	1.35 [0.64, 2.85]	-
Total (95% CI)		80		77	100.0%	1.35 [0.64, 2.85]	•
Total events Heterogeneity: Not ap	14		10				
Test for overall effect:						F	0.01 0.1 1 10 100

Figure 86: Incidence of pressure ulcers – alternating-pressure mattress (NIMBUS) in ICU/standard foam mattress post ICU versus alternating-pressure mattress (NIMBUS) in ICU/constant low-pressure mattress (TEMPUR) post-ICU




Figure 87: Incidence of pressure ulcers – standard foam mattress ICU/constant low-pressure mattress (TEMPUR) post-ICU versus alternating-pressure mattress (NIMBUS) in ICU/constant low-pressure mattress (TEMPUR) post-ICU

;	Standard ICU/CLP	postICU	AP ICU/CLP p	ost-ICU		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Laurent 1998	11	75	10	77	100.0%	1.13 [0.51, 2.50]	-
Total (95% CI)		75		77	100.0%	1.13 [0.51, 2.50]	*
Total events Heterogeneity: Not applic Test for overall effect: Z =			10			Fav	0.01 0.1 1 10 100 yours standard ICU Favours AP ICU

I.1.7.2 Comparisons between alternating-pressure devices

Figure 88: Incidence of pressure ulcers – all grades of pressure ulcers





Figure 89: Incidence of pressure ulcers - grade 2+ pressure ulcers AP device Control **Risk Ratio** Study or Subgroup **Events Total Events Total Weight** M-H, Fixed, 95% CI M-H, Fixed, 95% CI 8.2.1 Airwave vs Large Cell Ripple Exton-Smith 1982 5 31 100.0% 0.42 [0.17, 1.04] 31 12 Subtotal (95% CI) 31 31 100.0% 0.42 [0.17, 1.04] Total events 12 Heterogeneity: Not applicable Test for overall effect: Z = 1.87 (P = 0.06) 8.2.2 Airwave vs Pegasus Carewave Hampton 1997 39 Not estimable Subtotal (95% CI) 36 39 Not estimable Total events 0 Heterogeneity: Not applicable Test for overall effect: Not applicable 8.2.4 TheraPulse vs Duo Theaker 2005 3 30 6 32 100.0% 0.53 [0.15, 1.94] Subtotal (95% CI) 30 32 100.0% 0.53 [0.15, 1.94] Total events 6 Heterogeneity: Not applicable Test for overall effect: Z = 0.95 (P = 0.34) 8.2.5 AP overlay vs AP mattress Nixon 2006 989 101 982 100.0% 1.04 [0.81, 1.35] Subtotal (95% CI) 1.04 [0.81, 1.35] 989 982 100.0% Total events 106 101 Heterogeneity: Not applicable Test for overall effect: Z = 0.31 (P = 0.75) 8.2.6 Multi-stage inflation vs single-stage inflation Demarre, 2012 298 312 100.0% 0.99 [0.52, 1.88] Subtotal (95% CI) 312 100.0% 0.99 [0.52, 1.88] Total events 17 18 Heterogeneity: Not applicable Test for overall effect: Z = 0.03 (P = 0.97) 100 0.01 0.1 10 Favours AP device Favours control



I.1.7.3 Low-air-loss vs standard bed

Figure 91: Incidence of pressure ulcers – all grades of pressure ulcers



Figure 92: Incidence of pressure ulcers – grade 2+ pressure ulcers





Figure 93: Incidence of pressure ulcers – grade 2+ pressure ulcers (pooled)




1.1.7.4 Indentation load deflection operating room foam mattress vs operating room usual care

Figure 94: Incidence of pressure ulcers - all grades of pressure ulcers



Figure 95: Incidence of pressure ulcers – grade 2+ pressure ulcers



I.1.7.5 Operating table overlay vs no overlay

Figure 96: Incidence of pressure ulcers – all grades of pressure ulcers




Figure 97: Incidence of pressure ulcers – grades 2+ pressure ulcers

	Overla	ay	No Ove	rlay		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Feuchtinger 2006	2	85	1	90	100.0%	2.12 [0.20, 22.93]	
Total (95% CI)		85		90	100.0%	2.12 [0.20, 22.93]	
Total events	2		1				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.62 (I	P = 0.5	4)				Favours overlay Favours no overla

I.1.7.6 Face pillows in the operating theatre

Figure 98: Incidence of pressure ulcers - all grades of pressure ulcers

	OSI face	wolliq	ROHO face	pillow		Peto Odds Ratio	Peto Oc	dds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95%	CI Peto, Fix	ed, 95% CI
Grisell, 2008	10	22	0	22	100.0%	12.55 [3.11, 50.57	7]	_
Total (95% CI)		22		22	100.0%	12.55 [3.11, 50.57	1	-
Total events	10		0					
Heterogeneity: Not ap	plicable						0.01 0.1	1 10 100
Test for overall effect:	Z = 3.56 (P	= 0.0004	.)			(OSI positioner pillow	ROHO pillow

Figure 99: Incidence of pressure ulcers – grade 2+ pressure ulcers

	OSI face p	oillow	ROHO face	pillow		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Grisell, 2008	2	22	0	22	100.0%	7.75 [0.47, 128.03]	
Total (95% CI)		22		22	100.0%	7.75 [0.47, 128.03]	
Total events	2		0				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.43 (P =	= 0.15)					Favours OSI Favours ROHO

Figure 100: Incidence of pressure ulcers – all grades of pressure ulcers

	OSI face	wollic	Dupaco face	pillow		Peto Odds Ratio		Pet	o Odds Rat	io	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto	Fixed, 95%	6 CI	
Grisell, 2008	10	22	0	22	100.0%	12.55 [3.11, 50.57]			-		_
Total (95% CI)		22		22	100.0%	12.55 [3.11, 50.57]					_
Total events	10		0								
Heterogeneity: Not ap Test for overall effect:	•	= 0.0004	1)				0.01 Favours	0.1 OSI face pi	1 low Favou	10 Irs Dupaco 1	100

Figure 101: Incidence of pressure ulcers – grade 2+ pressure ulcers

	OSI face p	oillow	Dupaco face pillow		Peto Odds Ratio		Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI
Grisell, 2008	2	22	0	22	100.0%	7.75 [0.47, 128.03]	
Total (95% CI)		22		22	100.0%	7.75 [0.47, 128.03]	
Total events	2		0				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.43 (P =	= 0.15)					Favours OSI Favours Dupaco

Figure 102: Incidence of pressure ulcers – all grades of pressure ulcers

	ROHO face	pillow	Dupaco face	pillow	Peto Odds Ratio			Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I		Peto, Fix	ed, 95% C	1	
Grisell, 2008	0	22	0	22		Not estimable						
Total (95% CI)		22		22		Not estimable						
Total events	0		0									
Heterogeneity: Not ap Test for overall effect:	•					Fa	0.01 avours	0 expe	l .1 erimental	1 1 Favours	-	100

Figure 103: Incidence of pressure ulcers – grade 2+ pressure ulcers


	ROHO face	pillow	Dupaco face pillow			Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95%	CI Peto, Fix	ed, 95% CI			
Grisell, 2008	0	22	0	22		Not estimable	е				
Total (95% CI)		22		22		Not estimable	е				
Total events	0		0								
Heterogeneity: Not app	plicable						0.01 0.1	1 10	100		
Test for overall effect: Not applicable					F	avours experimental	Favours cont				

I.1.7.7 Micropulse system for surgical patients

Figure 104: Incidence of pressure ulcers – all grades of pressure ulcers



Figure 105: Incidence of pressure ulcers – grade 2+ pressure ulcers



I.1.7.8 Visco-elastic A&E overlay and ward mattress vs standard A&E overlay and ward mattress

Figure 106: Incidence of pressure ulcers – grade 2+ pressure ulcers

	Visco-elastic	Standa	ard		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed,	95% CI		
Gunningberg 2000	4	48	8	53	100.0%	0.55 [0.18, 1.72]	-			
Total (95% CI)		48		53	100.0%	0.55 [0.18, 1.72]				
Total events	4		8							
Heterogeneity: Not app	plicable					F	0.01 0.1 1	10	100	
Test for overall effect:				-		avours foar				

Figure 107: Incidence of pressure ulcers – all grades of pressure ulcers

	Visco-elastic f	Standa	ard		Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI	M-H, Fixe	ed, 95% CI	
Gunningberg 2000	12	48	17	53	100.0%	0.78 [0.42, 1.46]]	-	-	
Total (95% CI)		48		53	100.0%	0.78 [0.42, 1.46]		•	\	
Total events	12		17							
Heterogeneity: Not ap Test for overall effect:	•	4)					0.01 0		1 10 Favours st	100 andard

1.1.7.9 Profiling bed vs flat-based bed

Figure 108: Incidence of pressure ulcers – all grades of pressure ulcers

	Profiling	bed	Foam ma	ttress	Peto Odds Ratio			Peto O			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ced, 95% C	l	
Keogh 2001	0	35	0	35		Not estimable					
Total (95% CI)		35		35		Not estimable					
Total events	0		0								
Heterogeneity: Not app							0.01	0.1	1 10) 1	— 00
Test for overall effect: Not applicable								avours foam			

I.1.7.10 Seat cushions







Figure 110: Withdrawal due to discomfort



1.1.7.11 Pressure redistributing devices for the prevention of heel ulcers

Figure 111: Bunny boot vs. egg crate - incidence of heel pressure ulcers




Figure 112: Bunny boot vs. foot waffle- incidence of heel pressure ulcers

	Bunny	boot	Foot wa	affle		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	1	M-H, Fixe	ed, 95% C	1	
Gilcreast, 2005	3	77	5	76	100.0%	0.59 [0.15, 2.39]					
Total (95% CI)		77		76	100.0%	0.59 [0.15, 2.39]					
Total events	3		5								
Heterogeneity: Not app Test for overall effect:		P = 0.46)).1 unny boot		lO foot v	100 waffle

Figure 113: Egg crate vs. foot waffle- incidence of heel pressure ulcers

	Eggcra	ate	Foot wa	affle		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gilcreast, 2005	4	87	5	76	100.0%	0.70 [0.19, 2.51]	_
Total (95% CI)		87		76	100.0%	0.70 [0.19, 2.51]	
Total events	4		5				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.55 (1	P = 0.58	8)				Favours eggcrate Favours foot waffle

Figure 114: Foot waffle vs. pillow- incidence of heel pressure ulcers

	Foot wa	affle	Pillo	W		Peto Odds Ratio	Peto Od	lds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l Peto, Fix	ed, 95% CI
Tymec, 1997	0	26	1	26	100.0%	0.14 [0.00, 6.82]	—	
Total (95% CI)		26		26	100.0%	0.14 [0.00, 6.82]		
Total events	0		1					
Heterogeneity: Not app	olicable						0.01 0.1	1 10 100
Test for overall effect:	Z = 1.00 (F)	P = 0.32	2)			F	avours foot waffle	

Figure 115: Heel elevation device vs. standard care- incidence of heel pressure ulcers

Heel elevation		levice	Standard	care		Peto Odds Ratio	Peto O	to Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI				
Donnelly, 2011	0	120	17	119	100.0%	0.12 [0.04, 0.31]	_					
Total (95% CI)		120		119	100.0%	0.12 [0.04, 0.31]	•					
Total events	0		17									
Heterogeneity: Not app Test for overall effect:		01)					0.01 0.1 Favours heel elevation	1 10 Favours standard ca	100 are			

Figure 116: Silicone multi-layered foam dressing vs. standard care – incidence of heel pressure ulcers



Figure 117: Foam body support vs. usual care- incidence of heel pressure ulcers

	Foam body s	upport	Usual o	care		Risk Ratio	Risk	Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fix	ed, 95% CI				
Cadue, 2008	3	35	19	35	100.0%	0.16 [0.05, 0.49]	_					
Total (95% CI)		35		35	100.0%	0.16 [0.05, 0.49]						
Total events	3		19									
Heterogeneity: Not ap	•						0.01 0.1	1 10	100			
Test for overall effect:	Z = 3.22 (P = 0.0)	001)				Fa	vours foam body support	Favours usual ca	are			

Figure 118: Air mattress vs. standard hospital mattress- incidence of heel pressure ulcers – meta-analysed

	Air mattress		Contr	rol	Risk Ratio Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed,	95% CI	
Aronovitch, 1999	0	112	3	105	43.6%	0.13 [0.01, 2.56]	-	_	
Jesurum, 1996	2	16	1	20	10.7%	2.50 [0.25, 25.15]	-		
Russell, 2000	0	98	1	100	17.9%	0.34 [0.01, 8.25]	-		
Takala, 1996	0	11	2	13	27.8%	0.23 [0.01, 4.40]	-		
Total (95% CI)		237		238	100.0%	0.45 [0.14, 1.49]			
Total events	2		7						
Heterogeneity: Chi ² = 2	2.99, df = 3	(P = 0.	39); I ² = 0)%				10 100	
Test for overall effect:	Z = 1.31 (F	r = 0.19)			Fa	0.01 0.1 1 avours air mattress Fa	10 100 avours control	

Figure 119: Air mattress vs. standard hospital mattress – incidence of heel pressure ulcers

	Alternating air ma	ttress	SHN	1		Peto Odds Ratio	Peto Oc	lds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
Aronovitch, 1999	0	112	2	105	100.0%	0.13 [0.01, 2.02]	+	
Total (95% CI)		112		105	100.0%	0.13 [0.01, 2.02]		_
Total events	0		2					
Heterogeneity: Not app							0.01 0.1	1 10 100
Test for overall effect: 2	Z = 1.46 (P = 0.14)					Fav	ours alternating air	Favours SHM

Figure 120: Low-air-loss mattress vs. standard hospital mattress – incidence of heel pressure ulcers

	LAL mattress		SHM	Л		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Jesurum, 1996	2	16	1	20	100.0%	2.50 [0.25, 25.15]	
Total (95% CI)		16		20	100.0%	2.50 [0.25, 25.15]	
Total events	2		1				
Heterogeneity: Not ap	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.78 (P	r = 0.44				Fav	0.01 0.1 1 10 100 ours LAL mattress Favours SHM

Figure 121: Multi-cell pulsating dynamic mattress system vs. standard hospital mattress – incidence of heel pressure ulcers

	Multi-cell pulsa	ting	SHM	1		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l Peto, Fixed, 95% Cl
Russell, 2000	0	98	1	100	100.0%	0.14 [0.00, 6.96]	←
Total (95% CI)		98		100	100.0%	0.14 [0.00, 6.96]	
Total events	0		1				
Heterogeneity: Not app	olicable						
Test for overall effect: 2	Z = 0.99 (P = 0.32)	2)					0.01 0.1 1 10 100

Figure 122: Double air-cell mattress vs. standard hospital mattress – incidence of heel pressure ulcers

	Double air cell ma	ttress	SHI	/		Peto Odds Ratio	Peto Oc	lds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
Takala, 1996	0	11	2	13	100.0%	0.15 [0.01, 2.49]	+	
Total (95% CI)		11		13	100.0%	0.15 [0.01, 2.49]		
Total events	0		2					
Heterogeneity: Not ap	plicable						0.01 0.1	1 10 100
Test for overall effect:	Z = 1.33 (P = 0.18)					Favo	ours double air-cell	Favours SHM

Figure 123: Foam mattress (transfoamwave) vs. standard hospital mattress (transfoam)-incidence of heel pressure ulcers

	Foam mat	tress	SHN	1		Peto Odds Ratio	Peto O	dds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fi	xed, 95% CI
Gray, 2000	0	50	1	50	100.0%	0.14 [0.00, 6.82]	+	
Total (95% CI)		50		50	100.0%	0.14 [0.00, 6.82]		
Total events	0		1					
Heterogeneity: Not app	olicable						0.01 0.1	1 10 100
Test for overall effect:	Z = 1.00 (P =	= 0.32)				Fav	0.01 0.1 ours foam mattress	1 10 100 Favours SHM

Figure 124: Foam mattress (transfoamwave) vs. standard hospital mattress (transfoam)— comfort perception – very uncomfortable

	Foam mat	tress	SHI	Л		Peto Odds Ratio	Peto O	dds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	red, 95% CI
Gray, 2000	0	47	0	48		Not estimable		
Total (95% CI)		47		48		Not estimable		
Total events	0		0					
Heterogeneity: Not ap Test for overall effect:	•	le				Fav	0.01 0.1 ours transfoamwave	1 10 10 Favours SHM

Figure 125: Foam mattress (transfoamwave) vs. standard hospital mattress (transfoam)—
comfort perception – uncomfortable

	Foam mat	tress	SHN	Л		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ked, 95% CI	
Gray, 2000	0	47	1	48	100.0%	0.14 [0.00, 6.97]	+			
Total (95% CI)		47		48	100.0%	0.14 [0.00, 6.97]				
Total events	0		1							
Heterogeneity: Not ap	plicable						0.01	0.1	1 10	100
Test for overall effect:	Z = 0.99 (P = 0.00)	= 0.32)				Fav		foamwave		

Figure 126: Foam mattress (transfoamwave) vs. standard hospital mattress (transfoam)—
comfort perception – adequate

	Foam mat	tress	SHM	1		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	I M-H, Fixed, 95% CI
Gray, 2000	3	47	2	48	100.0%	1.53 [0.27, 8.76]	
Total (95% CI)		47		48	100.0%	1.53 [0.27, 8.76]	
Total events	3		2				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.48 (P	= 0.63)					0.01 0.1 1 10 100 Favours SHM Favours transfoamwa

Figure 127: Foam mattress (transfoamwave) vs. standard hospital mattress (transfoam)— comfort perception – comfortable

	Foam mat	tress	SHI	1		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95% (<u> </u>	
Gray, 2000	26	47	34	48	100.0%	0.78 [0.57, 1.07]					
Total (95% CI)		47		48	100.0%	0.78 [0.57, 1.07]		4			
Total events	26		34								
Heterogeneity: Not app	plicable						0.01	0.1	 	10	100
Test for overall effect:	Z = 1.54 (P	= 0.12)					0.01	Favours SHM	Favours		

Figure 128: Foam mattress (transfoamwave) vs. standard hospital mattress (transfoam)—
comfort perception – very comfortable

	Foam mat	ttress	SHI	1		Risk Ratio		Ris	k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fi	xed, 95	% CI	
Gray, 2000	18	47	11	48	100.0%	1.67 [0.89, 3.15]			+		
Total (95% CI)		47		48	100.0%	1.67 [0.89, 3.15]					
Total events	18		11								
Heterogeneity: Not ap	plicable						0.01	0.1	+	10	100
Test for overall effect:	Z = 1.59 (P	= 0.11)					0.01	Favours SHN	/ Favo		

Figure 129: Silicore overlay vs. air overlay- incidence of heel pressure ulcers

	Silicore ov	erlay	Air ove	rlay		Peto Odds Ratio		Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I	Peto, Fix	ed, 95% CI	
Daeschsel, 1985	0	16	1	16	100.0%	0.14 [0.00, 6.82]	+			
Total (95% CI)		16		16	100.0%	0.14 [0.00, 6.82]				
Total events	0		1							
Heterogeneity: Not ap	•						0.01	0.1	1 10	100
Test for overall effect:	Z = 1.00 (P =	0.32)				F	avours s	ilicore overlay	Favours air	overlay

Figure 130: Double-cell air cell vs. standard hospital mattress- incidence of heel pressure ulcers

	Double-layer air	r-cell	SHM	/		Risk Ratio	Risk R	atio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI M-H, Fixed	I, 95% CI
Sanada, 2003	2	29	2	27	100.0%	0.93 [0.14, 6.15	1 —	
Total (95% CI)		29		27	100.0%	0.93 [0.14, 6.15]		
Total events	2		2					
Heterogeneity: Not app	plicable						0.01 0.1 1	10 100
Test for overall effect:	Z = 0.07 (P = 0.94))				F		Favours SHM

Figure 131: Double-cell air cell vs. standard hospital mattress- incidence of heel pressure ulcers (grade 2)

	Double-layer air	-cell	SHM	1		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Sanada, 2003	0	29	2	27	100.0%	0.12 [0.01, 1.99]	
Total (95% CI)		29		27	100.0%	0.12 [0.01, 1.99]	
Total events	0		2				
Heterogeneity: Not app	olicable						
Test for overall effect:	Z = 1.48 (P = 0.14))				F	0.01 0.1 1 10 100 Favours double cell Favours SHM

Figure 132: Single-layer air-cell vs. standard hospital mattress- incidence of heel pressure ulcers

	Single-layer ai	r-cell	SHM	1		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI
Sanada, 2003	0	26	2	27	100.0%	0.14 [0.01, 2.22]	
Total (95% CI)		26		27	100.0%	0.14 [0.01, 2.22]	
Total events	0		2				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.40 (P = 0.16)	5)				Fa	avours single-layer Favours SHM

Figure 133: Single-layer air-cell vs. standard hospital mattress- incidence of heel pressure ulcers (grade 2)

	Single-layer a	ir-cell	SHM	1		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Sanada, 2003	1	26	2	27	100.0%	0.52 [0.05, 5.39]	
Total (95% CI)		26		27	100.0%	0.52 [0.05, 5.39]	
Total events	1		2				
Heterogeneity: Not ap Test for overall effect:	•	8)					0.01 0.1 1 10 100 Favours single-layer Favours standard

Figure 134: Double-layer air-cell vs. single-layer air-cell- incidence of heel pressure ulcers

	Double-layer	air-cell	Single-layer	air-cell		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Sanada, 2003	2	29	0	26	100.0%	6.91 [0.42, 113.79]	
Total (95% CI)		29		26	100.0%	6.91 [0.42, 113.79]	
Total events	2		0				
Heterogeneity: Not ap Test for overall effect:	•	18)					0.01 0.1 1 10 100 Favours double-layer Favours single-layer

Figure 135: Double-layer air-cell vs. single-layer air-cell- incidence of heel pressure ulcers (grade 2)

	•										
	Favours double	e layer	Single-layer	air-cell		Peto Odds Ratio		Peto Oc	dds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	l	Peto, Fix	ed, 95% CI		
Sanada, 2003	0	29	1	26	100.0%	0.12 [0.00, 6.11]	+				
Total (95% CI)		29		26	100.0%	0.12 [0.00, 6.11]					
Total events	0		1								
Heterogeneity: Not ap	plicable						0.01	0.1	1 1		100
Test for overall effect:	Z = 1.06 (P = 0.29)))						ouble layer		-	

Figure 136: Multi-stage versus single-stage inflation – incidence of heel pressure ulcers

	Multi-st	tage	Single-s	tage		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Demarre, 2012	4	298	5	312	100.0%	0.84 [0.23, 3.09]	
Total (95% CI)		298		312	100.0%	0.84 [0.23, 3.09]	
Total events	4		5				
Heterogeneity: Not app Test for overall effect:		P = 0.79	9)				0.01 0.1 1 10 100 Favours multi-stage Favours single-stage

Figure 137: Combined alternating pressure mattress vs. combined constant low pressure mattress- incidence of heel pressure ulcers

	Combine	d AP	Combine	d CLP		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI
Gebhardt, 1996	0	23	1	20	100.0%	0.12 [0.00, 5.93]	—
Total (95% CI)		23		20	100.0%	0.12 [0.00, 5.93]	
Total events	0		1				
Heterogeneity: Not app Test for overall effect:		= 0.28)					0.01 0.1 1 10 100 Favours combined AP Favours combined CLP

Figure 138: Alternating-pressure mattress vs. foam mattress- incidence of heel pressure ulcers

	AP		Foam ma	ttress		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fix	ed, 95% C	:	
Vanderwee, 2005	5	222	16	225	100.0%	0.32 [0.12, 0.85]		_			
Total (95% CI)		222		225	100.0%	0.32 [0.12, 0.85]		•			
Total events	5		16								
Heterogeneity: Not app Test for overall effect:		P = 0.02	2)				0.01	0.1 Favours AP	-	0 foa	100 m mattre


Figure 139: Alternating pressure overlay vs. alternating pressure mattress – incidence of heel pressure ulcers



Figure 140: Alternating pressure overlay vs. alternating pressure mattress - requests for mattress change

	AP ove	rlay	AP matt	ress		Risk Ratio		Ris	k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fi	ixed, 95% C	<u> </u>	
Nixon, 2006	230	989	186	982	100.0%	1.23 [1.03, 1.46]					
Total (95% CI)		989		982	100.0%	1.23 [1.03, 1.46]			♦		
Total events	230		186								
Heterogeneity: Not app Test for overall effect:		P = 0.02	2)				0.01 Favou	0.1 Irs AP overla	1 ay Favours	 0 AP n	100 nattress

Figure 141: Protective bandage vs. polyurethane foam hydrocellular dressing – incidence of heel pressure ulcers



I.1.8 Barrier creams

Figure 142: Mepentol (hyperoxygenated fatty acid compound) vs Placebo [Incidence of new pressure ulcers]

	Mepen	tol	Placel	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
BOU2005	12	164	29	167	100.0%	0.42 [0.22, 0.80]	-
Total (95% CI)		164		167	100.0%	0.42 [0.22, 0.80]	•
Total events	12		29				
Heterogeneity: Not app		_					0.01 0.1 1 10 100
Test for overall effect:	Z = 2.66 (1	P = 0.00	08)				Favours Mepentol Favours Placebo

Figure 143: Clinisan vs standard hospital soap [changes in skin integrity]

	Clinis	an	Standard	Soap		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95% CI		
COOPER2001	6	33	16	33	100.0%	0.38 [0.17, 0.84]					
Total (95% CI)		33		33	100.0%	0.38 [0.17, 0.84]		•			
Total events	6		16								
Heterogeneity: Not app Test for overall effect:		P = 0.0	2)				0.01	0.1 Favours Clinisan	1 10 10 Favours sta	-	100 soap

Figure 144: Clinisan vs standard hospital soap [broken skin]

	Clinis	an	Standard	Soap		Peto Odds Ratio		Peto Od	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
COOPER2001	0	33	4	33	100.0%	0.12 [0.02, 0.91]				
Total (95% CI)		33		33	100.0%	0.12 [0.02, 0.91]	-			
Total events	0		4							
Heterogeneity: Not app	olicable						0.01	0.1	1 10	100
Test for overall effect:	Z = 2.05 (1	P = 0.0	4)					ours Clinisan	Favours Sta	

Figure 145: Lotion containing Cosbiol and Allantoin vs placebo [skin deterioration]

	Active lo	otion	Placebo	lotion		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
GREEN1974	34	141	47	178	100.0%	0.91 [0.62, 1.34]	-
Total (95% CI)		141		178	100.0%	0.91 [0.62, 1.34]	•
Total events	34		47				
Heterogeneity: Not appropriate the Test for overall effect:		o = 0.64))				0.01 0.1 1 10 100 Favours active lotion Favours placebo lotion

Figure 146: Lotion containing Cosbiol and Allantoin vs placebo [sores only]

	Active Id	otion	Control	lotion		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
GREEN1974	14	141	31	178	100.0%	0.57 [0.32, 1.03]	-
Total (95% CI)		141		178	100.0%	0.57 [0.32, 1.03]	•
Total events	14		31				
Heterogeneity: Not app Test for overall effect:		= 0.06)					0.01 0.1 1 10 100 Favours active lotion Favours placebo lotion

Figure 147: Conotrane vs Placebo [Incidence of any pressure ulcers]

	Conotr	ane	Place	bo		Risk Ratio		F	Risk R	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (M-H,	Fixed	, 95% CI	
SMITH1985	35	129	47	129	100.0%	0.74 [0.52, 1.07]					
Total (95% CI)		129		129	100.0%	0.74 [0.52, 1.07]			•		
Total events	35		47								
Heterogeneity: Not app							0.01	0.1	 	10	100
Test for overall effect:	Z = 1.59 (I	P = 0.11	1)					s Conotra	ane F	avours pla	

Figure 148: Conotrane vs Placebo [Incidence of Grade III pressure ulcers]

	Conotr	ane	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
SMITH1985	5	129	4	129	100.0%	1.25 [0.34, 4.55]	
Total (95% CI)		129		129	100.0%	1.25 [0.34, 4.55]	
Total events	5		4				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect: 2	Z = 0.34 (F	P = 0.73	3)				Favours Conotrane Favours placebo

Figure 149: Conotrane vs Placebo [Incidence of Grade IV pressure ulcers]

	Conotra	ane	Placel	00		Peto Odds Ratio		Peto C	dds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	<u> </u>	Peto, Fi	xed, 95% C	<u> </u>	
SMITH1985	0	129	1	129	100.0%	0.14 [0.00, 6.82]	←		+		
Total (95% CI)		129		129	100.0%	0.14 [0.00, 6.82]					
Total events	0		1								
Heterogeneity: Not app	olicable						0.01	0.1	1 1	0	 100
Test for overall effect:	Z = 1.00 (F	P = 0.32	2)					Conotrane	-	-	

Figure 150: Conotrane vs Placebo [patient acceptability]

	Conotr	ane	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
SMITH1985	4	129	3	129	100.0%	1.33 [0.30, 5.84]	·] —
Total (95% CI)		129		129	100.0%	1.33 [0.30, 5.84]	
Total events	4		3				
Heterogeneity: Not app		7					0.01 0.1 1 10 100
Test for overall effect:	Z = 0.38 (1	r = 0.70	J)				Favours Conotrane Favours placebo

Figure 151: Prevasore vs. Dermalex [skin deterioration]

	Prevas	ore	Derma	lex		Risk Ratio		Ris	k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fi	ked, 95% CI		
VANDERCAMMEN1987	7	54	11	50	100.0%	0.59 [0.25, 1.40]			+		
Total (95% CI)		54		50	100.0%	0.59 [0.25, 1.40]		•	•		
Total events	7		11								
Heterogeneity: Not applica Test for overall effect: Z =		0.23)					0.01 F	0.1 avours Prevasore	1 Favours [10 Dermale	100

Figure 152: Prevasore vs. Dermalex [Skin blistering]




Figure 153: IPARZINE4A-SKR cream vs. placebo [Incidence of Category 1 pressure ulcers]

	IPARZINE4A	- SKR	Placebo d	ream		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
VERDU2012	6	99	7	95	100.0%	0.82 [0.29, 2.36]	6] — — — — — — — — — — — — — — — — — — —
Total (95% CI)		99		95	100.0%	0.82 [0.29, 2.36]	5]
Total events	6		7				
Heterogeneity: Not app Test for overall effect:		72)					0.01 0.1 1 10 100 Favours IPARZINE4A-SKR Favours placebo cream

I.2 Pressure ulcer management

I.2.1 Ulcer measurement

No meta-analysis was undertaken and data were not suitable for input into Revman therefore no forest plots were generated.

I.2.2 Categorisation

Figure 154: Accuracy

	E	PUAP		Stirling				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Russell and Reynolds 2001	0.15	0.21	86	0.045	0.21	85	100.0%	0.10 [0.04, 0.17]	
Total (95% CI)			86			85	100.0%	0.10 [0.04, 0.17]	•
Heterogeneity: Not applicable Test for overall effect Z = 3.27		01)							-0.2 -0.1 0 0.1 0.2 Favours EPUAP Favours Stirling

Figure 155: Precision

	E	PUAP		Stirling				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
Russell and Reynolds 2001	0.49	0.15	86	0.36	0.15	85	100.0%	0.13 [0.09, 0.17]			
Total (95% CI)			86			85	100.0%	0.13 [0.09, 0.17]			
Heterogeneity: Not applicable Test for overall effect: $Z = 5.67$		0001)							-0.5 -0.25 0 0.25 0.5 Favours EPUAP Favours Stirling		

I.2.3 Nutritional supplementation and hydration strategies

Figure 156: 500kcal, 34g protein, 6g arginine, 500mg vit C, 18mg zinc and standard hospital diet vs standard hospital diet – proportion with complete healing




Figure 157: 500kcal, 34g protein, 6g arginine, 500mg vit C, 18mg zinc and standard hospital diet vs standard hospital diet –mean reduction in ulcer size cm2 (change scores)




Figure 158: 500kcal, 34g protein, 6g arginine, 500mg vit C, 18mg zinc and standard hospital diet vs standard hospital diet –mean reduction in PUSH scores (change scores)

	Supp	oleme	ent		SHD			Mean Difference	Mean D	ifference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixe	d, 95% CI	
Cereda, 2009	-6.1	2.7	13	-3.3	2.4	15	100.0%	-2.80 [-4.71, -0.89]			
Total (95% CI)			13			15	100.0%	-2.80 [-4.71, -0.89]		,	
Heterogeneity: Not app Test for overall effect:	•	(P = 0	0.004)						-100 -50 Favours SHD	0 50 Favours su	100 upplement

Figure 159: 500kcal, 34g protein, 6g arginine, 500mg vit C, 18mg zinc and standard hospital diet vs standard hospital diet –all cause mortality

	Supplement		SHE)		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (CI Peto, Fixed, 95% CI
Cereda, 2009	2	15	0	15	100.0%	7.94 [0.47, 133.26]	1
Total (95% CI)		15		15	100.0%	7.94 [0.47, 133.26]	
Total events	2		0				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.44 (F	r = 0.15)			F	Favours supplement Favours SHD

Figure 160: 250kcal, 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals and standard hospital diet vs standard hospital diet and placebo – adverse events related to the product

	Supplen	nent	SHD)		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Van Anholt, 2010	9	22	4	21	100.0%	2.15 [0.78, 5.92]	+
Total (95% CI)		22		21	100.0%	2.15 [0.78, 5.92]	-
Total events	9		4				
Heterogeneity: Not app	licable						0.01 0.1 1 10 100
Test for overall effect: 2	Z = 1.48 (F	r = 0.14)			Fa	avours supplement Favours SHD

Figure 161: 250kcal, 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals and standard hospital diet vs standard hospital diet and placebo – Incidence of diarrhoea

	Supplen	nent	SHE)		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95%	CI M-H, Fixed, 95% CI
Van Anholt, 2010	6	22	2	21	100.0%	2.86 [0.65, 12.64	·) ————————————————————————————————————
Total (95% CI)		22		21	100.0%	2.86 [0.65, 12.64	1
Total events	6		2				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.39 (F	P = 0.16)			F	Favours supplement Favours SHD

Figure 162: 250kcal, 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals and standard hospital diet vs standard hospital diet and placebo – Incidence of nausea

	Supplen	nent	SHE)		Risk Ratio		Ri	sk Ra	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	i .	M-H, F	ixed,	95% CI	
Van Anholt, 2010	1	22	1	21	100.0%	0.95 [0.06, 14.30]					
Total (95% CI)		22		21	100.0%	0.95 [0.06, 14.30]					
Total events	1		1								
Heterogeneity: Not app	plicable						0.01	0.1	+	10	100
Test for overall effect:	Z = 0.03 (F	P = 0.97)			F		supplemei	nt F	avours S	

Figure 163: 250kcal, 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals and standard hospital diet vs standard hospital diet and placebo – Incidence of vomiting

	U							
	Suppler	nent	SHE)		Peto Odds Ratio	Peto Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Cl Peto, Fixed, 95% Cl	
Van Anholt, 2010	0	22	1	21	100.0%	0.13 [0.00, 6.51]] ←	
Total (95% CI)		22		21	100.0%	0.13 [0.00, 6.51]		
Total events	0		1					
Heterogeneity: Not ap	plicable						0.01 0.1 1 10	100
Test for overall effect:	Z = 1.02 (F	P = 0.31)			F	0.01 0.1 1 10 Favours supplement Favours SHD	100

Figure 164: 500kcal, 18g protein, 0g fat, 72mg vitamin C, 7.5 mg zinc and standard hospital diet vs standard hospital diet – PUSH scores at week 3




Figure 165: 500kcal, 21g protein, 0g fat, 500mg vitamin C, 30mg zinc, 9g arginine and standard hospital diet vs standard hospital diet – PUSH scores at week 3




Figure 166: 500kcal, 21g protein, 0g fat, 500mg vitamin C, 30mg zinc, 9g arginine and standard hospital diet vs 500kcal, 18g protein, 0g fat, 72mg vitamin C, 7.5 mg zinc and standard hospital diet – PUSH scores at week 3

	Arginine,	protein,	vit C	Proteir	n, vit C,	zinc		Mean Difference		Mea	n Differ	rence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	i .	IV, F	ixed, 9	5% CI	
Desneves, 2005	2.6	0.6	5	6	1.2	5	100.0%	-3.40 [-4.58, -2.22]					
Total (95% CI)			5			5	100.0%	-3.40 [-4.58, -2.22]			+		
Heterogeneity: Not app Test for overall effect:		0.00001)						-100 Favor	-50 urs Argin	0 ine Fa	50 avours Pr	100 rotein

Figure 167: per 100ml 4.38g protein, 2.23g fat, 15.62g carbohydrate, minerals and vitamins and standard hospital diet vs standard hospital diet – proportion with complete healing

	Supplement SHD)		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Ohura, 2011	7	21	4	29	100.0%	2.42 [0.81, 7.21]	+
Total (95% CI)		21		29	100.0%	2.42 [0.81, 7.21]	•
Total events	7		4				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect: 2	Z = 1.58 (F	P = 0.11)				0.01 0.1 1 10 100 Favours control Favours experimenta

Figure 168: per 100ml 4.38g protein, 2.23g fat, 15.62g carbohydrate, minerals and vitamins and standard hospital diet vs standard hospital diet – mean reduction in ulcer size (cm²)

	Sup	Supplement //ean SD Total Me			SHD			Mean Difference		Mea	an Diffe	rence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed, 9	95% CI	
Ohura, 2011	1.31	0.24	21	0.32	0.2	29	100.0%	0.99 [0.86, 1.12]					
Total (95% CI)			21			29	100.0%	0.99 [0.86, 1.12]					
Heterogeneity: Not ap Test for overall effect:			0.0000	01)					-100 Fa	-50 vours co	otrol F	50 avours ex	 -

Figure 169: per 100ml 4.38g protein, 2.23g fat, 15.62g carbohydrate, minerals and vitamins and standard hospital diet vs standard hospital diet – study-related adverse events

	Suppler	Supplement)	Risk Ratio			Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H, F	ixed, 95	5% CI	
Ohura, 2011	8	29	5	30	100.0%	1.66 [0.61, 4.47]				_	
Total (95% CI)		29		30	100.0%	1.66 [0.61, 4.47]				-	
Total events	8		5								
Heterogeneity: Not ap	plicable						0.01	0.1	+-	10	100
Test for overall effect: $Z = 0.99$ ($P = 0.32$)			F		experimenta	ıl Favo	ours con	

Figure 170: Very high protein dietary formula vs high protein dietary formula – proportion with complete healing

	, , ,		High pr	otein		Peto Odds Ratio	Peto Odds Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI			Peto, Fix	ed, 95% CI		
Chernoff 1990	4	6	0	6	100.0%	15.64 [1.57, 155.75]						
Total (95% CI)		6		6	100.0%	15.64 [1.57, 155.75]						
Total events	4		0									
Heterogeneity: Not ap	plicable						0.01		 	1 1	0	100
Test for overall effect:	Z = 2.35 (P = 0)	0.02)						-	high protein	Favours ve	-	

Figure 171: Very high protein dietary formula vs high protein dietary formula – mean surface reduction (%)




Figure 172: 500mg ascorbic acid and standard hospital diet vs standard hospital diet and placebo – proportion with complete healing

	Suppler	nent	SHE)		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Taylor 1974	6	10	3	10	12.2%	2.00 [0.68, 5.85]	<u>+</u> -
ter Riet 1995	17	43	22	45	87.8%	0.81 [0.50, 1.30]	-
Total (95% CI)		53		55	100.0%	0.95 [0.62, 1.47]	•
Total events	23		25				
Heterogeneity: Chi ² = 2	2.29, df = 1	(P = 0.	13); I ² = 5	66%			
Test for overall effect:	Z = 0.21 (F	P = 0.83)				0.01 0.1 1 10 100 Favours placebo Favours Ascorbic acid

Figure 173: 500mg ascorbic acid and standard hospital diet vs standard hospital diet and placebo – time to complete healing




Figure 174: 500mg ascorbic acid and standard hospital diet vs standard hospital diet and placebo – mean% surface area reduction




Figure 175: 500mg ascorbic acid and standard hospital diet vs standard hospital diet and placebo – all cause mortality

	Supplen	nent						Risk Rati	0	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-	H, Fixed, 9	5% CI	
Taylor 1974	1	10	1	10	17.0%	1.00 [0.07, 13.87]				
ter Riet 1995	3	43	5	45	83.0%	0.63 [0.16, 2.47]	_			
Total (95% CI)		53		55	100.0%	0.69 [0.21, 2.32]				
Total events	4		6							
Heterogeneity: Chi ² = 0 Test for overall effect:		•)%		F	0.01 0.1	1 acid Fay	10 rours place	100 ebo

Figure 176: Zinc sulphate 200mg vs placebo – proportion with complete healing

	Zinc su	lfate	Place	bo	Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Brewer, 1967	1	6	2	7	100.0%	0.58 [0.07, 4.95]	
Total (95% CI)		6		7	100.0%	0.58 [0.07, 4.95]	
Total events	1		2				
Heterogeneity: Not app	olicable						
Test for overall effect:	Z = 0.49 (F	P = 0.62	2)				0.01 0.1 1 10 100 Favours placebo Favours Zinc

Figure 177: Zinc sulphate 200mg vs placebo – mean reduction in pressure ulcer volume (ml)

	Zinc	Zinc sulfate Jean SD Total N		PI	acebo)		Mean Difference	Mean D	ifference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Rand	om, 95% CI	
Norris 1971	10.1	9	10	6	17.5	10	100.0%	4.10 [-8.10, 16.30]			
Total (95% CI)			10			10	100.0%	4.10 [-8.10, 16.30]			
Heterogeneity: Not ap Test for overall effect:	•	(P = 0	0.51)						-10 -5 Favours placebo	0 5 Favours Zind	10

Figure 178: Concentrated, fortified, collagen protein hydrolysate vs placebo – mean reduction in PUSH scores

	Supplement			PI				Mean Difference		Mea	n Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed, 95	% CI	
Lee, 2006	3.55	4.66	44	3.22	4.11	27	100.0%	0.33 [-1.74, 2.40]					
Total (95% CI)			44			27	100.0%	0.33 [-1.74, 2.40]			•		
Heterogeneity: Not appress for overall effect:		(P = 0).76)						-100 Favo	-50 ours place	0 ebo Fav	50 ours supp	100 element

Figure 179: Concentrated, fortified, collagen protein hydrolysate vs placebo – all cause mortality




Figure 180: Ornithine alpha-ketoglutarate vs placebo – time to complete healing




Figure 181: Ornithine alpha-ketoglutarate vs placebo – mean% reduction in ulcer size

	Ornit	Ornithine alpha			Placebo			Mean Difference	Mean Difference			ce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	ed, 95%	CI	
Meaume, 2009	59.5	71.4	85	54	69	75	100.0%	5.50 [-16.28, 27.28]		_			
Total (95% CI)			85			75	100.0%	5.50 [-16.28, 27.28]		•			
Heterogeneity: Not ap Test for overall effect:		(P = 0.	62)						-100 Fav	-50 rours placebo	0 Favo	50 urs ornith	100 ine alpha

Figure 182: Ornithine alpha-ketoglutarate vs placebo – mean surface area reduction (cm²)

	Ornithine alpha Placebo								iffe	erence				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	ed, 9	95% CI		
Meaume, 2009	2.3	4.2	85	1.7	1.7	75	100.0%	0.60 [-0.37, 1.57]						
Total (95% CI)			85			75	100.0%	0.60 [-0.37, 1.57]						
Heterogeneity: Not ap Test for overall effect:	•	(P = 0.	23)						-100 Fa	-50 vours placebo	0 F	50 avours or	-	100 e alpha


Figure 183: Ornithine alpha-ketoglutarate vs placebo – all cause mortality

	Ornithine	alpha	Place	bo		Risk Ratio	Risl	k Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fix	ked, 95% CI	
Meaume, 2009	5	89	3	76	100.0%	1.42 [0.35, 5.76]			
Total (95% CI)		89		76	100.0%	1.42 [0.35, 5.76]	-		
Total events	5		3						
Heterogeneity: Not app Test for overall effect: 2		0.62)				Fa	0.01 0.1 avours ornithine alpha	1 10 Favours place	100 ebo

I.2.4 Pressure redistributing devices

I.2.4.1 Water mattress overlay vs low-tech mattress

Figure 184: Proportion of people with pressure ulcers completely healed



1.2.4.2 3-D microporous overlay vs gel overlay

Figure 185: Proportion of people with pressure ulcers completely healed

	3-D overlay		Gel ove	erlay		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	ed, 95% C	:	
Cassino, 2013	3	35	5	37	100.0%	0.63 [0.16, 2.46]					
Total (95% CI)		35		37	100.0%	0.63 [0.16, 2.46]			_		
Total events	3		5								
Heterogeneity: Not appropriate to the Test for overall effect:		P = 0.51)					0.1 gel overlay	-	10 3-D (100 overlay

Figure 186: mortality (all-cause)

	3-D ove	rlay	Gel ove	rlay		Risk Ratio	Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixe	ed, 95% C		
Cassino, 2013	3	35	7	37	100.0%	0.45 [0.13, 1.62]				
Total (95% CI)		35		37	100.0%	0.45 [0.13, 1.62]		-		
Total events	3		7							
Heterogeneity: Not approved for overall effect:		P = 0.22	2)).1 -D overlay	1 1 Favours (0 gel ov	100 verlay

Figure 187: Suspension due to worsening of pressure ulcers

	3-D ove	rlay	Gel ove	rlay		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Cassino, 2013	9	35	17	37	100.0%	0.56 [0.29, 1.09]	-
Total (95% CI)		35		37	100.0%	0.56 [0.29, 1.09]	•
Total events	9		17				
Heterogeneity: Not app Test for overall effect:		P = 0.09)				0.01 0.1 1 10 100 Favours 3-D overlay Favours gel overlay

Figure 188: Suspension due to intolerance

	3-D ove	rlay	Gel ove	erlay		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Cassino, 2013	5	35	2	37	100.0%	2.64 [0.55, 12.75]	
Total (95% CI)		35		37	100.0%	2.64 [0.55, 12.75]	
Total events	5		2				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.21 (F	P = 0.23	3)				Favours 3-D overlay Favours gel overlay

Figure 189: unchanged/worsened pressure ulcers

	3-D ove	rlay	Gel ove	erlay		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Cassino, 2013	16	35	22	37	100.0%	0.77 [0.49, 1.20]	=
Total (95% CI)		35		37	100.0%	0.77 [0.49, 1.20]	•
Total events	16		22				
Heterogeneity: Not appropriate the Test for overall effect:		P = 0.25	5)				0.01 0.1 1 10 100 Favours 3-D overlay Favours gel overlay

Figure 190: improved pressure ulcers

	3-D ove	rlay	Gel ove	erlay		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Cassino, 2013	16	35	9	37	100.0%	1.88 [0.96, 3.68]	-
Total (95% CI)		35		37	100.0%	1.88 [0.96, 3.68]	•
Total events	16		9				
Heterogeneity: Not app Test for overall effect:		P = 0.07	')				0.01 0.1 1 10 100 Favours gel overlay Favours 3-D overlay

Figure 191: patient comfort (fair to excellent)

	3-D ove	rlay	Gel ove	erlay		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Cassino, 2013	27	35	19	37	100.0%	1.50 [1.05, 2.16]	
Total (95% CI)		35		37	100.0%	1.50 [1.05, 2.16]	•
Total events	27		19				
Heterogeneity: Not app	olicable						
Test for overall effect:	Z = 2.20 (F	P = 0.03)				0.01 0.1 1 10 100 Favours gel overlay Favours 3-D overlay

Figure 192: patient comfort (poor)

	3-D ove	rlay	Gel ove	erlay		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI	
Cassino, 2013	8	35	18	37	100.0%	0.47 [0.23, 0.94]	-	
Total (95% CI)		35		37	100.0%	0.47 [0.23, 0.94]	•	
Total events	8		18					
Heterogeneity: Not appropriate for overall effect:		P = 0.03	3)				0.01 0.1 1 10 Favours 3-D overlay Favours gel	100 overlay

1.2.4.3 Low-air-loss bed vs foam mattress overlay

Figure 193:Proportion of people with pressure ulcers completely healed




Figure 194: Proportion of people with pressure ulcers completely healed




Figure 195: Proportion of people with pressure ulcers completely healed (meta-analysed)

	LAL b	ed	Foam mattress of	overlay		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Ferrell 1993	26	43	19	41	83.7%	1.30 [0.87, 1.96]	
Mulder 1994	5	31	3	18	16.3%	0.97 [0.26, 3.58]	
Total (95% CI)		74		59	100.0%	1.25 [0.84, 1.86]	•
Total events	31		22				
Heterogeneity: Chi ² = Test for overall effect:	,	,	,,				0.01 0.1 1 10 100 Favours foam Favours LAL

Figure 196: Pressure ulcers reduced by one grade or more including healed completely

	Low-air-los	s bed	Foam mattress	overlay		Risk Ratio	Ris	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fix	red, 95% Cl		
Mulder 1994	10	31	5	18	100.0%	1.16 [0.47, 2.86]	_	_		
Total (95% CI)		31		18	100.0%	1.16 [0.47, 2.86]	<			
Total events	10		5							
Heterogeneity: Not ap	plicable						0.01 0.1	+ +	100	
Test for overall effect:	Z = 0.32 (P =	0.75)					0.01 0.1 Favours foam	1 10 Favours I		SS

Figure 197: Change in ulcer size of stage II ulcers (final values)

	Low-air-loss bed Foam mattress of					erlay		Mean Difference		Me	an Differei	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	:I	IV,	Fixed, 959	6 CI	
Day 1993	7.3	2.4	25	5.3	2.1	23	100.0%	2.00 [0.73, 3.27]					
Total (95% CI)			25			23	100.0%	2.00 [0.73, 3.27]			•		
Heterogeneity: Not ap Test for overall effect:	•	P = 0.0	002)					Fa	-100 vours foa	-50 am mat. ove	0 erlay Favo	50 ours LAL be	100

Figure 198: Change in ulcer size of stage III and IV ulcers (final values)

	LA	L be	d	Foam mat	tress ove	erlay		Mean Difference		Mean Di	fference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	CI	IV, Fixed	d, 95% CI	
Day 1993	37.1	8.1	17	12.4	3.5	12	100.0%	24.70 [20.37, 29.03]]			
Total (95% CI)			17			12	100.0%	24.70 [20.37, 29.03]			•	
Heterogeneity: Not ap Test for overall effect:	•		< 0.000	01)				F		-50 () 5 Favours I A	100

Figure 199: Mean comfort score





Figure 200: Mortality



1.2.4.4 Air-fluidised bed vs standard care

Figure 201: Proportion of people with 50% reduction in pressure ulcers total surface area

	Air-fluidise	d bed	Standard	care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
Allman 1987	9	31	8	34	100.0%	1.23 [0.54, 2.80]	1 -
Total (95% CI)		31		34	100.0%	1.23 [0.54, 2.80]	•
Total events	9		8				
Heterogeneity: Not ap							0.01 0.1 1 10 100
Test for overall effect:	Z = 0.50 (P =	0.61)					Favours standard care Favours air-fluidised

Figure 202: Proportion of people with improvement in pressure ulcers

	Air-fluidise	d bed	Standard	care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Strauss 1991	19	22	9	13	100.0%	1.25 [0.84, 1.86]	=
Total (95% CI)		22		13	100.0%	1.25 [0.84, 1.86]	*
Total events	19		9				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.09 (P = 0	0.28)					0.01 0.1 1 10 100 Favours standard care Favours air-fluidised bed

Figure 203: Proportion of people with improvement in pressure ulcers

	Air-fluidise	d bed	Standard	care		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H, Fix	ed, 95%	CI	
Allman 1987	22	31	16	34	100.0%	1.51 [0.99, 2.30]					
Total (95% CI)		31		34	100.0%	1.51 [0.99, 2.30]			•		
Total events	22		16								
Heterogeneity: Not app Test for overall effect:		0.06)					0.01 Favours	0.1 standard care	1 Favou	10 rs air-fluid	100 dised

Figure 204: Proportion of people with improvement in pressure ulcers

	Air-fluidise	d bed	Standard	care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Allman 1987	22	31	16	34	57.4%	1.51 [0.99, 2.30]	
Strauss 1991	19	22	9	13	42.6%	1.25 [0.84, 1.86]	-
Total (95% CI)		53		47	100.0%	1.40 [1.04, 1.88]	•
Total events	41		25				
Heterogeneity: Chi2 =	0.44, df = 1 (P	= 0.51);	$I^2 = 0\%$				0.01 0.1 1 10 100
Test for overall effect:	Z = 2.20 (P = 0)	0.03)					Favours standard care Favours air-fluidised

Figure 205: Reduction in pain




Figure 206: Increase in pain

	Favours air-flu	idised	Standard	care		Peto Odds Ratio	Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fiz	xed, 95% CI	
Allman 1987	0	13	3	14	100.0%	0.12 [0.01, 1.31]		+	
Total (95% CI)		13		14	100.0%	0.12 [0.01, 1.31]		+	
Total events	0		3						
Heterogeneity: Not ap Test for overall effect:	•)					0.01 0.1 Favours air-fluidised	1 10 Favours standa	100

Figure 207: Time in hospital

	Air-flui	dised	bed	Stand	dard ca	are		Mean Difference		Mean	Differe	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	1	IV, Fi	xed, 95	5% CI	
Strauss 1991	11.5	8.8	47	21.5	547	50	100.0%	-10.00 [-161.64, 141.64]	—				
Total (95% CI)			47			50	100.0%	-10.00 [-161.64, 141.64]	_				
Heterogeneity: Not appropriate the Test for overall effect:		P = 0.9	90)						-100 Favour	-50 rs air-fluidised be	0 d Fav	50 vours standard	100 d care

Figure 208: Patient satisfaction




Figure 209: Increase in comfort




Figure 210: Reduction in comfort





Figure 211: Mortality



1.2.4.5 Alternating-pressure mattress vs alternating-pressure mattress

Figure 212: Proportion of people with pressure ulcers completely healed

	AP mattre	ess 1	AP mattr	ess 2		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Devine 1995	10	16	5	14	100.0%	1.75 [0.79, 3.89]	_
Total (95% CI)		16		14	100.0%	1.75 [0.79, 3.89]	•
Total events	10		5				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.37 (P	= 0.17)					0.01 0.1 1 10 100 Favours AP mattress2 Favours AP mattress1

Figure 213: Proportion of people with pressure ulcers completely healed

	AP mattro	ess 1	AP mattr	ess 2		Risk Ratio	Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fix	ed, 95% Cl	<u> </u>	
Russell 2000	65	71	65	70	100.0%	0.99 [0.90, 1.09]				
Total (95% CI)		71		70	100.0%	0.99 [0.90, 1.09]				
Total events	65		65							
Heterogeneity: Not ap Test for overall effect:	•	= 0.77)					 0.1 P mattress2	1 Favours /	10 AP ma	100 attress1

Figure 214: Decrease in pressure ulcer size




Figure 215: Increase in pressure ulcer size



Figure 216: Mortality




Figure 217: Mortality

	AP mattro	ess 1	AP mattr	ess 2		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	I M-H, Fixed, 95% CI
Devine 1995	6	22	5	19	100.0%	1.04 [0.38, 2.86]	-
Total (95% CI)		22		19	100.0%	1.04 [0.38, 2.86]	•
Total events	6		5				
Heterogeneity: Not ap Test for overall effect:		= 0.95)					0.01 0.1 1 10 100 Favours AP mattress 1 Favours AP mattress 2

Figure 218: Mortality

	AP mattre	ess 1	AP mattr	ess 2		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Evans 2000	7	17	3	15	100.0%	2.06 [0.64, 6.57]	_
Total (95% CI)		17		15	100.0%	2.06 [0.64, 6.57]	
Total events	7		3				
Heterogeneity: Not ap Test for overall effect:	•	= 0.22)					0.01 0.1 1 10 100 Favours AP mattress 1 Favours AP mattress 2

1.2.4.6 Alternating-pressure mattress overlay vs alternating-pressure mattress

Figure 219: Proportion of people with pressure ulcers completely healed

	AP ove	rlay	AP matt	ress		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Nixon 2006	20	59	19	54	100.0%	0.96 [0.58, 1.60]	-
Total (95% CI)		59		54	100.0%	0.96 [0.58, 1.60]	*
Total events	20		19				
Heterogeneity: Not ap Test for overall effect:	•	o = 0.89	9)				0.01 0.1 1 10 100 Favours AP mattress Favours AP overlay

Figure 220: Absolute change in surface area (cm2) – change values

	AP	overl	ay	AP m	nattre	ss		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
Nixon 2006	1	2.3	33	2	6.1	36	100.0%	-1.00 [-3.14, 1.14]	_
Total (95% CI)			33			36	100.0%	-1.00 [-3.14, 1.14]	•
Heterogeneity: Not appress for overall effect:		(P =	0.36)						-100 -50 0 50 100 Favours AP mattress Favours AP overlay

Figure 221: % change in surface area – change values

	AF	overla	y	AP	mattres	ss		Mean Difference		Mea	n Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I	IV, F	ixed, 95	% CI	
Nixon 2006	-35	605.5	33	34.4	108.6	36	100.0%	-69.40 [-279.01, 140.21]	←				
Total (95% CI)			33			36	100.0%	-69.40 [-279.01, 140.21]					
Heterogeneity: Not ap Test for overall effect:			52)						-100 Favou	-50 rs AP mattre	0 ss Fav	50 Yours AP ov	100 verlay

Figure 222: Pressure ulcer improvement

	AP mattress ov	erlay	AP matt	ress		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Russell 2003	56	75	60	83	100.0%	1.03 [0.86, 1.25]	•
Total (95% CI)		75		83	100.0%	1.03 [0.86, 1.25]	•
Total events	56		60				
Heterogeneity: Not app Test for overall effect:		1)					0.01 0.1 1 10 100 Favours AP mattress Favours AP overlay

Figure 223: Worsening of pressure ulcers




Figure 224: Patient acceptability (requested changes for comfort or other device-related reasons)

	AP matt	ress	AP mattress	overlay		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95% CI		
Nixon 2006	230	989	186	982	100.0%	1.23 [1.03, 1.46]					
Total (95% CI)		989		982	100.0%	1.23 [1.03, 1.46]			*		
Total events	230		186								
Heterogeneity: Not ap Test for overall effect:	•	P = 0.02)				0.01 Favours	0.1 AP mattress	-	10 .P ma	100 att overlay

Figure 225: Proportion of patients with negative comments on mattress motion

	AP ove	rlay	AP matt	ress		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI	
Nixon 2006	328	929	285	891	100.0%	1.10 [0.97, 1.26]			
Total (95% CI)		929		891	100.0%	1.10 [0.97, 1.26]		•	
Total events	328		285						
Heterogeneity: Not app Test for overall effect:		P = 0.13	3)				0.01 0.1 Favours AP overlay		100 tress

Figure 226: Proportion of patients with positive comments for mattress motion

	AP ove	rlay	AP matt	ress		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	i .	M-H, Fix	ed, 95% CI		
Nixon 2006	272	929	263	891	100.0%	0.99 [0.86, 1.14]					
Total (95% CI)		929		891	100.0%	0.99 [0.86, 1.14]			♦		
Total events	272		263								
Heterogeneity: Not ap Test for overall effect:	•	P = 0.91)				0.01 Favours	0.1 AP mattress	1 10 Favours A	-	100 erlay

Figure 227: Proportion of patients commenting negatively on getting into/out of bed

	AP ove	rlay	AP matt	ress		Risk Ratio		F	lisk Ratio)	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H,	Fixed, 95	5% CI	
Nixon 2006	124	929	127	891	100.0%	0.94 [0.74, 1.18]					
Total (95% CI)		929		891	100.0%	0.94 [0.74, 1.18]			•		
Total events	124		127								
Heterogeneity: Not ap Test for overall effect:	•	P = 0.58	3)				0.01 Favor	0.1 urs AP ove	1 rlay Favo	10 ours AP	100 mattress

Figure 228: Proportion of patients commenting negatively on movement in bed

	AP ove	rlay	AP matt	ress		Risk Ratio		Risk F	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed	d, 95% CI		
Nixon 2006	290	929	260	891	100.0%	1.07 [0.93, 1.23]					
Total (95% CI)		929		891	100.0%	1.07 [0.93, 1.23]		•			
Total events	290		260								
Heterogeneity: Not ap Test for overall effect:	•	P = 0.34	1)				0.01 0. Favours A	.1 1 AP overlay	1 Favours A	-	100 attress

Figure 229: Proportion of patients commenting positively on movement in bed

ents	Total									
	IOtal	Events	Total	Weight	M-H, Fixed, 95% C	l	M-H, Fixe	ed, 95% (CI	
25	929	27	891	100.0%	0.89 [0.52, 1.52]		-	-		
	929		891	100.0%	0.89 [0.52, 1.52]		•			
25 able = 0.43 (F	P = 0.66	27						1 Eavoure	10	100
	25 able	929 25 able	929 25 27	929 891 25 27 able	929 891 100.0% 25 27 able	929 891 100.0% 0.89 [0.52, 1.52] 25 27 able	929 891 100.0% 0.89 [0.52, 1.52] 25 27 able 0.043 (P = 0.66)	929 891 100.0% 0.89 [0.52, 1.52] 25 27 able 0.043 (P = 0.66) 0.01 0.1	929 891 100.0% 0.89 [0.52, 1.52] 25 27 able 0.043 (P = 0.66)	929 891 100.0% 0.89 [0.52, 1.52] 25 27 able

Figure 230: Proportion of patients commenting on temperature as hot/warm

	AP matt	ress	AP ove	rlay		Risk Ratio		R	isk Ratio)	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, I	Fixed, 95	% CI	
Nixon 2006	67	929	50	891	100.0%	1.29 [0.90, 1.83]					
Total (95% CI)		929		891	100.0%	1.29 [0.90, 1.83]			•		
Total events	67		50								
Heterogeneity: Not approximately Test for overall effect:		9 = 0.17))				0.01 Favo	0.1 urs AP over	1 lay Favo	10 ours AP n	100 nattress

Figure 231: Proportion of patients commenting on sweaty/sticky temperature

	AP ove	AP overlay AP				Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Nixon 2006	32	929	23	891	100.0%	1.33 [0.79, 2.26]	-
Total (95% CI)		929		891	100.0%	1.33 [0.79, 2.26]	*
Total events Heterogeneity: Not app Test for overall effect:		P = 0.28	23				0.01 0.1 1 10 100 Favours AP overlay Favours AP mattress

Figure 232: Proportion of patients commenting on cold/cool temperature

	AP ove	rlay	AP matt	ress		Risk Ratio			Risk Ratio)	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H	, Fixed, 95	% CI	
Nixon 2006	11	929	11	891	100.0%	0.96 [0.42, 2.20]					
Total (95% CI)		929		891	100.0%	0.96 [0.42, 2.20]					
Total events	11		11								
Heterogeneity: Not appropriate the Test for overall effect:		P = 0.92	2)				0.01 Favo	0.1 urs AP ov	1 erlay Favo	10 ours AP i	100 mattress

Figure 233: Proportion of mattresses not working/not working properly

	AP ove	rlay	AP matt	ress		Risk Ratio			Risk Ratio	1	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H	, Fixed, 95	% CI	
Nixon 2006	16	929	18	891	100.0%	0.85 [0.44, 1.66]					
Total (95% CI)		929		891	100.0%	0.85 [0.44, 1.66]			•		
Total events	16		18								
Heterogeneity: Not app Test for overall effect:		P = 0.64	1)				0.01 Favou	0.1 Irs AP ov	1 erlay Favo	10 ours AP r	100 mattress

Figure 234: Hard to tuck sheet under/sheets come off or gather/mattress cover slips

	AP ove	rlay	AP matt	ress		Risk Ratio		Ri	sk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, F	ixed, 95°	% CI	
Nixon 2006	19	929	6	891	100.0%	3.04 [1.22, 7.57]					
Total (95% CI)		929		891	100.0%	3.04 [1.22, 7.57]			•	>	
Total events	19		6								
Heterogeneity: Not ap Test for overall effect:	•	2 0 00)				0.01	0.1	1	10	100
rest for overall effect.	Z = 2.38 (I	= 0.02	2)				Favou	ırs AP over	lay Favo	urs AP r	nattress

Figure 235: Mattress/bed too high

	AP ove	rlay	AP matt	ress		Risk Ratio		Ri	sk Ratio	1	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, F	ixed, 95	% CI	
Nixon 2006	72	929	48	891	100.0%	1.44 [1.01, 2.05]					
Total (95% CI)		929		891	100.0%	1.44 [1.01, 2.05]			•		
Total events	72		48								
Heterogeneity: Not approximately Test for overall effect:		o = 0.04	1)				0.01 Favo	0.1 urs AP overl	1 ay Favo	10 ours AP n	100 nattress

Figure 236:Mattress slippy




Figure 237: Mattress too soft/edges soft or slope

	AP ove	rlay	AP matt	ress		Risk Ratio		F	Risk Ratio)	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H,	Fixed, 95	% CI	
Nixon 2006	19	929	29	891	100.0%	0.63 [0.35, 1.11]					
Total (95% CI)		929		891	100.0%	0.63 [0.35, 1.11]			•		
Total events	19		29								
Heterogeneity: Not ap	•						0.01	0.1	1	10	100
Test for overall effect:	Z = 1.59 (I	$^{2} = 0.11$	1)				Favou	irs AP ove	erlay Favo	ours AP n	nattress

Figure 238: Not able to use backrest

	AP ove	rlay	AP matt	ress		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	ed, 95% CI		
Nixon 2006	4	929	2	891	100.0%	1.92 [0.35, 10.45]				-	
Total (95% CI)		929		891	100.0%	1.92 [0.35, 10.45]		-		-	
Total events	4		2								
Heterogeneity: Not app Test for overall effect:		P = 0.45	5)				0.01 0 Favours A	.1 AP overlay		0 AP m	100 nattress

Figure 239: Mattress-related fall

	AP ove	rlay	AP matt	ress		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Nixon 2006	0	828	4	891	100.0%	0.14 [0.02, 1.03]	
Total (95% CI)		828		891	100.0%	0.14 [0.02, 1.03]	
Total events	0		4				
Heterogeneity: Not app Test for overall effect:		P = 0.05	5)				0.01 0.1 1 10 100 Favours AP overlay Favours AP mattress

Figure 240: Mattress-related suspected contact dermatitis

•											
	AP ove	rlay	AP matt	ress		Peto Odds Ratio		Peto	Odds Ra	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl		Peto, I	Fixed, 95	i% CI	
Nixon 2006	0	929	1	891	100.0%	0.13 [0.00, 6.54]	+			_	
Total (95% CI)		929		891	100.0%	0.13 [0.00, 6.54]				_	
Total events	0		1								
Heterogeneity: Not ap Test for overall effect:	•	P = 0.31)				0.01 Favou	0.1 urs AP over	1 av Favo	10 ours AP n	100

Figure 241: Mattress-related climbed over/fell through cot sides




Figure 242: Mattress deflation during transfer


	AP ove	rlay	AP matt	ress		Peto Odds Ratio		Peto Od	ds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fixe	ed, 95% CI		
Nixon 2006	0	929	1	891	100.0%	0.13 [0.00, 6.54]	+				
Total (95% CI)		929		891	100.0%	0.13 [0.00, 6.54]					
Total events	0		1								
Heterogeneity: Not app Test for overall effect:		P = 0.31)).1 AP overlay	1 1 Favours A	-	100 nattress

Figure 243: Mortality

	AP matt	ress	AP mattress of	overlay		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fix	ed, 95% CI
Nixon 2006	20	59	12	54	100.0%	1.53 [0.83, 2.82]	-	-
Total (95% CI)		59		54	100.0%	1.53 [0.83, 2.82]		•
Total events	20		12					
Heterogeneity: Not app	plicable						0.01	1 10 100
Test for overall effect:	Z = 1.35 (F	P = 0.18)				0.01 0.1 Favours AP mattress	

1.2.4.7 Alternating-pressure mattress vs air-filled devices

Figure 244: Proportion of people with pressure ulcers completely healed



1.2.4.8 Alternating-pressure cushion vs dry flotation cushion

Figure 245: Proportion of people with pressure ulcers completely healed




Figure 246: Rate of healing cm2/day

	AP	cushi	on	Dry flota	ation cus	hion		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% (CI IV, Fixed, 95% CI
Clark 1998	0.13	0.37	14	0.27	0.56	11	100.0%	-0.14 [-0.52, 0.24]	ı
Total (95% CI)			14			11	100.0%	-0.14 [-0.52, 0.24]	
Heterogeneity: Not ap Test for overall effect:		! (P = 0	0.47)						-100 -50 0 50 100 Favours dry flot. cushion Favours AP cushion

Figure 247: Rate of healing cm3/day

	AP	cushi	on	Dry flot	ation cus	hion		Mean Difference		Me	an Differen	ice	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% (CI	IV,	Fixed, 95%	6 CI	
Clark 1998	0.56	0.86	14	0.49	0.86	11	100.0%	0.07 [-0.61, 0.75]]				
Total (95% CI)			14			11	100.0%	0.07 [-0.61, 0.75]			•		
Heterogeneity: Not ap Test for overall effect:) (P = 0	0.84)						-100 Favours	-50 dry flot. cus	0 hion Favo	50 ours AP cus	100 shion


Figure 248: % change in surface area per day

	AP	cushi	on	Dry flot	ation cus	hion		Mean Difference		Me	an Differer	ice	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	CI .	IV,	Fixed, 95%	6 CI	
Clark 1998	2.56	7.86	14	5.71	5.57	11	100.0%	-3.15 [-8.42, 2.12]					
Total (95% CI)			14			11	100.0%	-3.15 [-8.42, 2.12]			•		
Heterogeneity: Not app Test for overall effect:		(P = 0).24)						-100 Favours	-50 dry flot. cus	0 hion Favo	50 ours AP cus	100 shion

Figure 249: % change in volume per day

	AP	cushic	on	Dry flot	ation cus	hion		Mean Difference		Me	an Differer	ıce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% (CI	IV,	Fixed, 95%	6 CI	
Clark 1998	1	1.83	14	0.68	0.86	11	100.0%	0.32 [-0.76, 1.40]				
Total (95% CI)			14			11	100.0%	0.32 [-0.76, 1.40]			1		
Heterogeneity: Not ap Test for overall effect:		(P = 0).56)						-100 Favours	-50 dry flot. cus	0 shion Favo	50 ours AP cus	100 shion

Figure 250: Mortality



1.2.4.9 Profiling bed vs foam mattress

Figure 251: Proportion of people with healed grade 1 pressure ulcers

	Profiling	j bed	Foam ma	ttress		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Keogh 2001	4	4	2	10	100.0%	3.96 [1.28, 12.24]	
Total (95% CI)		4		10	100.0%	3.96 [1.28, 12.24]	
Total events	4		2				
Heterogeneity: Not ap	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 2.39 (F	P = 0.02)				Favours foam mattress Favours profiling bed

I.2.4.10 Constant force mattress vs LAL mattress

Figure 252: mean % rate of closure per week (%/week)

	orce matt	ress	LAL	mattre	ess		Mean Difference	Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed, 95%	6 CI	
Branom 2001	9	4.8	10	5	3.7	8	100.0%	4.00 [0.07, 7.93]					
Total (95% CI)			10			8	100.0%	4.00 [0.07, 7.93]			•		
Heterogeneity: Not app Test for overall effect:		0.05)							-100 Favou	-50 urs LAL mattr	0 ess Favo	50 ours constar	100 nt force

I.2.4.11 Wheelchair cushion with individualised cyclic pressure-relief protocol vs standard wheelchair cushion

Figure 253: Pressure ulcer closure (cm2)

	Pressure-	relief cus	hion	Standard cushion				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixe	d, 95% CI	
Makhous, 2009	78.5	74.4	22	12.49	52	22	100.0%	66.01 [28.08, 103.94]			\rightarrow
Total (95% CI)			22			22	100.0%	66.01 [28.08, 103.94]			-
Heterogeneity: Not app									-100 -50	0 50	100
lest for overall effect:	st for overall effect: $Z = 3.41$ ($P = 0.0006$)								Favours standard	Favours c	yclic

Figure 254: Pressure ulcer closure rate (cm2/day)

	Pressure-	relief cus	hion	Standard cushion				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI
Makhous, 2009	2.17	1.46	22	0.23	2.04	22	100.0%	1.94 [0.89, 2.99]	
Total (95% CI)			22			22	100.0%	1.94 [0.89, 2.99]	
Heterogeneity: Not app	•								-100 -50 0 50 100
Test for overall effect:	Z = 3.63 (P =	0.0003)							Favours standard Favours cyclic

Figure 255: PUSH score improvement

	Pressure-r	elief cus	hion	Standa	Standard cushion Mean Difference			Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% CI
Makhous, 2009	2.5	2.3	22	0.7	1.1	22	100.0%	1.80 [0.73, 2.87]	.
Total (95% CI) Heterogeneity: Not apple Test for overall effect:		0.0009)	22			22	100.0%	1.80 [0.73, 2.87]	-100 -50 0 50 100 Favours standard Favours cyclic

Figure 256: % surface area reduction

	Pressure-re	elief cus	hion	n Standard cushion			Mean Difference			Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	l	IV, Fi	xed, 95	5% CI	
Makhous, 2009	45	21	22	10.2	34.9	22	100.0%	34.80 [17.78, 51.82]			-	-	
Total (95% CI)			22			22	100.0%	34.80 [17.78, 51.82]			-	•	
Heterogeneity: Not appress for overall effect:		0.0001)							-100 Favou	-50 rs standar	0 d Fav	50 vours cyc	100 clic

Figure 257: % PUSH score improvement

	Pressure-	relief cus	hion	Standard cushion				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI
Makhous, 2009	21.9	24.6	22	5.8	9.2	22	100.0%	16.10 [5.13, 27.07]	-
Total (95% CI)			22			22	100.0%	16.10 [5.13, 27.07]	•
Heterogeneity: Not app Test for overall effect:		0.004)							-100 -50 0 50 100 Favours standard Favours cyclic

I.2.5 Adjunctive therapies

I.2.5.1 Electrotherapy versus placebo or no stimulation

Figure 258: Electrotherapy vs control - Proportion of participants completely healed – end of study




Figure 259: Electrotherapy vs control - Proportion of ulcers completely healed - end of study

	Electroth	Contr	ol		Risk Ratio	Risk Ratio			•		
Study or Subgroup	Events Total		Events	Total	Weight	MH, Fixed, 95% C	1	M·H,	Fixed, 95	5% CI	
1.2.2 Ulcers VVcod, 1993 Subtotal (95% CI)	25	43 43	- 1	31	100.0%	18.02 [2.58, 126.01] 18.02 [2.58, 126.01]					
Total events Heterogenety, Not ap	25	45	1	31	100.078	10.02 [2.50, 120.01]					
Test for overall effect:		=0.004)									
							0.01	0.1 avours con	trol Fau	10 ourselect	100

Figure 260: Electrotherapy vs control - >80% decrease in ulcer area

	Electrothe	Contr	lor		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	MH, Fix	ed, 95% CT
Wood, 1993	31	43	4	31	100.0%	5.59 [2.20, 14.21]	9.7	
Total (95% CI)		43		31	100.0%	5.59 (2.20, 14.21)		•
Total events	31		4					
Heterogeneity: Not ap	plicable						5.0 10.0	1 10 100
Test for overall affect	Z=3.81 (P	=0,0003	ð				Favours control	

Figure 261: Electrotherapy vs control - % ulcers reduced by at least 50% at 3 months

	Bedroth	Contr	ol		Risk Ratio	Risk Ratio	
Study or Subgroup	Events Total		Events	Total	Weight	M-H, Fixed, 95% C	M.H., Fixed, 95% C1
Houghton, 2010	12	15	5	14	100.0%	2.24 [1.06, 4.73]	
Total (95% CI)		15		14	100.0%	2.24 (1.05, 4.73)	•
Total events	12		5				
Heterogeneity: Not app	plicable						201 01 1 10 100
Testion overall effect	Z=2.12(P	0.03)					Favours control Favours electrothers;

Figure 262: Electrotherapy vs control - Proportion with improved PWAT scores

	Electrothe	Contr	lo!		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% 0	I MH, Fixe	ed, 95% CT
Houghton, 2010	12	16	8	18	100.0%	1.69 p.94, 3.04	1	
Total (95% CI)		15		18	100.0%	1.69 (0.94, 3.04)		•
Total events	12		8					
Heterogeneity: Not ap Test for overell effect:		=0.03)					0.1 0.2 0.5 Favours control	2 5 10 Favoure electrolinarap

Figure 263: Electrotherapy vs control - Proportion with improved PSST scores

	Bectrothe	Contr	ol		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M.H. Fixed, 95% C	M-H, Fixed, 95% CI
Houghton, 2010	8	16	9	18	100.0%	1.00 [0.51, 1.98]	
Total (95% CI)		16		18	100.0%	1.00 (0.51, 1.96)	
Total events	8		9				
Heterogeneity: Not app	plicable						total total
Test for overall effect	Z=0.00(P	1.00)					0.1 0.2 0.5 1 2 5 10 Favours control Favours electrotherus

Figure 264: Electrotherapy vs control - proportion of patients with decreased ulcers

	Electrotherapy Control				Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C		Peto, F	ixed, 95% CI	
Asbjornsen, 1990	3	7	0	9	100.0%	13.98 [1.21, 162.00]				—
Total (95% CI)		7		9	100.0%	13.98 [1.21, 162.00]				
Total events	3		0							
Heterogeneity: Not app Test for overall effect:		= 0.03)					0.01 Fa	0.1 avours contr	1 1 ol Favours e	0 100

Figure 265: Electrotherapy vs control - proportion of people with increased pressure ulcers





Figure 266: Electrotherapy vs control - proportion of people with increased pressure ulcers - geriatric patients, pressure ulcer grade not reported


	Electrothe	erapy	Contr	ol		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95%	CI Peto, Fixed, 95% CI
Asbjornsen, 1990	3	7	0	9	100.0%	13.98 [1.21, 162.00	
Total (95% CI)		7		9	100.0%	13.98 [1.21, 162.00	
Total events	3		0				
Heterogeneity: Not app Test for overall effect:		= 0.03)					0.01 0.1 1 10 100 Favours electrotherapy Favours control

Figure 267: Electrotherapy vs control - proportion of people with increased pressure ulcers – community patients with spinal cord injuries, pressure ulcers grade 2 to 4 (NPUAP)

	Electrothe	erapy	Contr	ol		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Houghton, 2010	0	16	4	18	100.0%	0.13 [0.02, 0.98]	
Total (95% CI)		16		18	100.0%	0.13 [0.02, 0.98]	
Total events	0		4				
Heterogeneity: Not app Test for overall effect:		= 0.05)					0.01 0.1 1 10 100 vours electrotherapy Favours control

Figure 268: Electrotherapy vs control - Proportion of ulcers which increased in size, pressure ulcers grade 2 to 3 (classification system not reported)








Figure 270: Electrotherapy vs control - % mean reduction in wound surface area (participants)

	Electr	other	ару	- 0	ortrol			Mean Difference	Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	N, Fixed, 95%	CI IV, Fixed, 95%	0		
1.11.1 patients												
Franek, 2012	88.9	14	26	44.4	63.1	24	586%	44.50 [18.69, 70.31	1) -	-		
Houghton, 2010 Subtratal (95% CI)	70	25	16 42	36	61	18 42	41.4% 100.0%	34.00 B.27, 64.73 40.16 [20.39, 59.92		-		
Heterogeneity: Chi ² = Test for overall effect;				2 = 0 %								
vee 0.13100-310	2											
									100 50 C	50 100		
									Fancura control Fancur	व क्षेत्रदेश व्यवस्था		

Figure 271: Electrotherapy vs control - % mean reduction in wound surface area (ulcers)




Figure 272: Electrotherapy vs control - Healing rate (%/week) (participants)

	Elect	rothera	ру	D	ortrol		Mean Difference			Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	1	IV, Fixe	d. 95% C		
1.15.1 Patients													
Moth, 1988 Subtobal (95% CI)	44.8	22.6	9	-11.69	18.6	7	100.0% 100.0%	56.39 [86.19, 76.59] 58.39 [86.19, 76.58]					
remogeneity: Not ap Test for overall effect:	and the second	(P < 0.	000013										
									-10	-8 Payours commi	d Favours	6 electrothe	10°

Figure 273: Electrotherapy vs control - Healing rate (%/week) (ulcers)

	Electr	other	apy.	E	antra	100		Mean Difference		Mea	in Diff	erence		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	1	N,	fixed	,95% CI		
Baker, 1996	29.7	5.1	58	32.7	7	25	999%	-300 [-6.04, 0.04]			-			
Gentzkow, 1991	12.5	167	21	5.8	187	19	0.1%	6.70 [96.94, 110.34]						-+
Total (95% CI)			79			44	100.0%	-2.99 [-6.03, 0.05]						
Heterogeneity: Chi*=	0.03,df=	1 (P =	0.85);	L= DX					-100	-50	- 1	***	-	100
Test for overall effect:	Z= 1.93	(P = D	25)						100	avours con	rtro1	Fa vours ele		1000

Figure 274: Electrotherapy vs control - Healing rate (%/day) (participants)

	Electr	othera	ру	0	ontrol			Mean Difference		Me	on Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV.	Fixed, 95	% CI	
Karba, 1995	7.13	1.46	6	-0.66	1.16	6	100.0%	7.79 [6.30, 9.28]					
Total (95% CI)			6			6	100.0%	7,79 [6,30, 9,28]			1		
Heterogeneity: Not ap Test for overall effect:		3 (P < 1	0,0000	0					-100 Fa	-50 WOURS CO	û ntro) Fav	50 rours elect	100

Figure 275: Electrotherapy vs control - Healing rate (%/day) (linear fitting)

	Bectr	other	Фy	CC	ontro	1		Mean Difference		Me	an Differe	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	-	N.	Fixed, 98	5% CL -	
Jercinovic, 1994	22	2.1	61	1.5	1.7	48	100.0%	0.70 [-0.01, 1.41]	1				
Total (95% CI)			61			48	100.0%	0.70 [-0.01, 1.41]					
Heterogeneity: Not ap Test for overall effect:		(P=0	05)						-10 F	-5 erous co	Ó ntrol Far	5 rours elect	10 trotherap

Figure 276: Electrotherapy vs control - Healing rate (%/day) (exponential fitting)

1.00 V T W C	Bedr	other	а ру	Co	ontro		100	Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% CI
Jercinovic, 1994	5.7	7.1	01	2.7	3.6	48	100.0%	3.00 [0.95, 5.05]	
Total (95% CI)			61			48	100.0%	3.00 [0.95, 5.05]	4
Helerogenety: Not ay Test for overall effect:		(P=0	.00g						-100 do 6 do 100 Faveus control Favours electrolisespo

Figure 277: Electrotherapy vs control - Healing rate (%/day) (exponential fitting) – crossover group

	Bedr	other:	фу	Co	ontro	d		Mean Difference	Mean Difference
Study or Subgroup	Mean.	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I M, Fixed, 95% CI
Jercinovic, 1994	5	42	20	1.2	2.1	20	100.0%	3.80 [1.74, 5.80]	
Total (95% CI)			20			20	100.0%	3.80 [1.74, 5.86]	4
Heberogeneily: Not ap Test for everal effect		(P=S)	00000						Farry and C de tor

Figure 278: Electrotherapy vs control - Healing rate (%/day) (linear fitting) – crossover group




Figure 279: Electrotherapy vs control - Time to complete healing

	Elect	rother	ару	0	ontro	ł		Mean Difference		Me	ari Dif	ference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed	,95% CI	
Adunsky, 2005	63.4	15.1	9	89.7	9.2	10	100.0%	-26.30 [-37.69, -14.91]					
Total (95% CI)			9			10	100.0%	-26:30 [-37:69,-14:91]		4			
Heterogeneity: Not ap Test for overall effect:		(P < 0.	00001)	F,					-100 vours	-50 electrothe	0 rapy	50 Favours of	 100

Figure 280: Electrotherapy vs control - speed of healing (% change from baseline – days)

	Bect	rothera	ару	C	ontrol			Mean Difference	Mean Di	fference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	N, Fixed, 95% C	IV, Fixe	d, 95% CI
Adunsky, 2005	-0.24	0.14	35	-0.25	0.14	28	100.0%	[80.0,80.0] 10.0		
Total (95% CI)			35			28	100,0%	0.04 [-0.06, 0.08]		
Heterogeneity: Not ap Test for overall effect		(P=0.	78)						-100 -50 Favous control	50 100 Favours electrofherape

Figure 281: Electrotherapy vs control - mean reduction in length (%)

	Bect	rother:	фу		ontrol			Mean Difference		Mean Di	fference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	1	IV, Fixe	d, 95% Cl	
Franek, 2012	74	29.6	26	36.1	33.9	24	100.0%	37.90 [20.20, 55.60]			-	
Total (95% CI)			26			24	100,0%	37.90 [20.20, 55.60]				
Heterogeneity: Not ap Test for overall effect:		(P < 0.	(1000						-100	-50 Secure control	50 Feworas elec	100

Figure 282: Electrotherapy vs control - mean reduction in the longest width (%)

	Bect	rother	фу	.0	ontrol			Mean Difference		Mean D	ifference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	1	IV, Fixed, 95% CI		
Franck, 2012	79	25.1	26	36.3	41.9	24	100.0%	42.70 [23.36,62.04]			-	
Total (95% CI)			26			24	100,0%	42,70 [23,36,62,04]			-	
Heterogeneity: Not ap Test for overall effect			(1000)						-100	-50 svous control	0 50 Favorum elec	100 homeran

Figure 283: Electrotherapy vs control - mean reduction in cavity volume (%)




Figure 284: Electrotherapy vs control - mean reduction in granulation tissue area (%)

	Elec	trother	ару.	(Control			Mean Difference		Mean	Differen	ce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	1	N. Fi	æd, 95%	k CI	
Franek, 2012	37.66	76.17	26	10.36	43.46	24	100.0%	27.30 [-6.75, 61.35]		_			
Total (95% CI)			26			-24	100,0%	27.30 [-6.75,61.35]			-	-	
Helerogeneity: Not ap Test for overall effect:	(2)						-100 F	-50 avours contri	D of Favo	50 urseled	100 rotherapy		

Figure 285: Electrotherapy vs control - Gilman parameter

	Rect	rothera	aDV .	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean	41.11			IV, Fixed, 95% C	
Franek, 2011	0.86	0.45	29	0.42	0.51	29	27.2%	0.44 [0.19, 0.69]	•
Franek, 2012	0.66	024	26	026	0.3	24	72.8%	0.40 [0.25, 0.55]	
Total (95% CI)			55			53	100.0%	0.41 [0.28, 0.54]	
Heterogenally: ChF = Test for overall effect:									-100 -50 0 50 100 Farous corriol Farous decharings

I.2.5.2 Asymmetric biphasic electrostimulation at 100μsec versus control

Figure 27: Asymmetric biphasic electrostimulation at 100μsec vs control; mean reduction in wound surface area (%/week)

	Asymmet	Asymmetric biphasic			ontro	l		Mean Difference	Mean	Differenc	е	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fix	ed, 95%	CI	
Baker, 1996	36.4	6.2	67	32.7	7	25	100.0%	3.70 [0.58, 6.82]				
Total (95% CI)			67			25	100.0%	3.70 [0.58, 6.82]		\		
Heterogeneity: Not app Test for overall effect:		= 0.02)							 + 50 urs contro	0 ol Favou	50 rs asy	100 mmetric


1.2.5.3 Symmetric biphasic electrostimulation at 300µsec versus control

Figure 28: Symmetric biphasic electrostimulation at 300μsec vs control; mean reduction in wound surface area (%/week)

	Symmet	Symmetric biphasic			ontro	ı		Mean Difference		Mean	Diffe	rence		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fix	ed, 9	95% CI		
Baker, 1996	29.7	5.1	58	32.7	7	25	100.0%	-3.00 [-6.04, 0.04]						
Total (95% CI)			58			25	100.0%	-3.00 [-6.04, 0.04]			•			
Heterogeneity: Not app Test for overall effect:		= 0.05)							-100	-50 Favours contro	0 I F	5 avours sy	-	100 etric bipha


1.2.5.4 Microcurrent versus control

Figure 29: Microcurrent vs control; mean reduction in wound surface area (%/week)




1.2.5.5 Asymmetric biphasic electrostimulation at 100μsec versus 300μsec

Figure 30: Asymmetric biphasic electrostimulation at 100usec vs symmetric biphasic electrostimulation at 300usec vs control; mean reduction in wound surface area (%/week)




1.2.5.6 Asymmetric biphasic electrostimulation at 100μsec versus microcurrent

Figure 31: Asymmetric biphasic electrostimulation at 100μsec versus microcurrent; mean reduction in wound surface area (%/week)



1.2.5.7 Asymmetric biphasic electrostimulation at 300µsec versus microcurrent

Figure 32: Asymmetric biphasic electrostimulation at 300μsec versus microcurrent; mean reduction in wound surface area (%/week)



1.2.5.8 Hard to heal ulcers (grade 3 and 4) electrotherapy vs control

Figure 286: proportion of participants completely healed

Adunsky, 2005 9 35 10 28 88.1% 0.72 [0.34, 1.53] Griffin, 1991 1 6 0 7 3.7% 3.43 [0.16, 71.36] Houghton, 2010 5 15 1 14 8.2% 4.67 [0.62, 35.17] Subtotal (95% CI) 56 49 100.0% 1.14 [0.60, 2.20]												
Adunsky, 2005 9 35 10 28 88.1% 0.72 [0.34, 1.53] Griffin, 1991 1 6 0 7 3.7% 3.43 [0.16, 71.36] Houghton, 2010 5 15 1 14 8.2% 4.67 [0.62, 35.17] Subtotal (95% CI) 56 49 100.0% 1.14 [0.60, 2.20] Fotal events 15 11 Heterogeneity: Chi² = 3.82, df = 2 (P = 0.15); l² = 48% Fest for overall effect: Z = 0.40 (P = 0.69)		Electrothe	erapy	Contr	ol		Risk Ratio		F	lisk Ratio		
Adunsky, 2005 9 35 10 28 88.1% 0.72 [0.34, 1.53] Griffin, 1991 1 6 0 7 3.7% 3.43 [0.16, 71.36] Houghton, 2010 5 15 1 14 8.2% 4.67 [0.62, 35.17] Subtotal (95% CI) 56 49 100.0% 1.14 [0.60, 2.20] Fotal events 15 11 Heterogeneity: Chi² = 3.82, df = 2 (P = 0.15); l² = 48% Fest for overall effect: Z = 0.40 (P = 0.69)	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H,	Fixed, 959	% CI	
Griffin, 1991 1 6 0 7 3.7% 3.43 [0.16, 71.36] Houghton, 2010 5 15 1 14 8.2% 4.67 [0.62, 35.17] Subtotal (95% CI) 56 49 100.0% 1.14 [0.60, 2.20] Fotal events 15 11 Heterogeneity: Chi² = 3.82, df = 2 (P = 0.15); l² = 48% Fest for overall effect: Z = 0.40 (P = 0.69)	14.1.1 patients											
Houghton, 2010 5 15 1 14 8.2% 4.67 [0.62, 35.17] Subtotal (95% CI) 56 49 100.0% 1.14 [0.60, 2.20] Fotal events 15 11 Heterogeneity: Chi² = 3.82, df = 2 (P = 0.15); l² = 48% Fest for overall effect: Z = 0.40 (P = 0.69)	Adunsky, 2005	9	35	10	28	88.1%	0.72 [0.34, 1.53]		-			
Subtotal (95% CI) 56 49 100.0% 1.14 [0.60, 2.20] Fotal events 15 11 Heterogeneity: Chi² = 3.82, df = 2 (P = 0.15); l² = 48% Fest for overall effect: Z = 0.40 (P = 0.69)	Griffin, 1991	1	6	0	7	3.7%	3.43 [0.16, 71.36]			-		
Fotal events 15 11 Heterogeneity: Chi² = 3.82, df = 2 (P = 0.15); l² = 48% Fest for overall effect: Z = 0.40 (P = 0.69)	Houghton, 2010	5	15	1	14	8.2%	4.67 [0.62, 35.17]				-	_
Heterogeneity: Chi² = 3.82, df = 2 (P = 0.15); l² = 48% Fest for overall effect: Z = 0.40 (P = 0.69)	Subtotal (95% CI)		56		49	100.0%	1.14 [0.60, 2.20]					
Test for overall effect: Z = 0.40 (P = 0.69)	Total events	15		11								
0.01 0.1 1 10 100	Heterogeneity: Chi2 =	3.82, df = 2	P = 0.15	5); I ² = 48 ⁴	%							
****	Test for overall effect:	Z = 0.40 (P = 0.40)	= 0.69)									

****								0.01	0.1	1	10	100
									•	trol Favo		

Figure 287: Mortality

	Electrothe	erapy	Contr	rol		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	l	M-H, Fixe	ed, 95% CI	
Kloth, 1988	0	9	0	7		Not estimable				
Total (95% CI)		9		7		Not estimable				
Total events	0		0							
Heterogeneity: Not appli Test for overall effect: N		ماد				_		0.1	1 10	100
rest for overall effect. IN	ot applicat	ne .				Fa	vours elec	ctrotherapy	Favours con	trol

Figure 288: Absolute reduction in size of pressure ulcer at end of treatment (cm)

	Electr	Electrotherapy Control Mean SD Total Mean SD Total						Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Adunsky, 2005	11.15	1.1	21	16.7	1	25	100.0%	-5.55 [-6.16, -4.94]	•
Total (95% CI)			21			25	100.0%	-5.55 [-6.16, -4.94]	
Heterogeneity: Not ap Test for overall effect:	•	(P < 0	0.0000	1)					-100 -50 0 50 100 Favours control Favours electrotherapy

Figure 289: Absolute reduction in size of pressure ulcer at end of follow-up (cm)

	Elect	Electrotherapy Control						Mean Difference		Mea	n Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 95	% CI	
Adunsky, 2005	2.53	2.11	21	2.88	1.92	25	100.0%	-0.35 [-1.53, 0.83]					
Total (95% CI)			21			25	100.0%	-0.35 [-1.53, 0.83]			1		
Heterogeneity: Not ap Test for overall effect:		(P = 0.	.56)						-100 F:	-50 avours con	0 trol Fav	50 ours elect	100 rotherapy

Figure 290: healing rate (%/week)





Figure 291: time to complete healing (days)

	Elect	rothera	ару	C	ontro) l		Mean Difference		Mean I	Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95%	CI	IV, Fix	ed, 95% C	1	
Adunsky, 2005	63.4	15.1	9	89.7	9.2	10	100.0%	-26.30 [-37.69, -14.9	1]	-			
Total (95% CI)			9			10	100.0%	-26.30 [-37.69, -14.9	1]	•			
Heterogeneity: Not ap Test for overall effect:		(P < 0.	.00001))					-100 Favours	-50	0 / Favours	50 s contro	100

Figure 292: speed of healing (% change from baseline – days)



I.2.5.9 NPWT vs wet-to-wet or wet-to dry gauze

Figure 293: Time to 50% of initial wound volume

	NPWT				ry/wet-to-we	et	Mean Difference			Mean Di	fference		
Study or Subgroup	Mean	SD	Total	Mean	SD T	otal	Weight	IV, Fixed, 95% CI		IV, Fixe	d, 95% CI		
Wanner, 2003	27	10	11	28	7	11	100.0%	-1.00 [-8.21, 6.21]					
Total (95% CI)			11			11	100.0%	-1.00 [-8.21, 6.21]		•	•		
Heterogeneity: Not ap Test for overall effect:		(P =	0.79)						-100	-50 (Favours NPWT		+ 50 Wet-to	100 o-wet/ddr

I.2.5.10 NPWT vs modern dressings: wound gel products

Figure 4: Pressure ulcers healed within 6 weeks

	NPW	Т	Modern dres	ssings		Risk Ratio		Ris	k Ratio)	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fi	ixed, 95	% CI	
Ford, 2002	2	20	2	15	100.0%	0.75 [0.12, 4.73]				_	
Total (95% CI)		20		15	100.0%	0.75 [0.12, 4.73]				_	
Total events	2		2								
Heterogeneity: Not approximately Test for overall effect:		P = 0.7	(6)			Favo	0.01 ours mo	0.1 odern dressing	1 Favo	10 ours NPW	100 T

1.2.5.11 NPWT vs spun hydrocolloid dressing, a foam dressing or an alginate dressing

Figure 294: Proportion completely healed

	NPWT		Dressii	ngs		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (Peto, Fixed, 95% CI
Ashby, 2012	1	6	0	6	100.0%	7.39 [0.15, 372.38	
Total (95% CI)		6		6	100.0%	7.39 [0.15, 372.38]	
Total events	1		0				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect: 2	Z = 1.00 (P = 0.3	2)				0.01 0.1 1 10 100 Favours dressings Favours NPWT

Figure 295: Mortality

	NPW	Т	Dressi	ngs		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI
Ashby, 2012	2	6	0	6	100.0%	9.03 [0.49, 165.19]	
Total (95% CI)		6		6	100.0%	9.03 [0.49, 165.19]	
Total events	2		0				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect: 2	Z = 1.48 (l	P = 0.1	4)				Favours NPWT Favours dressing

Figure 296: Pain

	NPW	Т	Dressii	ngs		Peto Odds Ratio	Peto Od	ds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixe	ed, 95% CI
Ashby, 2012	1	6	0	6	100.0%	7.39 [0.15, 372.38]		
Total (95% CI)		6		6	100.0%	7.39 [0.15, 372.38]		
Total events	1		0					
Heterogeneity: Not app	olicable						0.01 0.1	10 100
Test for overall effect:	Z = 1.00 (I	P = 0.32	2)					10 100 Favours dressings

I.2.6 Debridement

Figure 297: Collagenase ointment versus preparation of inactivated collagenase - proportion of pressure ulcers that decreased in volume.

	Collage	nase	Inactivated collag	genase		Peto Odds Ratio	Peto Od	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI	
Lee 1975	8	17	0	11	100.0%	9.24 [1.78, 48.04]			
Total (95% CI)		17		11	100.0%	9.24 [1.78, 48.04]			-
Total events	8		0						
Heterogeneity: Not app Test for overall effect:		= 0.008))				0.01 0.1 Favours inactivated colla	1 10 Favours collage	100 nase

Figure 298: Collagenase versus preparation of inactivated collagenase - proportion of pressure ulcers that increased in volume.

	Collage	nase	Inactivated collag	genase		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	red, 95% CI		
Lee 1975	4	17	6	11	100.0%	0.43 [0.16, 1.19]					
Total (95% CI)		17		11	100.0%	0.43 [0.16, 1.19]		•			
Total events	4		6								
Heterogeneity: Not app Test for overall effect:		= 0.10)					0.01 Fav	0.1 ours collagenas		0 ctivat	100 ed colla

Figure 299: Collagenase versus preparation of inactivated collagenase - proportion of pressure ulcers with odor at the end of treatment.

	Collage	nase	Inactivated collagenase			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Lee 1975	7	17	5	11	100.0%	0.91 [0.38, 2.14]	_
Total (95% CI)		17		11	100.0%	0.91 [0.38, 2.14]	•
Total events	7		5				
0 , 11	Heterogeneity: Not applicable Fest for overall effect: Z = 0.22 (P = 0.82)						0.01 0.1 1 10 100 Favours collagenase Favours inactivated colla

Figure 300: Collagenase versus preparation of inactivated collagenase - number of side effects observed

	Collagenase			genase	Peto Odds Ratio			Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fixe	ed, 95% CI			
Lee 1975	1	17	0	11	100.0%	5.19 [0.09, 287.21]						
Total (95% CI)		17		11	100.0%	5.19 [0.09, 287.21]						
Total events	1		0									
Heterogeneity: Not app	olicable						0.01	0.1	1 10	100		
Test for overall effect: 2	Z = 0.80 (P	= 0.42)						avours collagenase	Favours inactiva			

Figure 301: Collagenase versus preparation of inactivated collagenase - mortality

	Collage	nase	Inactivated colla	genase		Peto Odds Ratio	Peto O	dds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l Peto, Fix	red, 95% CI
Lee 1975	0	17	0	11		Not estimable		
Total (95% CI)		17		11		Not estimable		
Total events	0		0					
Heterogeneity: Not ap Test for overall effect:		able					0.01 0.1 Favours collagenase	1 10 100 Favours inactivated

Figure 302: Collagenase versus Dextranomer - proportion of pressure ulcers that improved

	Collage	nase	Drextranomer			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Parish 1979	5	11	12	14	100.0%	0.53 [0.27, 1.05]	-
Total (95% CI)		11		14	100.0%	0.53 [0.27, 1.05]	•
Total events	5		12				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.82 (P	= 0.07)					Favours dextranomer Favours collagenase

Figure 303: Collagenase versus Dextranome - proportion of pressure ulcers that closed

	Collage	nase	Dextran	omer		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI			
Parish 1979	1	11	6	14	100.0%	0.21 [0.03, 1.51]					
Total (95% CI)		11		14	100.0%	0.21 [0.03, 1.51]					
Total events	1		6								
Heterogeneity: Not app	olicable						0.01 0.1	1 10 100			
Test for overall effect:	Z = 1.55 (P	= 0.12)					Favours dextranomer	Favours collagenase			

Figure 304: Collagenase versus dextranomer, outcome: 2.3 Proportion of patients with pressure ulcers closure

	Collage	nase	Dextranomer			Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI				
Parish 1979	1	5	4	7	100.0%	0.35 [0.05, 2.26]					
Total (95% CI)		5		7	100.0%	0.35 [0.05, 2.26]					
Total events	1		4								
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100				
Test for overall effect:	Z = 1.10 (P	= 0.27)					Favours dextranomer Favours collagenase				

Figure 305: Collagenase versus Dextranomer - proportion of patients that improved

	Collagei	nase	Dextran	omer		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Parish 1979	2	5	7	7	100.0%	0.44 [0.17, 1.16]	
Total (95% CI)		5		7	100.0%	0.44 [0.17, 1.16]	
Total events	2		7				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.65 (P	= 0.10)					Favours dextranomer Favours collagenase

Figure 306: Collagenase versus Dextranomer - proportion of PU improved after 1 week

	Collage	nase	Dextranomer			Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI			
Parish 1979	0	11	6	14	100.0%	0.10 [0.02, 0.64]					
Total (95% CI)		11		14	100.0%	0.10 [0.02, 0.64]					
Total events	0		6								
Heterogeneity: Not app	olicable						0.01 0.1	1 10 100			
Test for overall effect:	Z = 2.44 (P	= 0.01)					Favours dextranomer	Favours collagenase			

Figure 307: Collagenase versus Dextranomer - proportion of pressure ulcers improved after 1 month.

Collager	nase	Dextranomer			Risk Ratio	Risk Ratio				
Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI				
3	11	8	14	100.0%	0.48 [0.16, 1.39]					
	11		14	100.0%	0.48 [0.16, 1.39]					
3		8								
	= 0.17)					0.01 0.1 1 10 100 Favours dextranomer Favours collagenase				
	Events 3 olicable	3 11 11 3	EventsTotalEvents31181138olicable8	Events Total Events Total 3 11 8 14 11 14 3 14 3 8 8 9 olicable 9 <t< td=""><td>Events Total Events Total Weight 3 11 8 14 100.0% 11 14 100.0% 3 8 8</td><td>Events Total Events Total Weight M-H, Fixed, 95% CI 3 11 8 14 100.0% 0.48 [0.16, 1.39] 11 14 100.0% 0.48 [0.16, 1.39] 3 8 8</td></t<>	Events Total Events Total Weight 3 11 8 14 100.0% 11 14 100.0% 3 8 8	Events Total Events Total Weight M-H, Fixed, 95% CI 3 11 8 14 100.0% 0.48 [0.16, 1.39] 11 14 100.0% 0.48 [0.16, 1.39] 3 8 8				

Figure 308: Collagenase versus Dextranomer - proportion of pressure ulcers improved after 2 months

	Collage	nase	Dextran	omer		Risk Ratio			Risk F	latio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-	H, Fixed	95% CI		
Parish 1979	5	11	8	14	100.0%	0.80 [0.36, 1.75]			-	_		
Total (95% CI)		11		14	100.0%	0.80 [0.36, 1.75]				>		
Total events	5		8									
Heterogeneity: Not app	olicable						0.01	0.1	+		10	100
Test for overall effect:	Z = 0.57 (P	= 0.57)						ırs dextran	omer	Favours	collage	

Figure 309: Collagenase versus Dextranomer - proportion improved after > 2 months

	Collage	nase	Dextran	omer				Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI			M-H, Fixe	d, 95% CI		
Parish 1979	5	11	12	14	100.0%	0.53 [0.27, 1.05]			-	†		
Total (95% CI)		11		14	100.0%	0.53 [0.27, 1.05]			•			
Total events	5		12									
Heterogeneity: Not app	plicable						0.01	0.	1	1	10	100
Test for overall effect:	Z = 1.82 (P	= 0.07)						-	ktranomer	Favours	collage	

Figure 310: Collagenase versus sugar and egg white - proportion of pressure ulcers that improved

	Collage	nase	Sugar and egg	white		Peto Odds Ratio		Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l	Peto, Fi	xed, 95% CI			
Parish 1979	5	11	0	9	100.0%	10.00 [1.38, 72.67]						
Total (95% CI)		11		9	100.0%	10.00 [1.38, 72.67]						
Total events	5		0									
Heterogeneity: Not app	olicable						0.01	0.1	+	10	100	
Test for overall effect: 2	Z = 2.28 (P	= 0.02)					• • • •	sugar and egg whi	Favours co	llagena		

Figure 311: Collagenase versus sugar and egg white - proportion of pressure ulcers that closed

Collagenase			Sugar and egg	white		Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l	Pete	, Fixed, 95%	CI	
Parish 1979	1	11	0	9	100.0%	6.16 [0.12, 316.67]					─
Total (95% CI)		11		9	100.0%	6.16 [0.12, 316.67]					
Total events	1		0								
Heterogeneity: Not app Test for overall effect: 2		= 0.37)					0.01 Favours	0.1 sugar and egg	1 whi Favou	10 urs collagena	100

Figure 312: Collagenase versus sugar and egg white - proportion of patients with pressure ulcers closure

Collagenase			Sugar and egg	white		Peto Odds Ratio			Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l	Peto,	Fixed, 95% (CI			
Parish 1979	1	5	0	5	100.0%	7.39 [0.15, 372.38]							
Total (95% CI)		5		5	100.0%	7.39 [0.15, 372.38]							
Total events	1		0										
Heterogeneity: Not app							0.01	0.1	1	10	100		
Test for overall effect: 2	Z = 1.00 (P	= 0.32)					Favours	sugar and egg v	vhi Favour	s collagena	se		

Figure 313: Collagenase versus sugar and egg white - proportion of patients that improved

	Collagenase		Sugar and egg white			Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fixe	ed, 95% CI	
Parish 1979	2	5	0	5	100.0%	9.49 [0.50, 179.46]		_		
Total (95% CI)		5		5	100.0%	9.49 [0.50, 179.46]		_		
Total events	2		0							
Heterogeneity: Not app		0.40					0.01	0.1	1 10	100
Test for overall effect: 2	∠ = 1.50 (P	= 0.13)					Favours su	ugar and egg whi	Favours collag	enase

Figure 314: Collagenase versus sugar and egg white - proportion of pressure ulcers improved after 1 week

	Collage	Collagenase Sugar and egg white				Peto Odds Ratio		Peto Odds Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	l	Pet	to, Fixe	ed, 95% CI			
Parish 1979	0	11	0	9		Not estimable							
Total (95% CI)		11		9		Not estimable							
Total events	0		0										
Heterogeneity: Not app	licable						0.01	0.1		<u> </u>	10	100	
Test for overall effect: N	Not applicat	ole						ugar and eg	g whi	Favours coll			

Figure 315: Collagenase versus sugar and egg white - proportion of pressure ulcers improved after 1 month

	Favours collag	enase	Favours sugar and e	gg whi		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Parish 1979	3	11	0	9	100.0%	7.63 [0.69, 84.50]	-
Total (95% CI)		11		9	100.0%	7.63 [0.69, 84.50]	
Total events	3		0				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.66 (P = 0.10)						Favours sugar and egg whi Favours collagenase

Figure 316: Collagenase versus sugar and egg white - proportion of pressure ulcers improved after 2 months

	Experim	ental	Contr	rol		Peto Odds Ratio	Peto Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI	
Parish 1979	5	11	0	9	100.0%	10.00 [1.38, 72.67]		_
Total (95% CI)		11		9	100.0%	10.00 [1.38, 72.67]		_
Total events	5		0					
Heterogeneity: Not app	olicable						0.01 0.1 1 10	100
Test for overall effect: 2	Z = 2.28 (P	= 0.02)					Favours sugar and egg whi Favours collagenase	100

Figure 317: Collagenase versus papain/urea- percentage reduction in pressure ulcers size after 1 week

	Coll	agenas	se	papa	in/ure	a		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Alvarez 2000	5.8	17.4	10	1.9	7.6	11	100.0%	3.90 [-7.78, 15.58]	+
Total (95% CI)			10			11	100.0%	3.90 [-7.78, 15.58]	•
Heterogeneity: Not app Test for overall effect: 2		P = 0.5	51)						-100 -50 0 50 100 Favours papain/urea Favours collagenase

Figure 318: Collagenase versus papain/urea - percentage reduction in pressure ulcers size after 2 weeks

Collage		agenas	se	Papain/urea			Mean Difference	Mean D			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixe	d, 95% CI	
Alvarez 2000	19.9	29.2	10	23.7	25.8	11	100.0%	-3.80 [-27.46, 19.86]		_	
Total (95% CI)			10			11	100.0%	-3.80 [-27.46, 19.86]	⋖		
Heterogeneity: Not app Test for overall effect: 2		(P = 0.7	'5)						-100 -50 Favours papain/urea	0 50 Favours colla	100 Igenase

Figure 319: Collagenase versus papain/urea - percentage reduction in pressure ulcers size after 3 weeks

Collagenase		se	Papain/urea				Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Alvarez 2000	27.3	28.5	10	34.8	25.2	11	100.0%	-7.50 [-30.60, 15.60]	—
Total (95% CI)			10			11	100.0%	-7.50 [-30.60, 15.60]	
Heterogeneity: Not approximately Test for overall effect:		P = 0.5	52)						-100 -50 0 50 100 Favours papain/urea Favours collagenase

Figure 320: Collagenase versus papain/urea, outcome - percentage reduction in pressure ulcers size after 4 weeks

	Col	lagenas	е	Papa	ain/ure	a		Mean Difference		Mean	Differen	ce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fix	ed, 95%	CI	
Alvarez 2000	33.9	26.17	10	55.4	33.5	11	100.0%	-21.50 [-47.09, 4.09]		_	+		
Total (95% CI)			10			11	100.0%	-21.50 [-47.09, 4.09]					
Heterogeneity: Not app Test for overall effect:		P = 0.10)						-100 Favo	-50 urs papain/urea	0	50 ours collage	100

Figure 321: Collagenase versus papain/urea, outcome - number of side effects observed

	Collagenase		Papain/	urea		Peto Odds Ratio	Peto Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixe	ed, 95% CI	
Alvarez 2000	1	10	0	11	100.0%	8.17 [0.16, 413.39]			→
Total (95% CI)		10		11	100.0%	8.17 [0.16, 413.39]			
Total events	1		0						
Heterogeneity: Not app	olicable						0.01 0.1	1 10	100
Test for overall effect:	Z = 1.05 (P	= 0.29)					Favours papain/urea	Favours collagen	

Figure 322: Collagenase versus fibrinolysis/DNAse - proportion of persons reporting adverse events

	Collage	nase	Fibrinolysis/D	NAse		Risk Ratio		Risk Ratio)	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M	-H, Fixed, 95	% CI	
Püllen 2002	45	66	34	69	100.0%	1.38 [1.03, 1.85]				
Total (95% CI)		66		69	100.0%	1.38 [1.03, 1.85]		•		
Total events	45		34							
Heterogeneity: Not app	licable						0.01 0.1		10	100
Test for overall effect: 2	Z = 2.19 (P	= 0.03)					Favours colla	genase Fav	ours fibrinoly:	

Figure 323: Collagenase versus fibrinolysis/DNAse - proportion of serious adverse events

6					,	p p			
	Collage	nase	Fibrinolysis/	DNAse		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixe	ed, 95% CI	
Püllen 2002	54	118	24	103	100.0%	1.96 [1.31, 2.93]		-	
Total (95% CI)		118		103	100.0%	1.96 [1.31, 2.93]		•	
Total events	54		24						
Heterogeneity: Not ap	plicable							10 100	
Test for overall effect:	7 = 3.29 (F	= 0.00	10)				0.01 0.1 1		
. SSC .S. SVOIGH OHOOL.	_ = 5.20 (1	- 5.00	. 0,				Favours collagenase	Favours fibrinolysis/DNAs	

Figure 324: Collagenase versus hydrocolloid dressing - proportion of patients with reduction in pressure ulcers area after 12 weeks of treatment.

	Collage	nase	Hydrocolloid dr	essing		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI	
Burgos 2000 (a)	15	18	14	19	100.0%	1.13 [0.81, 1.59]		-	
Total (95% CI)		18		19	100.0%	1.13 [0.81, 1.59]		•	
Total events	15		14						
Heterogeneity: Not app	licable						0.01 0.1	1 10	100
Test for overall effect: 2	Z = 0.71 (P)	= 0.48)					Favours hydrocolloid dres	Favours collagena	

Figure 325: Collagenase versus hydrocolloid dressing - proportion of patients with complete healing of pressure ulcers

	Collage	nase	Hydrocolloid dr	essing		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI	
Burgos 2000 (a)	3	18	3	19	28.6%	1.06 [0.24, 4.57]		+	
Muller 2001	11	12	7	11	71.4%	1.44 [0.89, 2.32]		+	
Total (95% CI)		30		30	100.0%	1.33 [0.80, 2.23]		•	
Total events	14		10						
Heterogeneity: Chi ² = 0	0.20, df = 1	(P = 0.6)	5); I ² = 0%				0.01 0.1	+ -	10 100
Test for overall effect: 2	Z = 1.09 (P	= 0.28)					Favours hydrocolloid dres	Favours col	

Figure 326: Collagenase versus hydrocolloid dressing - mean reduction in pressure ulcers area after 12 weeks of treatment

	Coll	agena	se	Hydrocoll	oid dress	sing		Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	I IV, Fixed, 95% CI	
Burgos 2000 (a)	9.1	12.7	18	6.2	9.8	19	100.0%	2.90 [-4.44, 10.24]	#	
Total (95% CI)			18			19	100.0%	2.90 [-4.44, 10.24]	•	
Heterogeneity: Not app Test for overall effect:		P = 0.4	14)						-100 -50 0 50 1 Favours hydrocolloid dres Favours collagenase	00

Figure 327: Collagenase versus hydrocolloid dressing - mean time to healing (weeks).

_	Collager		se	Hydrocolle	oid dress	ing		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Muller 2001	10	1.5	12	14	1.2	11	100.0%	-4.00 [-5.11, -2.89]	
Total (95% CI)			12			11	100.0%	-4.00 [-5.11, -2.89]	•
Heterogeneity: Not ap Test for overall effect:		P < 0.0	00001)						-100 -50 0 50 100 Favours collagenase Favours hydrocolloid dres

Figure 328: Collagenase versus hydrocolloid dressing - proportion of patients reporting adverse events

	Collage	nase	Hydrocolloid dr	essing		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI	
Burgos 2000 (a)	1	18	2	19	100.0%	0.53 [0.05, 5.33]			
Total (95% CI)		18		19	100.0%	0.53 [0.05, 5.33]			
Total events	1		2						
Heterogeneity: Not app	olicable						0.01 0.1	1 10	100
Test for overall effect: 2	Z = 0.54 (P)	= 0.59)					Favours collagenase	Favours hydrocolloi	

Figure 329: Collagenase versus hydrocolloid dressing - mortality

	Collagen	ase	Hydrocolloid dre	essing		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Burgos 2000 (a)	3	18	1	19	100.0%	3.17 [0.36, 27.72]	-
Muller 2001	0	12	0	12		Not estimable	
Total (95% CI)		30		31	100.0%	3.17 [0.36, 27.72]	
Total events	3		1				
Heterogeneity: Not ap	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.04 (P	= 0.30)				Favours collagenase Favours hydrocolloid

Figure 330: Collagenase ointment application every 24 hours versus every 48 hours - proportion of pressure ulcers that showed complete healing after 8 weeks.

	Collagenase ever	y 24 h	Collagenase ev	ery 48 h		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI	
Burgos 2000 (b)	12	43	9	43	100.0%	1.33 [0.63, 2.83]	_	_	
Total (95% CI)		43		43	100.0%	1.33 [0.63, 2.83]	•	•	
Total events	12		9						
Heterogeneity: Not app	olicable						0.01 0.1	1 10	100
Test for overall effect:	Z = 0.75 (P = 0.45)						Favours every 48 h	Favours every	

Figure 331: Collagenase ointment application every 24 hours versus every 48 hours - proportion of patients reporting adverse events.

	Collagenase ever	y 24 h	Collagenase ever	y 48 h		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Burgos 2000 (b)	3	46	3	46	100.0%	1.00 [0.21, 4.70]	
Total (95% CI)		46		46	100.0%	1.00 [0.21, 4.70]	
Total events	3		3				
Heterogeneity: Not app Test for overall effect: 2							0.01 0.1 1 10 100 Favours every 24 h Favours every 48 h

Figure 332: Collagenase ointment application every 24 hours versus every 48 hours - mortality

	Collagenase eve	ry 24 h	Collagenase ev	ery 48 h		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixe	ed, 95% C	I	
Burgos 2000 (b)	4	46	7	46	100.0%	0.57 [0.18, 1.82]			_		
Total (95% CI)		46		46	100.0%	0.57 [0.18, 1.82]			-		
Total events	4		7								
Heterogeneity: Not ap Test for overall effect:	•						0.01 C		1 10 Favours) 48 h	100 ours

Figure 333: Collagenase versus hydrogel: proportion of people with pressure ulcers completely healed

	Collage	nase	Hydro	gel		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Milne, 2012	9	13	3	14	100.0%	3.23 [1.11, 9.39]	
Total (95% CI)		13		14	100.0%	3.23 [1.11, 9.39]	-
Total events	9		3				
Heterogeneity: Not app	olicable						
Test for overall effect:	Z = 2.16 (F	P = 0.03)				0.01 0.1 1 10 100 Favours hydrogel Favours collagenase

Figure 334: Collagenase versus hydrogel: mortality

	Collage	nase	Hydro	gel		Peto Odds Ratio		Peto Od	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	CI	Peto, Fix	ed, 95% CI	
Milne, 2012	0	13	0	14		Not estimable	e			
Total (95% CI)		13		14		Not estimable	e			
Total events	0		0							
Heterogeneity: Not app Test for overall effect:		able					0.01	0.1	1 10	100
							ravours	collagenase	Favours hydr	ogel

I.2.7 Topical antimicrobials and antibiotics

1.2.7.1 Saline vs. hydrocolloid dressing

Figure 335: Saline versus hydrocolloid dressing – proportion of patients completely healed




Figure 336: Saline versus hydrocolloid dressing – proportion of ulcers completely healed (all grades – all sites)

0		,						
	Salin	е	Hydroco	olloid		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI M-H, Fixed, 95% C	CI
9.2.1 General popular	tion							
Neill 1989	10	45	13	42	37.3%	0.72 [0.35, 1.46]] —	
Subtotal (95% CI)		45		42	37.3%	0.72 [0.35, 1.46]	◆	
Total events	10		13					
Heterogeneity: Not app	plicable							
Test for overall effect:	Z = 0.92 (P = 0.3	6)					
9.2.2 Patients with a	spinal cor	d injur	у					
Hollisaz 2004	8	30	23	31	62.7%	0.36 [0.19, 0.67	ı -	
Subtotal (95% CI)		30		31	62.7%	0.36 [0.19, 0.67]	◆	
Total events	8		23					
Heterogeneity: Not app	plicable							
Test for overall effect:	Z = 3.19 (P = 0.0	01)					
Total (95% CI)		75		73	100.0%	0.49 [0.31, 0.78]	•	
Total events	18		36					
Heterogeneity: Chi ² = 2	2.05, df =	1 (P = 0).15); I ² = 5	51%			0.01 0.1 1 1	0 100
Test for overall effect:	Z = 2.99 (1	P = 0.0	03)			F	avours hydrocolloid Favours	
Test for subgroup diffe	rences: C	$hi^2 = 2.0$	05, df = 1	(P = 0.1)	5), $I^2 = 51$.	.2%	avours rigaroconoid i avours	oaiii io

Figure 337: Saline versus hydrocolloid dressing – proportion of ulcers completely healed (grade I – all sites)

	Salin	1e	Hydroco	biolic		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 959	CI
Hollisaz 2004	5	11	11	13	100.0%	0.54 [0.27, 1.07	1 -	
Total (95% CI)		11		13	100.0%	0.54 [0.27, 1.07]	1	
Total events	5		11					
Heterogeneity: Not as	plicable						0.01 0.1 1	10 100
Test for overall effect	Z = 1.77	(P = 0.0)	08)				Favours hydrocolloid Favo	1 1 2 1

Figure 338: Saline versus hydrocolloid dressing – proportion of ulcers completely healed (grade II – all sites)




Figure 339: Saline versus hydrocolloid dressing – proportion of ulcers completely healed (grade III – all sites)

10		,					
	Salin	1e	Hydroco	biollo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Neill 1989	1	11	2	17	100.0%	0.77 [0.08, 7.54	1 -
Total (95% CI)		11		17	100.0%	0.77 [0.08, 7.54	
Total events	1		2				
Heterogeneity: Not ap	plicable						0.01 0.1 10 100
Test for overall effect	Z = 0.22	(P = 0.8)	32)				0.01 0.1 1 10 100 Favours hydrocolloid Favours saline

Figure 340: Saline versus hydrocolloid dressing – proportion of ulcers completely healed (all grades – sacral area)

	Salin	ie	Hydroco	biollo		Peto Odds Ratio		Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	1	Peto, F	ixed, 95% CI		
Hollisaz 2004	4	8	0	7	100.0%	10.87 [1.19, 99.73	1			-	
Total (95% CI)		8		7	100.0%	10.87 [1.19, 99.73]	1		-	-	
Total events	4		0								
Heterogeneity: Not as	pplicable						0.005	0.1	1 10	200	
Test for overall effect	Z= 2.11	(P = 0.0)	03)						id Favours salin		

Figure 341: Saline versus hydrocolloid dressing – proportion of ulcers improved

	Salin	le e	Hydroco	bloid		Risk Ratio	Risk	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fix	ed, 95% CI			
Hollisaz 2004	29	60	27	31	100.0%	0.55 [0.41, 0.75]					
Total (95% CI)		60		31	100.0%	0.55 [0.41, 0.75]	•				
Total events	29		27								
Heterogeneity: Not as	oplicable						0.5 0.7	1 1 2			
Test for overall effect	Z = 3.92	(P < 0.0	0001)				Favours hydrocolloid	Favours saline			

Figure 342: Saline versus hydrocolloid dressing – proportion of ulcers worsened (all grades)

	Salin	ie	Hydroco	biollo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
9.10.1 General popul	lation						
Neill 1989	15	45	14	42	59.0%	1.00 [0.55, 1.81]	_
Subtotal (95% CI)		45		42	59.0%	1.00 [0.55, 1.81]	•
Total events	15		14				
Heterogeneity: Not as	oplicable						
Test for overall effect	Z = 0.00	(P = 1.0	00)				
9.10.2 Patients with	a spinal c	ord inj	ury				
Hollisaz 2004	9	30	2	31	41.0%	4.65 [1.09, 19.78]	
Subtotal (95% CI)		30		31	41.0%	4.65 [1.09, 19.78]	
Total events	9		2				
Heterogeneity. Not as	plicable						
Test for overall effect	Z= 2.08	(P = 0.0)	14)				
Total (95% CI)		75		73	100.0%	1.88 [0.41, 8.68]	
Total events	24		16				
Heterogeneity: Tau* =	0.94; Ch	= 3.9	5, df = 1 ()	P = 0.05); 12 = 759	6	0.05 0.2 1 5 2
Test for overall effect	Z= 0.81	(P = 0.4)	12)				Favours saline Favours hydrocoll
Test for subgroup dif	ferences:	Chi2=	3.70. df=	1 (P = 0	.05), P = 7	73.0%	ravora some ravora njuroco

Figure 343: Saline versus hydrocolloid dressing – proportion of ulcers worsened (grade II)

	Salir	1e	Hydroco	biollo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Neill 1989	11	34	7	25	100.0%	1.16 [0.52, 2.56]	_
Total (95% CI)		34		25	100.0%	1.16 [0.52, 2.56]	•
Total events	11		7				
Heterogeneity: Not as	pplicable						0.05 0.2 5 20
Test for overall effect	Z = 0.36	(P = 0.7)	72)				Favours saline Favours hydrocolloid

Figure 344: Saline versus hydrocolloid dressing – proportion of ulcers worsened (grade III)

	Salin	1e	Hydroco	biollo		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI			
Neill 1989	4	11	7	17	100.0%	0.88 [0.34, 2.32]	-			
Total (95% CI)		11		17	100.0%	0.88 [0.34, 2.32]	•			
Total events	4		7							
Heterogeneity: Not as	pplicable						0.01 0.1 10 100			
Test for overall effect	Z = 0.25	(P = 0.8	30)				Favours saline Favours hydrocolloic			

Figure 345: Saline versus hydrocolloid dressing – mean percentage reduction in ulcer size

No. of the same of		Saline			arocollon	0		Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI			
Chang 1998	-9	102.45	17	34	102.45	17	100.0%	-43.00 [-111.87, 25.87	1 -			
Total (95% CI)			17			17	100.0%	-43.00 [-111.87, 25.87				
Heterogeneity: Not ap Test for overall effect			2)						-100 -50 0 50 100 Favours experimental Favours control			

Figure 346: Saline versus hydrocolloid dressing – mean percentage reduction in ulcer volume

	S	aline		Hydrocolloid				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 9	5% CI	
Matzen 1999	64	16	15	26	10	17	100.0%	38.00 [28.61, 47.39]			
Total (95% CI)			15			17	100.0%	38.00 [28.61, 47.39]		•	
Heterogeneity. Not as									-50 -25 0	25 50	
Test for overall effect	Z = 7.93	(P «	0.000	01)					Favours hydrocolloid Fa	avours saline	

Figure 347: Saline versus hydrocolloid dressing – median percentage reduction in ulcer size

	S	aline		Hydr	ocollo	bid		Mean Difference	Mean C	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	CI IV, Fixe	d, 95% CI
Alm 1989	85.7	0	21	100	0	29		Not estimable	e	
Total (95% CI)			21			29		Not estimable	le	
Heterogeneity: Not as Test for overall effect			le						-100 -50 Favours experimenta	0 50 100 I Favours control

Figure 348: Saline versus hydrocolloid dressing – median percentage reduction in ulcer size (grade II)

	S	aline		Hydr	ocollo	oid		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% CI
Neill 1989	48	0	34	91	0	25		Not estimable	e
Total (95% CI)			34			25		Not estimable	e
Heterogeneity: Not as Test for overall effect			ile						-100 -50 0 50 100 Favours experimental Favours control

Figure 349: Saline versus hydrocolloid dressing – median percentage reduction in ulcer size (grade III)

	S	aline		Hydr	ocollo	oid		Mean Difference	9	Mean	Difference	e	
Study or Subgroup	Mean S		Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	CI	IV, Fix	ed, 95% (
Neill 1989	30	0	- 11	0.3	0	17		Not estimable	le				
Total (95% CI)			11			17		Not estimable	le				
Heterogeneity: Not as Test for overall effect	9		le						-100 Favours	-50 experiment	0 al Favou	50 irs cont	100 trol

Figure 350: Saline versus hydrocolloid dressing – median days to healing

	S	aline		Hydr	ocollo	bid		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	eight IV, Fixed, 95% C	CI IV, Fixed, 95% CI
Xakellis 1992	11	0	21	9	0	18		Not estimable	le
Total (95% CI)			21			18		Not estimable	le
Heterogeneity: Not as Test for overall effect	, ,		le						-100 -50 0 50 100 Favours experimental Favours control

Figure 351: Saline versus hydrocolloid dressing – proportion of patients with pain at dressing removal

	Salin	ie	Hydroco	biolic		Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events Total		Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI		
Chang 1998	0	17	7	17	100.0%	0.09 [0.02, 0.45]	_			
Total (95% CI)		17		17	100.0%	0.09 [0.02, 0.45]	-			
Total events	0		7							
Heterogeneity: Not as	plicable						0.01 0.1	1 10 100		
Test for overall effect	Z = 2.92	(P = 0.0)	003)					Favours hydrocolloid		

Figure 352: Saline versus hydrocolloid dressing – median pain score

	S	aline		Hydr	ocollo	bid		Mean Difference		Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C		IV.	Fixed, 959	6 CI	
Matzen 1999	2	0	15	2	0	17		Not estimable	е				
Total (95% CI)			15			17		Not estimable	e				
Heterogeneity: Not as Test for overall effect	4 4 11 11 11 11 11 11		le						-100 Favours	-50 experime	0 ental Fav	50 ours con	100 trol

Figure 353: Saline versus hydrocolloid dressing – proportion of patients with discomfort

	Salir	1e	Hydroco	biollo		Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, F	ixed, 9	5% CI	
Chang 1998	0	17	9	17	100.0%	0.07 [0.02, 0.32]	_				
Total (95% CI)		17		17	100.0%	0.07 [0.02, 0.32]	-				
Total events	0		9								
Heterogeneity: Not as	pplicable						0.01	0.1	+	10	100
Test for overall effect	Z= 3.45	(P = 0.0)	(3000					o. i avours sali	ne Fav	ours hyd	

Figure 354: Saline versus hydrocolloid dressing – median comfort score

	S	aline		Hydrocolloid			M	ean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% CI		
Matzen 1999	3	0	15	4	0	17		Not estimable	е		
Total (95% CI)			15			17		Not estimable	e		
Heterogeneity: Not a Test for overall effect	4 4 12 1 1 1 1 1 1 1 1		le						-100 -50 0 5		

Figure 355: Saline versus hydrocolloid dressing – proportion of patients with an infection

	Salir	1e	Hydroco	biollo		Peto Odds Ratio		Peto Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	1	Peto, Fixe	ed, 95% CI	
Chang 1998	0	17	0	17		Not estimable	9			
Total (95% CI)		17		17		Not estimable	9			
Total events	0		0							
Heterogeneity: Not as	pplicable						0.01	0.1	10	100
Test for overall effect	Not appli	icable							Favours cont	

Figure 356: Saline versus hydrocolloid dressing – median smell score

	S	aline		Hydr	ocollo	bid		Mean Difference	9	Mea	n Diff	ference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	CI	IV, F	ixed,	95% CI		
Matzen 1999	2	0	15	2	0	17		Not estimable	le					
Total (95% CI)			15			17		Not estimable	le					
Heterogeneity: Not as Test for overall effect			le						-100 Favours	-50 experimen	ntal	Favours	50 cont	100

Figure 357: Saline versus hydrocolloid dressing – proportion of patients with skin irritation

	Saline		Hydrocolloid			Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
Neill 1989	0	50	9	50	100.0%	0.11 [0.03, 0.44]			24 2 2	
Total (95% CI)		50		50	100.0%	0.11 [0.03, 0.44]		•		
Total events	0		9							
Heterogeneity: Not as	pplicable						0.002	0.1	1 10	500
Test for overall effect	Z= 3.13	(P = 0.0)	002)					ours saline	Favours hy	

Figure 358: Saline versus hydrocolloid dressing - mortality

	Saline	•	Hydroco	lloid		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Chang 1998	0	17	0	17		Not estimable	
Hollisaz 2004	0	27	0	28		Not estimable	
Matzen 1999	1	15	2	17	77.7%	0.57 [0.06, 5.64]	
Xakellis 1992	3	21	0	18	22.3%	6.05 [0.33, 109.75]	-
Total (95% CI)		80		80	100.0%	1.79 [0.38, 8.46]	
Total events	4		2				
Heterogeneity: Chi2 =	1.64, df = 1	(P = 0)	$(0.20); I^2 = 3$	39%			
Test for overall effect:	Z = 0.73 (P	= 0.47	7)				0.01 0.1 1 10 100 Favours saline Favours hydrocolloic

1.2.7.2 Saline vs. hydrogel dressing

Figure 359: Saline versus hydrogel dressing – proportion of patients completely healed

	Salin	ie	Hydro	gel		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Thomas 1998	9	14	10	16	100.0%	1.03 [0.60, 1.77]	-
Total (95% CI)		14		16	100.0%	1.03 [0.60, 1.77]	•
Total events	9		10				
Heterogeneity: Not ap	pplicable						04 02 05 1 3 5 40
Test for overall effect	Z = 0.10	P = 0.9	32)				Favours hydrogel Favours saline

Figure 360: Saline versus hydrogel dressing – proportion of patients worsened

	Salir	1e	Hydro	gel		Risk Ratio		Risi	k Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95% CI	
Thomas 1998	1	19	1	22	100.0%	1.16 (0.08, 17.28)		-		-
Total (95% CI)		19		22	100.0%	1.16 [0.08, 17.28]				-
Total events	1		1							
Heterogeneity: Not as	pplicable						0.01	0.1	1 10	100
Test for overall effect	Z = 0.11	(P = 0.9)	32)					vours saline	1 10 Favours	

Figure 361: Saline versus hydrogel dressing – mean weeks to healing

	Saline			Hydrogel				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
Thomas 1998	5.2	2.4	14	5,3	2.3	16	100.0%	-0.10 [-1.79, 1.59]	-		
Total (95% CI)			14			16	100.0%	-0.10 [-1.79, 1.59]	-		
Heterogeneity: Not as	pplicable								1 1 1 1		
Test for overall effect	Z = 0.12	(P=	0.91)						Favours hydrogel Favours saline		

Figure 362: Saline versus hydrogel dressing - mortality

	Salin	е	Hydro	gel		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Thomas 1998	2	19	4	22	100.0%	0.58 [0.12, 2.82]	
Total (95% CI)		19		22	100.0%	0.58 [0.12, 2.82]	
Total events	2		4				
Heterogeneity: Not app Test for overall effect: 2		P = 0.50	0)				0.01 0.1 1 10 100 Favours saline Favours hydrogel

I.2.7.3 Phenytoin vs. saline

Figure 363: Phenytoin versus saline – proportion of patients completely healed

	Pheny	toin	Salir	ie		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Hollisaz 2004	11	28	8	27	100.0%	1.33 [0.63, 2.78]	_
Total (95% CI)		28		27	100.0%	1.33 [0.63, 2.78]	•
Total events	11		8				
Heterogeneity; Not as	oplicable						01 02 06 1 3 6 10
Test for overall effect	Z = 0.75	(P = 0.4)	(6)				Favours saline Favours phenytoin

Figure 364: Phenytoin versus saline - mortality

	Phenyl	toin	Salin	e		Peto Odds Ratio	Peto Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI	
Hollisaz 2004	0	28	0	27		Not estimable		
Subbanna 2007	0	14	0	14		Not estimable		
Total (95% CI)		42		41		Not estimable		
Total events	0		0					
Heterogeneity: Not app	olicable							100
Test for overall effect:	Not applic	able				F	0.01 0.1 1 10 avours phenytoin Favours salin	100 ne

I.2.7.4 Saline vs. foam dressing

Figure 365: Saline versus foam dressing – proportion of patients completely healed

	Salir	1e	Foar	m		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Kraft 1993	3	14	10	24	45.3%	0.51 [0.17, 1.56]	-
Payne 2009	6	16	10	20	54.7%	0.75 [0.35, 1.62]	-
Total (95% CI)		30		44	100.0%	0.64 [0.34, 1.22]	•
Total events	9		20				
Heterogeneity: Chi2=	0.31, df=	1 (P=	0.58); 12:	= 0%			0.01 0.1 1 10 100
Test for overall effect	Z = 1.35		Favours foam Favours saline				

Figure 366: Saline versus foam dressing – median days to 50% healing

	S	aline		F	oam			Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% (CI IV, Fixed, 95% CI	
Payne 2009	28	0	16	28	0	20		Not estimable	le	
Total (95% CI)			16			20		Not estimable	le	
Heterogeneity. Not as Test for overall effect			le						-100 -50 0 50 1 Favours experimental Favours control	00

Figure 367: Saline versus foam dressing - mortality

	Saline	Foam		Risk Ratio	Risk Ratio
Study or Subgroup	Events Tota	al Events To	otal Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Kraft 1993	2 1	4 0	24 12.3%	8.33 [0.43, 162.13]	<u> </u>
Payne 2009	2 1	6 3	20 87.7%	0.83 [0.16, 4.40]	
Total (95% CI)	3	0	44 100.0%	1.76 [0.49, 6.34]	
Total events	4	3			
Heterogeneity: Chi ² = 1	.83, df = 1 (P =	$= 0.18$); $I^2 = 45^\circ$	%	ŀ	0.01 0.1 1 10 100
Test for overall effect: 2	Z = 0.86 (P = 0)	`	Favours saline Favours foam		

1.2.7.5 Saline vs. polyurethane dressing

Figure 368: Saline versus polyurethane dressing – proportion of ulcers completely healed

	Salin	1e	Polyuret	hane		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
Oleske 1986	0	10	1	9	100.0%	0.12 [0.00, 6.14]	_			
Total (95% CI)		10		9	100.0%	0.12 [0.00, 6.14]		-		
Total events	0		1							
Heterogeneity: Not a							0.001	0.1	1 10	1000
Test for overall effect	Z = 1.05	(P = 0.2)	29)			1		olyurethane	Favours sa	

Figure 369: Saline versus polyurethane dressing – proportion of ulcers worsened

	Salin	e	Polyurethane			Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fix	ed, 95% CI	
Oleske 1986	2	10	1	9	100.0%	1.80 [0.19, 16.66]			
Total (95% CI)		10		9	100.0%	1.80 [0.19, 16.66]	-		
Total events	2		1						
Heterogeneity: Not as	plicable						0.01 0.1	10	100
Test for overall effect	Z = 0.52	(P = 0.6)	80)				Favours saline	Favours poly	

1.2.7.6 Saline vs. dextranomer

Figure 370: Saline versus dextranomer – proportion of ulcers improved

	Gauz	e	Dextran	omer		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	1	M-H, Fix	ed, 95% CI	
Ljungberg 2009	2	15	11	15	100.0%	0.18 [0.05, 0.68	3]			
Total (95% CI)		15		15	100.0%	0.18 [0.05, 0.68	1	•		
Total events	2		11							
Heterogeneity: Not as	pplicable						0.001	0.1	1 10	1000
Test for overall effect	Z= 2.52	(P = 0.0)	01)						Favours g	

Figure 371: Saline versus dextranomer – proportion of people with adverse events

	Gauz	e	Dextran	omer		Peto Odds Ratio		Peto C	dds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fi	xed, 95% C	1	
Ljungberg 2009	0	15	0	15		Not estimable					
Total (95% CI)		15		15		Not estimable					
Total events	0		0								
Heterogeneity: Not app							0.01	0.1	1 1	0	100
Test for overall effect: Not applicable							Fa	vours gauze	e Favours	dex	ranome

I.2.7.7 Phenytoin vs. saline

Figure 372: Phenytoin versus saline – proportion of patients completely healed




Figure 373: Phenytoin versus saline – proportion of ulcers completely healed (all grades – all sites)

	Phenyl	toin	Salir	ie		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Hollisaz 2004	12	30	8	30	100.0%	1.50 [0.72, 3.14]	-
Total (95% CI)		30		30	100.0%	1.50 [0.72, 3.14]	•
Total events	12		8				
Heterogeneity: Not as	oplicable						0.01 0.1 1 10 100
Test for overall effect	Z=1.08	P = 0.2	28)				Favours saline Favours phenytoin

Figure 374: Phenytoin versus saline – proportion of ulcers completely healed (grade I – all sites)

5.4 ct 5 o 5T	Phenyl	toin	Salir	ie		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Hollisaz 2004	2	9	5	.11	100.0%	0.49 [0.12, 1.95]	
Total (95% CI)		9		11	100.0%	0.49 [0.12, 1.95]	-
Total events	2		5				
Heterogeneity: Not ap	plicable						0.01 0.1 1 10 100
Test for overall effect.	Z = 1.01	P = 0.3	31)				Favours saline Favours phenytoin

Figure 375: Phenytoin versus saline – proportion of ulcers completely healed (grade II – all sites)

	Pheny	toin	Salir	ie		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI	
Hollisaz 2004	10	21	3	19	100.0%	3.02 [0.97, 9.35]		-	
Total (95% CI)		21		19	100.0%	3.02 [0.97, 9.35]		•	
Total events	10		3						
Heterogeneity: Not as	plicable						0.002 0.1	1 10 50	+
Test for overall effect	Z=1.91	(P = 0.0)	(8)				4.444	1 10 50 Favours phenyto	-

Figure 376: Phenytoin versus saline – proportion of ulcers completely healed (all grades – sacral)

	Pheny	toin	Salir	ie		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Hollisaz 2004	2	5	4	8	100.0%	0.80 [0.22, 2.87]	
Total (95% CI)		5		8	100.0%	0.80 [0.22, 2.87]	-
Total events	2		4				
Heterogeneity: Not ap	oplicable						0.01 0.1 1 10 100
Test for overall effect.	Z=0.34	(P = 0.7)	73)				0.01 0.1 1 10 100 Favours saline Favours phenytoin

Figure 377: Phenytoin versus saline – proportion of ulcers improved

	Pheny	toin	Salir	ie		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Hollisaz 2004	16	30	13	30	100.0%	1.23 [0.73, 2.09]	
Total (95% CI)		30		30	100.0%	1.23 [0.73, 2.09]	-
Total events	16		13				
Heterogeneity: Not as	pplicable						01 02 05 1 2 5 10
Test for overall effect	Z = 0.77	(P = 0.4)	(4)				Favours saline Favours phenytoin

Figure 378: Phenytoin versus saline – proportion of ulcers worsened

	Pheny	toin	Salir	ie		Risk Ratio	Risk R	tatio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed	I, 95% CI
Hollisaz 2004	2	30	9	30	100.0%	0.22 [0.05, 0.94]		
Total (95% CI)		30		30	100.0%	0.22 [0.05, 0.94]	-	
Total events	2		9					
Heterogeneity: Not as	pplicable						0.01 0.1 1	10 100
Test for overall effect	Z = 2.04	(P = 0.0)	04)				Favours phenytoin	

Figure 379: Phenytoin versus saline – mean percentage reduction in ulcer size

	Pt	enytoir	1	Saline				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Subbanna 2007	47.83	20.94	12	36.03	17.63	14	100.0%	11.80 [-3.22, 26.82]	
Total (95% CI)			12			14	100.0%	11.80 [-3.22, 26.82]	-
Heterogeneity: Not a Test for overall effect			12)						-20 -10 0 10 20 Favours saline Favours phenytoin

Figure 380: Phenytoin versus saline – mean percentage reduction in ulcer volume

	Ph	enytoi	n		Saline			Mean Difference		Mean	n Diff	erence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, F	xed.	95% CI	
Subbanna 2007	53.94	31.2	12	55.76	27.75	14	100.0%	-1.82 [-24.69, 21.05]		_			
Total (95% CI)			12			14	100.0%	-1.82 [-24.69, 21.05]		-	-		
Heterogeneity, Not as Test for overall effect			0.88)						-50	-25	6	25	50

Figure 381: Phenytoin versus saline – mean percentage reduction in PUSH score

	Ph	enytoi	n	Saline				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Subbanna 2007	19.53	17.7	12	11.39	11.09	14	100.0%	8.14 [-3.44, 19.72]	
Total (95% CI)			12			14	100.0%	8.14 [-3.44, 19.72]	-
Heterogeneity: Not a	pplicable								-20 -10 0 10 20
Test for overall effect	Z=1.38	(P = (0.17)						Favours saline Favours phenyloin

Figure 382: Phenytoin versus saline – proportion of people with treatment-related adverse events

	Phenyt	oin	Salin	е		Peto Odds Ratio		Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	CI	Peto, Fix	ed, 95% CI	
Subbanna 2007	0	12	0	14		Not estimable	Э			
Total (95% CI)		12		14		Not estimable	e			
Total events	0		0							
Heterogeneity: Not approximately Test for overall effect:		able						0.1 ohenytoin	1 10 Favours sa	100 aline

Figure 383: Phenytoin versus saline - mortality

	Pheny	toin	Salin	е		Peto Odds Ratio	Peto Odds Ratio	0
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95%	CI
Hollisaz 2004	0	28	0	27		Not estimable		
Subbanna 2007	0	14	0	14		Not estimable		
Total (95% CI)		42		41		Not estimable		
Total events	0		0					
Heterogeneity: Not app	olicable					I	0.01 0.1 1	10 100
Test for overall effect: I	Not applic	able					avours phenvtoin Favour	

1.2.7.8 Phenytoin vs. hydrocolloid dressing

Figure 384: Phenytoin versus hydrocolloid dressing – proportion of patients completely healed




Figure 385: Phenytoin versus hydrocolloid dressing – proportion of ulcers completely healed (all grades – all sites)

	Pheny	toin	Hydroco	biollo		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fix	ed, 95% CI
Hollisaz 2004	12	30	23	31	100.0%	0.54 [0.33, 0.88]	-	
Total (95% CI)		30		31	100.0%	0.54 [0.33, 0.88]		
Total events	12		23					
Heterogeneity: Not as	pplicable						0.01 0.1	1 10 100
Test for overall effect	Z = 2.50	(P = 0.0)	01)				Favours hydrocolloid	A

Figure 386: Phenytoin versus hydrocolloid dressing – proportion of ulcers completely healed (grade I – all sites)




Figure 387: Phenytoin versus hydrocolloid dressing – proportion of ulcers completely healed (grade II – all sites)

	Pheny	toin	Hydroco	olloid		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	ed, 95% CI		
Hollisaz 2004	10	21	12	18	100.0%	0.71 [0.41, 1.24]			-		
Total (95% CI)		21		18	100.0%	0.71 [0.41, 1.24]		•	-		
Total events	10		12								
Heterogeneity: Not as	pplicable						0.01	014	1		100
Test for overall effect	Z=1.19	(P = 0.2)	23)					s hydrocolloid	Favours p	heny	

Figure 388: Phenytoin versus hydrocolloid dressing – proportion of ulcers completely healed (all grades - sacral)




Figure 389: Phenytoin versus hydrocolloid dressing – proportion of ulcers improved

	Pheny	toin	Hydroco	lloid		Risk Ratio			Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI			M-H, Fixe	d, 95% C	1	
Hollisaz 2004	16	30	27	31	100.0%	0.61 [0.43, 0.88]						
Total (95% CI)		30		31	100.0%	0.61 [0.43, 0.88]						
Total events	16		27									
Heterogeneity: Not a	pplicable						01	0.2	0.5	1 1	1	10
Test for overall effect	Z = 2.66	(P = 0.0)	008)				Fayo	urs hy	drocolloid	Favours	s phen	7.9

Figure 390: Phenytoin versus hydrocolloid dressing – proportion of ulcers worsened

	Pheny	toin	Hydroco	biollo		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95% CI		
Hollisaz 2004	2	30	2	31	100.0%	1.03 [0.16, 6.87]		_			
Total (95% CI)		30		31	100.0%	1.03 [0.16, 6.87]					
Total events	2		2								
Heterogeneity: Not as	pplicable						0.01	011	1 1	2	100
Test for overall effect	Z = 0.03	(P = 0.9)	37)				717.	ours phenytoin	C		

Figure 391: Phenytoin versus hydrocolloid dressing – mean days of healing

	Phe	enytoi	n	Hydrocolloid				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Rhodes 2001	35.3	14.3	15	51.8	19.6	13	100.0%	-16.50 [-29.38, -3.62]	-
Total (95% CI)			15			13	100.0%	-16.50 [-29.38, -3.62]	•
Heterogeneity. Not applicable Test for overall effect Z = 2.51 (P = 0.01)									-100 -50 0 50 100 Favours phenytoin Favours hydrocolloid

Figure 392: Phenytoin versus hydrocolloid dressing - mortality

	Phenyt	oin	Hydroco	lloid		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Hollisaz 2004	0	28	0	28		Not estimable	
Rhodes 2001	2	18	2	16	100.0%	0.89 [0.14, 5.60]	
Total (95% CI)		46		44	100.0%	0.89 [0.14, 5.60]	
Total events	2		2				
Heterogeneity: Not app Test for overall effect:	P = 0.90	0)				0.01 0.1 1 10 100 Favours phenytoin Favours hydrocolloid	

1.2.7.9 Phenytoin vs. triple antibiotics

Figure 393: Phenytoin versus triple antibiotics – mean days to healing

	Ph	enytoi	n	Triple antibiotic			Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Rhodes 2001	35.3	14.3	15	53.8	8.5	- 11	100.0%	-18.50 [-27.31, -9.69]	
Total (95% CI)			15			11	100.0%	-18.50 [-27.31, -9.69]	-
Heterogeneity: Not as Test for overall effect	A second		0.0001)						-20 -10 0 10 20

Figure 394: Phenytoin versus triple antibiotics – proportion of people with treatment-related adverse events

	Pheny	toin	Triple antil	oiotics		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
Rhodes 2001	0	15	0	11		Not estimable				
Total (95% CI)		15		11		Not estimable				
Total events	0		0							
Heterogeneity: Not ap Test for overall effect:		able					0.01 Favo	0.1 ours phenytoin	1 10 Favours trip	

Figure 395: Phenytoin versus triple antibiotics - mortality

	Phenyt	oin	Contr	ol		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fix	ed, 95% CI	
Rhodes 2001	2	16	1	13	100.0%	1.63 [0.17, 15.99]				_
Total (95% CI)		16		13	100.0%	1.63 [0.17, 15.99]				-
Total events	2		1							
Heterogeneity: Not app Test for overall effect:		P = 0.68	3)				0.01 Favour	0.1 rs phenytoin	1 1 Favours tri	0 100 iple antibiotic

I.2.7.10 Dialysate vs. placebo

Figure 396: Dialysate versus placebo – mean ml reduction in ulcer area




Figure 397: Dialysate versus placebo – mean healing half-time (days)




Figure 398: Dialysate versus placebo – proportion of people with treatment-related adverse events

	Dialys	ate	Place	bo		Peto Odds Ratio		Peto Od	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l	Peto, Fix	ed, 95% CI	
Knudsen 1982	0	5	0	3		Not estimable				
Total (95% CI)		5		3		Not estimable				
Total events	0		0							
Heterogeneity: Not app Test for overall effect:		abla					0.01	0.1	 	100
rest for overall effect.	тчот арріїс	abie					Favou	ırs dialysate	Favours p	acebo

I.2.7.11 Topical ointment with petrolatum vs. petrolatum (base component)

Figure 399: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients completely healed – grade 1 and 2 pressure ulcers

Figure 400: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients completely healed – grade 2 pressure ulcers

	Ointm	ent	Petrola	tum		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl		Peto, Fi	xed, 95% CI	
Kuflik 2001	1	5	0	3	100.0%	4.95 [0.09, 283.86]				
Total (95% CI)		5		3	100.0%	4.95 [0.09, 283.86]				
Total events	1		0							
Heterogeneity: Not app	olicable						0.01	0.1	1 10	100
Test for overall effect:	Z = 0.77 (1	P = 0.4	4)					•	Favours pe	

Figure 401: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients improved – grades 1 and 2 pressure ulcers

	Ointme	ent	Petrola	tum		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l Peto, Fixed, 95% Cl
Kuflik 2001	4	10	0	9	100.0%	9.78 [1.14, 83.93]	
Total (95% CI)		10		9	100.0%	9.78 [1.14, 83.93]	
Total events	4		0				
Heterogeneity: Not app	olicable						0.000 0.1 1 10 500
Test for overall effect: 2	Z = 2.08 (I	P = 0.0	4)				0.002 0.1 1 10 500 Favours petrolatum Favours ointment

Figure 402: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients improved – grades 2 pressure ulcers

	Ointme	ent	Petrola	tum		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI
Kuflik 2001	3	5	0	3	100.0%	9.39 [0.59, 149.25]	
Total (95% CI)		5		3	100.0%	9.39 [0.59, 149.25]	
Total events	3		0				
Heterogeneity: Not app Test for overall effect:		P = 0.1	1)				Favours ointment Favours petrolatum

Figure 403: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients worsened – grades 1 and 2 pressure ulcers

	Ointme	ent	Petrola	tum		Peto Odds Ratio	P	eto Oc	lds Rat	io	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Pe	to, Fix	ed, 95%	6 CI	
Kuflik 2001	0	10	6	9	100.0%	0.05 [0.01, 0.35]	-				
Total (95% CI)		10		9	100.0%	0.05 [0.01, 0.35]	-	—			
Total events	0		6								
Heterogeneity: Not app	olicable						0.001 0	 	 1 1	n	1000
Test for overall effect:	Z = 3.04 (I	P = 0.00	02)				Favours oin			-	trolatum

Figure 404: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients worsened – grades 2 pressure ulcers

	Ointme	ent	Petrola	tum		Peto Odds Ratio		Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
Kuflik 2001	0	5	3	3	100.0%	0.02 [0.00, 0.38]	+			
Total (95% CI)		5		3	100.0%	0.02 [0.00, 0.38]				
Total events	0		3							
Heterogeneity: Not app Test for overall effect:		o = 0.00	08)				0.01 Favor	0.1 urs ointment	1 10 Favours p	

Figure 405: Topical ointment with petrolatum versus petrolatum (base component) – mortality

	Ointm	ent	Petrola	tum		Peto Odds Ratio			Peto Od	ds Rati	io	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI			Peto, Fixe	ed, 95%	CI	
Kuflik 2001	0	10	0	9		Not estimable						
Total (95% CI)		10		9		Not estimable						
Total events	0		0									
Heterogeneity: Not app	plicable						<u> </u>		4	!	10	100
Test for overall effect:	Not applic	able					0.01 Favou	.0 urs o	i ointment	r Favou	rs pet	100 rolatum

I.2.7.12 Zinc oxide versus streptokinase-streptodornase

Figure 406: Zinc oxide versus streptokinase-streptodornase – median percentage reduction in ulcer area

	Zino	oxid	ie	Streptokina	se-strept	odorn		Mean Difference		Mea	n Differ	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	1	IV, F	ixed, 95	5% CI	
Agren 1985	2.4	0	14	-18.7	0	14		Not estimable					
Total (95% CI)			14			14		Not estimable	,				
Heterogeneity: Not as	pplicable								-100	-50	-	50	100
Test for overall effect	Not app	licab	le							experime	ntal Fa		

Figure 407: Zinc oxide versus streptokinase-streptodornase – proportion of patients with an infection




Figure 408: Zinc oxide versus streptokinase-streptodornase – proportion of patients with skin reaction

	Zinc ox	cide	Streptokinase-stre	ptodorn		Peto Odds Ratio		Peto Oc	ids Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
Agren 1985	0	14	- 1	14	100.0%	0.14 [0.00, 6.82]	-			
Total (95% CI)		14		14	100.0%	0.14 [0.00, 6.82]		-	_	
Total events	0		4							
Heterogeneity. Not as	pplicable						0.002	ot.	10	500
Test for overall effect	Z=1.00	P = 0.3	2)				717	rs zinc oxide	1 10 Favours stre	

Figure 409: Zinc oxide versus streptokinase-streptodornase – mortality

	Zinc ox	ride	Streptokinase-strep	todorn		Peto Odds Ratio		Peto Od	ds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fixe	ed, 95% CI	
Agren 1985	0	14	0	14		Not estimable				
Total (95% CI)		14		14		Not estimable				
Total events	0		0							
Heterogeneity: Not app	olicable						0.01	0.1	10	100
Test for overall effect:	Not applic	able							Favours stre	

I.2.7.13 Oxyquinoline versus A&D treatment

Figure 410: Oxyquinoline versus A&D treatment – proportion of ulcers completely healed (all grades)

	Oxyquin	oline	A&D trea	tment		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	43	86	21	51	100.0%	1.21 [0.82, 1.79]	
Total (95% CI)		86		51	100.0%	1.21 [0.82, 1.79]	-
Total events	43		21				
Heterogeneity. Not as	pplicable						02 05 1 2
Test for overall effect	Z = 0.98 (P = 0.33	()				Favours A&D treatment Favours oxyquinoline

Figure 411: Oxyquinoline versus A&D treatment – proportion of ulcers completely healed (grade I)

	Oxyquin	oline	A&D treat	tment		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	23	41	16	28	100.0%	0.98 [0.65, 1.49]	
Total (95% CI)		41		28	100.0%	0.98 [0.65, 1.49]	-
Total events	23		16				
Heterogeneity. Not as	pplicable						00 05 1 1
Test for overall effect	Z = 0.09 (P = 0.93)				0.2 0.5 1 2 5 Favours A&D treatment Favours oxyquinoline

Figure 412: Oxyquinoline versus A&D treatment – proportion of ulcers completely healed (grade II)

	Oxyguin	oline	A&D treat	tment		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI				
Gerding 1993	20	45	5	23	100.0%	2.04 [0.88, 4.74]		-			
Total (95% CI)		45		23	100.0%	2.04 [0.88, 4.74]		•			
Total events	20		5								
Heterogeneity. Not as	pplicable						0.01 0.1	10 100			
Test for overall effect	Z = 1.67 (P = 0.10))				Favours A&D treatment				

Figure 413: Oxyquinoline versus A&D treatment – proportion of ulcers improved on day 15 (grade I)

	Oxyquin	oline	A&D treat	tment		Risk Ratio	Risk Ratio
Study or Subgroup	Events Total		Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	15	41	6	28	100.0%	1.71 [0.76, 3.86]	+
Total (95% CI)		41		28	100.0%	1.71 [0.76, 3.86]	
Total events	15		6				
Heterogeneity. Not as	pplicable						0.01 0.1 1 10 100
Test for overall effect	Z = 1.29 (P = 0.20)				Favours A&D treatment Favours oxyquinoline

Figure 414: Oxyquinoline versus A&D treatment – proportion of ulcers improved on day 22 (grade II)

	Oxyquinoline		A&D treatment		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	19	45	8	23	100.0%	1.21 [0.63, 2.34]	J
Total (95% CI)		45		23	100.0%	1.21 [0.63, 2.34]	-
Total events	19		8				
Heterogeneity. Not as	plicable						0.1 0.2 0.5 1 2 5 10
Test for overall effect	Z = 0.58 (P = 0.56)				0.1 0.2 0.5 1 2 5 10 Favours A&D treatment Favours oxyquinolin

Figure 415: Oxyquinoline versus A&D treatment – proportion of ulcers not changed on day 15 (grade I)

	Oxyquin	oline	A&D trea	tment		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	4	41	4	28	100.0%	0.68 [0.19, 2.51]	-
Total (95% CI)		41		28	100.0%	0.68 [0.19, 2.51]	
Total events	4		4				
Heterogeneity. Not as	pplicable						0.01 0.1 1 10 100
Test for overall effect	Z = 0.58 (P = 0.57)				0.01 0.1 1 10 100 Favours oxyquinoline Favours A&D treatment

Figure 416: Oxyquinoline versus A&D treatment – proportion of ulcers not changed on day 22 (grade II)

(0: -:-	,							
	Oxyquinoline		A&D treatment			Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Gerding 1993	- 5	45	7	23	100.0%	0.37 [0.13, 1.02]		
Total (95% CI)		45		23	100.0%	0.37 [0.13, 1.02]	-	
Total events	5		7					
Heterogeneity. Not as	pplicable						0.01 0.1 1	100
Test for overall effect	Z= 1.91 (P = 0.00	6)				Favours oxyquinoline Favours A&	

Figure 417: Oxyquinoline versus A&D treatment – proportion of ulcers worsened on day 15 (grade I)

(0: -:-	· ,							
	Oxyquin	Oxyquinoline		tment		Peto Odds Ratio	Peto Oc	dds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
Gerding 1993	0	41	2	28	100.0%	0.08 [0.00, 1.41]		
Total (95% CI)		41		28	100.0%	0.08 [0.00, 1.41]		-
Total events	0		2					
Heterogeneity: Not as	pplicable						0.002 0.1	1 10 500
Test for overall effect	Z=1.72 (P = 0.08	1)					1 10 500 Favours A&D treatment

Figure 418: Oxyquinoline versus A&D treatment – proportion of ulcers worsened on day 22 (grade II)




Figure 419: Oxyquinoline versus A&D treatment – mean days to complete healing (all grades)

	Oxy	quinoli	ne	A&D treatment				Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI			
Gerding 1993	7.23	4.15	86	8.62	5.16	51	100.0%	-1.39 [-3.06, 0.28]	-			
Total (95% CI)			86			51	100.0%	-1.39 [-3.06, 0.28]				
Heterogeneity: Not a									-2 -1 0 1 2			
Test for overall effect	Z = 1.64	(P = (0.10)						Favours oxyguinoline Favours A&D treatment			

Figure 420: Oxyquinoline versus A&D treatment – mean days to complete healing (grade I)

	Oxyq	uinoli	ne	A&D treatment				Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixed	1, 95% CI		
Gerding 1993	6.75	3.9	41	7.25	4.8	28	100.0%	-0.50 [-2.64, 1.64]					
Total (95% CI)			41			28	100.0%	-0.50 [-2.64, 1.64]			-		
Heterogeneity: Not a Test for overall effect			0.65)						-4 Favour	-2 s oxyguinoline	Favour	s A&D tre	4 atment

Figure 421: Oxyquinoline versus A&D treatment – mean days to complete healing (grade II)

	Oxy	quinoli	ne	A&D treatment				Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI			
Gerding 1993	7.8	4.47	45	13	3.94	23	100.0%	-5.20 [-7.27, -3.13]				
Total (95% CI)			45			23	100.0%	-5.20 [-7.27, -3.13]	•			
Heterogeneity, Not as Test for overall effect			0.00001)					-10 -5 0 5 Favours oxyquinoline Favours A&D trea	10 atment		

I.2.7.14 Ethoxy-diaminoacridine plus nitrofuazone versus honey

Figure 422: Ethoxy-diaminoacridine plus nitrofuazone versus honey – proportion of ulcers completely healed

	Ethoxy-diaminoac	ridine	Hone	ey .		Peto Odds Ratio	Peto Od	ds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixe	ed, 95% CI
Günes 2007	0	25	5	25	100.0%	0.11 [0.02, 0.71]		
Total (95% CI)		25		25	100.0%	0.11 [0.02, 0.71]	-	
Total events	0		5					
Heterogeneity: Not as	pplicable						0.01 0.1	10 100
Test for overall effect	Z = 2.33 (P = 0.02)						Favours honey	Favours ethoxy

Figure 423: Ethoxy-diaminoacridine plus nitrofuazone versus honey – mean percentage reduction in PUSH score

Ethoxy-diaminoacric			idine		Honey			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Günes 2007	12.9	28.92	25	56.3	28.92	25	100.0%	-43.40 [-59.43, -27.37]	
Total (95% CI)			25			25	100.0%	-43.40 [-59.43, -27.37]	•
Heterogeneity. Not as Test for overall effect:	B. 112 2 2 2 2	< 0.00001)						-100 -50 0 50 100 Favours honey Favours ethoxy

Figure 424: Ethoxy-diaminoacridine plus nitrofuazone versus honey – mean percentage reduction in ulcer size

	Ethoxy-d	liaminoaci	ridine		Honey			Mean Difference	Mean D	ifference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixe	d, 95% CI		
Günes 2007	13	29.39	25	56	29.39	25	100.0%	-43.00 [-59.29, -26.71]				
Total (95% CI)			25			25	100.0%	-43.00 [-59.29, -26.71]	•			
Heterogeneity: Not ap Test for overall effect:	B	< 0.00001)						 -50 ours honey	0 5 Favours	0 eth	100 0xy

Figure 425: Ethoxy-diaminoacridine plus nitrofuazone versus honey – proportion of people with treatment-related adverse events

	Ethoxy-diaminoa	cridine	Hone	ey .		Peto Odds Ratio		Pet	o Od	ds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto	, Fixe	ed, 95% C)	
Günes 2007	0	11	0	15		Not estimable						
Total (95% CI)		11		15		Not estimable						
Total events	0		0									
Heterogeneity: Not app Test for overall effect:							0.01	0.1	1)	100
rest for overall effect.	i voi applicable						Favo	urs eth	oxyl	Favours	hor	ey

Figure 426: Ethoxy-diaminoacridine plus nitrofuazone versus honey – mortality

	Ethoxy-diaminoad	ridine	Hone	эy		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Günes 2007	1	12	0	15	100.0%	9.49 [0.18, 489.97]	
Total (95% CI)		12		15	100.0%	9.49 [0.18, 489.97]	
Total events	1		0				
Heterogeneity: Not app Test for overall effect: 2						Fav	0.01 0.1 1 10 100

I.2.7.15 Povidone-iodine versus hydrocolloid

Figure 427: Povidone-iodine versus hydrocolloid – proportion of patients completely healed

	Povidone-i	odine	Hydroce	biolic		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Kim 1996	14	18	21	26	100.0%	0.96 [0.71, 1.31]	
Total (95% CI)		18		26	100.0%	0.96 [0.71, 1.31]	•
Total events	14		21				
Heterogeneity. Not as	pplicable						02 05 1 2 5
Test for overall effect	Z= 0.24 (P=	0.81)					Favours hydrocolloid Favours povidone-iodine

Figure 428: Povidone-iodine versus hydrocolloid – mean speed of healing (mm²/day)

	Povido	ne-lod	line	Hydr	ocollo	bid		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Kim 1996	7.9	4.7	18	9.1	5.4	26	100.0%	-1.20 [-4.20, 1.80]	
Total (95% CI)			18			26	100.0%	-1.20 [-4.20, 1.80]	
Heterogeneity: Not as Test for overall effect		(P = 0.	43)						-4 -2 0 2 4 Favours hydrocolloid Favours povidone-iodine

Figure 429: Povidone-iodine versus hydrocolloid – proportion of patients with hypergranulation


	Povidone-	odine	Hydroco	biollo		Peto Odds Ratio	Peto Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI	
Kim 1996	0	18	3	26	100.0%	0.17 [0.02, 1.79]	1	
Total (95% CI)		18		26	100.0%	0.17 [0.02, 1.79]		
Total events	0		3					
Heterogeneity. Not ap	pplicable						0.005 0.1 1 10	200
Test for overall effect	Z= 1.48 (P=	0.14)					0.005 0.1 1 10 Favours povidone-lodine Favours hydroco	



	Povidone-i	odine	Hydroco	olloid		Peto Odds Ratio		Peto Oc	lds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% C	I	
Kim 1996	0	18	0	26		Not estimable					
Total (95% CI)		18		26		Not estimable					
Total events	0		0								
Heterogeneity: Not appress for overall effect:		Э					0.01 0 Favours		1 1 Favours	l 0 1ydr	100 ocolloid

I.2.7.16 Povideon-iodine vs. hydrogel

Figure 431: Povidone-iodine versus hydrogel – mean cm²/day to healing



1.2.7.17 Cadexomer iodine vs. standard treatment

Figure 432: Cadexomer iodine versus standard treatment – proportion of ulcers reduced > 50%

	Cadexomer	iodine	Standard trea	atment		Risk Ratio	Risi	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fix	ed, 95% CI
Moberg 1983	8	16	. 1	18	100.0%	9.00 [1.26, 64.33]		
Total (95% CI)		16		18	100.0%	9.00 [1.26, 64.33]		
Total events	8		1					
Heterogeneity. Not ap	pplicable						0.01 0.1	1 10 100
Test for overall effect	Z= 2.19 (P=1	0.03)					9191	f Favour cadexomer lodine

Figure 433: Cadexomer iodine versus standard treatment – mean percentage reduction in ulcer area

	Cadexo	mer io	dine	Standa	rd treatr	nent		Mean Difference			Me	an Differ	rence		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI			IV.	Fixed, 9	5% CI		
Moberg 1983	30.9	46	16	19.6	83.16	18	100.0%	11.30 [-33.24, 55.84]			_			_	
Total (95% CI)			16			18	100.0%	11.30 [-33.24, 55.84]				-		_	
Heterogeneity: Not as Test for overall effect		P = 0.63	2)						-100 Favou	-5 ir stand		nent Fa	avour c	50 adexome	100 riodine

Figure 434: Cadexomer iodine versus standard treatment – mean cm² reduction in ulcer area

	Cadexo	mer lo	dine	Standar	rd treatn	nent		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Moberg 1983	2.9	5.2	16	2.5	4.67	18	100.0%	0.40 [-2.94, 3.74]	
Total (95% CI)			16			18	100.0%	0.40 [-2.94, 3.74]	-
Heterogeneity: Not ag Test for overall effect:		P = 0.81	1)						-10 -5 0 5 10 Favour standard treatment Favour cadexomer iodii

Figure 435: Cadexomer iodine versus standard treatment – mortality

	Cadexomer	iodine	Standard trea	tment		Peto Odds Ratio		Peto Oc	lds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI		
Moberg 1983	0	19	0	19		Not estimable					
Total (95% CI)		19		19		Not estimable					
Total events	0		0								
Heterogeneity: Not app Test for overall effect:							0.01 Favours	0.1 s cadexomer	1 1 Favours s	0 tanda	100 ard tmt

1.2.7.18 Silver sulfazidine cream vs. silver dressing

Figure 436: Silver sulfazidine cream versus silver dressing – mean percentage reduction in ulcer area

	(cream		D	ressing			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Chuangsuwanich 2011	25.06	56.13	20	36.95	56.13	20	100.0%	-11.89 [-46.68, 22.90]	
Total (95% CI)			20			20	100.0%	-11.89 [-46.68, 22.90]	•
Heterogeneity: Not applic Test for overall effect: Z =		0.50)							-100 -50 0 50 100 Favours cream Favours dressing

Figure 437: Silver sulfazidine cream versus silver dressing – proportion of people with treatment-related adverse events

	Crea	m	Dressi	ng		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ced, 95% CI	
Chuangsuwanich 2011	0	20	0	20		Not estimable				
Total (95% CI)		20		20		Not estimable				
Total events	0		0							
Heterogeneity: Not applie	cable						0.01	01	1 10	100
Test for overall effect: No	ot applicab	le						0.1 vours cream	1 10 Favours dr	

Figure 438: Silver sulfazidine cream versus silver dressing – mortality

	Crean	n	Dressi	ing		Peto Odds Ratio	Peto Od	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI	
Chuansuwanich 2011	0	17	0	17		Not estimable			
Total (95% CI)		17		17		Not estimable			
Total events	0		0						
Heterogeneity: Not appl Test for overall effect: N		ole					0.01 0.1 Favours cream	1 10 Favours dres	100 ssing

I.2.7.19 Resin salve vs. hydrofibre

Figure 439: Resin salve versus hydrofibre – proportion of patients completely healed




Figure 440: Resin salve versus hydrofibre – proportion of ulcers completely healed




Figure 441: Resin salve versus hydrofibre – proportion of ulcers improved

	Resin s	alve	Hydrof	ibre		Risk Ratio	Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	ed, 95%	CI		
Sipponen 2008	18	18	10	11	100.0%	1.11 [0.89, 1.40]		-				
Total (95% CI)		18		11	100.0%	1.11 [0.89, 1.40]		-	-			
Total events	18		10									
Heterogeneity: Not as	pplicable						0,5	0.7	-	16	1	
Test for overall effect	Z = 0.93 (P = 0.3	5)				Favour	s hydrofibre	Favou	rs res	sin salve	

Figure 442: Resin salve versus hydrofibre – proportion of ulcers worsened

	Resin s	alve	Hydrof	ibre		Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fixe	ed, 95% CI		
Sipponen 2008	0	18	1	- 11	100.0%	0.07 [0.00, 4.07]	+				
Total (95% CI)		18		11	100.0%	0.07 [0.00, 4.07]					
Total events	0		- 1								
Heterogeneity: Not as	pplicable						0.005	01	10 200		
Test for overall effect	Z=1.28 (P = 0.2	0)					4.1	Favours hydrofibre		

Figure 443: Resin salve versus hydrofibre – proportion of patients with allergic skin reactions

	Resin s	alve	Hydrof	ibre		Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events Total		Events Total		Weight	Peto, Fixed, 95% CI		Peto, Fixed, 95% CI			
Sipponen 2008	1	21	0	16	100.0%	5.82 [0.11, 304.33]	ME.	-		_	
Total (95% CI)		21		16	100.0%	5.82 [0.11, 304.33]		-			
Total events	1		0								
Heterogeneity: Not as	pplicable						0.002	0.1	10	500	
Test for overall effect	Z = 0.87 (P = 0.3	8)					9.7	Favours hyd		

Figure 444: Resin salve versus hydrofibre – mortality

	Resin salve Hydrofibre					Risk Ratio		Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	1	M-H, F	ixed, 95	5% CI			
Sipponen 2008	3	21	4	16	100.0%	0.57 [0.15, 2.20]		_					
Total (95% CI)		21		16	100.0%	0.57 [0.15, 2.20]							
Total events	3		4										
Heterogeneity: Not ap	plicable						0.01	0.1	+	10	100		
Test for overall effect:	Z = 0.81 (F	P = 0.42	2)					u.ı rs resin salv	e Fav	10 ours hydi			

1.2.7.20 Antibiotic ointment vs. foam dressing

Figure 445: Antibiotic ointment versus foam dressing – proportion of patients completely healed

	Antibio	otic	Foar	n		Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H	, Fixe	d, 95%	CI	
Yastrub 2004	15	23	18	21	100.0%	0.76 [0.54, 1.08]					
Total (95% CI)		23		21	100.0%	0.76 [0.54, 1.08]					
Total events	15		18								
Heterogeneity: Not app Test for overall effect:		P = 0.12	2)				0.1 0.2 0 Favours f	1 	2 Favours	5 s anti	10 ibiotic

I.2.7.21 Insulin vs. standard treatment

Figure 446: Insulin versus standard treatment - mortality

	Insuli	in	Placel	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	I M-H, Fixed, 95% CI
Van Ort 1976	0	6	0	8		Not estimable	
Total (95% CI)		6		8		Not estimable	
Total events	0		0				
Heterogeneity: Not app Test for overall effect:		able					0.01 0.1 1 10 100 Favours insulin Favours placebo

I.2.7.22 Growth factors vs. placebo

Figure 447: Growth factors versus placebo – proportion of patients completely healed




Figure 448: Proportion of patients completely healed – growth factors versus placebo – inpatients – grade 3 and 4

	Growth fa	actor	Place	bo		Peto Odds Ratio	Peto Odds Ratio	
Study or Subgroup	up Events Total		Events Total		Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI	
38.1.1 TGF-beta3 ver	sus placeb	ю						
Hirshberg 2003 Subtotal (95% CI)	1	9	0	5	3.0%	4.74 [0.08, 283.15] 4.74 [0.08, 283.15]		
Total events Heterogeneity: Not as Test for overall effect.		= 0.46)	0					

Figure 449: Proportion of patients completely healed – growth factors versus placebo – nursing home patients – grade 2 and above


			- 0 -			-			
	NGF		Placebo			Risk Ratio	Risk		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	l M-H, Fix	ed, 95% CI	
Landi 2003	8	18	1	18	100.0%	8.00 [1.11, 57.57]			
Total (95% CI)		18		18	100.0%	8.00 [1.11, 57.57]		~	
Total events	8		1						
Heterogeneity: Not app	olicable						0.002 0.1	 1 10	500
Test for overall effect: 2	Z = 2.07 (I	P = 0.0	4)				Favours placebo	Favours N	

1.2.7.23 Topical growth factor – beta 3: 1.0ug/cm² versus placebo

Figure 450: Topical growth factor – beta 3: 1.0ug/cm² versus placebo – proportion of people with pressure ulcers completely healed

	TGF-beta 3	3 (1.0)	placel	bo		Peto Odds Ratio		Pet	o Odds I	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto	, Fixed,	95% CI	
Hirshberg 2003	0	4	0	5		Not estimable					
Total (95% CI)		4		5		Not estimable					
Total events	0		0								
Heterogeneity: Not ap							0.01	0.1	1	10	100
Test for overall effect:	Not applicabl	е							ebo Fa	vours TGF	

Figure 451: Topical growth factor – beta 3: 1.0ug/cm² versus placebo – mortality



1.2.7.24 Topical growth factor – beta 3: 2.5ug/cm² versus placebo

Figure 452: Topical growth factor – beta 3: 2.5ug/cm2 versus placebo

	TGF 2	2.5	Placel	bo		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Hirshberg 2003	1	5	0	5	100.0%	7.39 [0.15, 372.38]	
Total (95% CI)		5		5	100.0%	7.39 [0.15, 372.38]	
Total events	1		0				
Heterogeneity: Not ap	plicable						0.002 0.1 1 10 500
Test for overall effect:	Z = 1.00 (I	= 0.3	2)				Favours placebo Favours TGF 2.5

Figure 453: Topical growth factor – beta 3: 2.5ug/cm2 versus placebo

	TGF 2	.5	Place	bo		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI
Hirshberg 2003	0	5	1	4	100.0%	0.11 [0.00, 5.44]	
Total (95% CI)		5		4	100.0%	0.11 [0.00, 5.44]	
Total events	0		1				
Heterogeneity: Not app	licable						
Test for overall effect: 2	Z = 1.12 (F	P = 0.26	6)				0.01

1.2.7.25 Topical growth factor – beta 3: 1.02g/cm² versus 2.52g/cm²

Figure 454: Topical growth factor – beta 3: 1.02g/cm² versus 2.52g/cm² – proportion of patients completely healed




Figure 455: Topical growth factor – beta 3: 1.02g/cm² versus 2.52g/cm² – mortality

	TGF-beta	3 (1.0)	TGF-beta	3 (2.5)		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Hirshberg 2003	1	4	0	5	100.0%	9.49 [0.18, 489.97]	
Total (95% CI)		4		5	100.0%	9.49 [0.18, 489.97]	
Total events	1		0				
Heterogeneity: Not ap Test for overall effect:	•	0.26)					1

1.2.7.26 Nerve growth factor (2.5 S murine) versus placebo

Figure 456: Nerve growth factor (2.5 S murine) versus placebo – proportion of patients completely healed (foot ulcers)

Secretary in	NGF	Place	Placebo		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ced, 95% CI	
Landi 2003	8	18	1	18	100.0%	8.00 [1.11, 57.57]		4.16		
Total (95% CI)		18		18	100.0%	8.00 [1.11, 57.57]			-	
Total events	8		1							
Heterogeneity: Not as		m - 0.0					0.002	0.1	1 10	500
Test for overall effect	Z= 2.07	(P = 0.0	14)				Favour	rs placeb	Favours NG	-

Figure 457: Nerve growth factor (2.5 S murine) versus placebo – proportion of patients improved by 3 or more grades (foot ulcers)

	NGF		Place	bo		Peto Odds Ratio	Peto Oc	lds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
Landi 2003	5	18	0	18	100.0%	9.56 [1.48, 61.61]		_
Total (95% CI)		18		18	100.0%	9.56 [1.48, 61.61]		•
Total events	5		0					
Heterogeneity: Not as	plicable						0.001 0.1	10 1000
Test for overall effect	Z = 2.38	Favours placebo						

Figure 458: Nerve growth factor (2.5 S murine) versus placebo – proportion of patients improved by 2 grades (foot ulcers)

	NGF		Place	bo		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI
Landi 2003	14	18	2	18	100.0%	7.00 [1.85, 26.46]		-
Total (95% CI)		18		18	100.0%	7.00 [1.85, 26.46]	11	•
Total events	14		2					
Heterogeneity: Not as	plicable						0.002 0.1 1	10 500
Test for overall effect	Z= 2.87	(P = 0.0)	004)				Favours placebo	

Figure 459: Nerve growth factor (2.5 S murin) versus placebo – proportion of patients improved by 1 grade (foot ulcers)

	NGF		Placebo			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Landi 2003	18	18	8	18	100.0%	2.18 [1.31, 3.61]	
Total (95% CI)		18		18	100.0%	2.18 [1.31, 3.61]	•
Total events	18		8				
Heterogeneity: Not as	pplicable						005 00
Test for overall effect	Z = 3.02	P = 0.0	003)				0.05 0.2 1 5 2 Favours placebo Favours NGF

Figure 460: Nerve growth factor (2.5 S murin) versus placebo – mean mm² reduction in ulcer area (foot ulcers)

		NGF Placebo						Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
Landi 2003	738	393	18	485	384	18	100.0%	253.00 [-0.83, 506.83]			
Total (95% CI)			18			18	100.0%	253.00 [-0.83, 506.83]	-		
Heterogeneity, Not as Test for overall effect			0.05)						-1000 -500 0 500 1000 Favours placebo Favours NGF		

Figure 461: Nerve growth factor (2.5 S murin) versus placebo – mean mm2 reduction in ulcer area (foot ulcers) – grade 2 and above




Figure 462: Nerve growth factor (2.5 S murin) versus placebo – proportion of people with treatment-related adverse events

	NGF	:	Placel	00		Peto Odds Ratio	Peto Od	lds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
Landi 2003	0	18	0	18		Not estimable		
Total (95% CI)		18		18		Not estimable		
Total events	0		0					
Heterogeneity: Not app Test for overall effect: I		able					0.01 0.1 Favours NGF	1 10 100 Favours placebo

Figure 463: Nerve growth factor (2.5 S murin) versus placebo – mortality

	NGF	=	Placel	bo		Peto Odds Ratio	Peto Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI	
Landi 2003	1	19	0	19	100.0%	7.39 [0.15, 372.38]		→
Total (95% CI)		19		19	100.0%	7.39 [0.15, 372.38]		
Total events	1		0					
Heterogeneity: Not approximately Test for overall effect:		P = 0.3	2)				0.01 0.1 1 10 1 Favours mNGF Favours place	100 ebo

1.2.7.27 Recombinant platelet-derived growth factor (1002g/ml) versus placebo

Figure 464: Recombinant platelet-derived growth factor (100½g/ml) versus placebo – proportion of patients completely healed


	PDGF-BB	PDGF-BB 100 Placebo				Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Mustoe 1994	6	16	2	14	77.0%	2.63 [0.63, 10.98]	-
Robson 1992b	2	13	0	7	23.0%	2.86 [0.16, 52.42]	•
Total (95% CI)		29		21	100.0%	2.68 [0.74, 9.74]	•
Total events	8		2				
Heterogeneity: Chi2=	0.00, df=	(P = 0	96); 12=	0%			101 101 100
Test for overall effect							0.01 0.1 1 10 100 Favoursplacebo Favours PDGF-BB 100

Figure 465: Recombinant platelet-derived growth factor (100 g/ml) versus placebo – mortality

	PDGF-B	PDGF-BB 100		00		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Cl Peto, Fixed, 95% Cl
Robson 1992b	0	35	0	15		Not estimable	9
Total (95% CI)		35		15		Not estimable	
Total events	0		0				
Heterogeneity: Not app Test for overall effect:		ble					0.01 0.1 1 10 100 Favours rPDGF-BB Favours placebo


I.2.7.28 Recombinant platelet-derived growth factor: 100 g/ml versus 300 g/ml

Figure 466: Recombinant platelet-derived growth factor: 1002g/ml versus 3002g/ml – proportion of patients completely healed



I.2.7.29 Recombinant platelet-derived growth factor (3002g/ml) versus placebo

Figure 467: Recombinant platelet-derived growth factor (300@g/ml) versus placebo – proportion of patients completely healed



I.2.7.30 Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus placebo

Figure 468: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus placebo – proportion of patients completely healed (after 1 year)




Figure 469: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus placebo – proportion of patients worsened (after 1 year)

	GM-C	SF	Place	bo		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Payne 2001	2	2 14	0	13	100.0%	7.43 [0.44, 125.76]	
Total (95% CI)		14		13	100.0%	7.43 [0.44, 125.76]	
Total events	2		0				
Heterogeneity: Not as	pplicable						0.002 0.1 1 10 500
Test for overall effect	Z=1.39	(P = 0.1)	6)				Favours GM-CSF Favours placebo

Figure 470: Granulo-macrophage/colony-stimulating factor (2.0⊡g/cm²) versus placebo – mean percentage reduction in ulcer area

	GN	GM-CSF				0		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Robson 2000	67	24	15	71	11	15	100.0%	-4.00 [-17.36, 9.36]	_
Total (95% CI)			15			15	100.0%	-4.00 [-17.36, 9.36]	•
Heterogeneity, Not as Test for overall effect			0.56)						-50 -25 0 25 50 Favours placebo Favours GM-CSF

Figure 471: Granulo-macrophage/colony-stimulating factor (2.0⊡g/cm²) versus placebo –

	GM-CS	SF	Placel	00		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Robson 2000	0	15	0	15		Not estimable	
Total (95% CI)		15		15		Not estimable	
Total events	0		0				
Heterogeneity: Not app Test for overall effect: I		able				F	0.01 0.1 1 10 100 avours rGM-CSF 2.0 Favours placebo

I.2.7.31 Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus basic fibroblast growth factor (5.0½g/cm²)

Figure 472: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus basic fibroblast growth factor (5.02g/cm²) – proportion of patients completely healed (after 1 year)




Figure 473: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus basic fibroblast growth factor (5.02g/cm²) – proportion of patients worsened (after 1 year)

	GM-C	SF	BFG	F		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI			
Payne 2001	2	14	4	14	100.0%	0.50 [0.11, 2.30]	_			
Total (95% CI)		14		14	100.0%	0.50 [0.11, 2.30]	-			
Total events	2		4							
Heterogeneity: Not as	pplicable						0.002 0.1 1 10 500			
Test for overall effect	Z = 0.89	(P = 0.3)	37)				Favours GM-CSF Favours BFGF			

Figure 474: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus basic fibroblast growth factor (5.02g/cm²) – mean percentage reduction in ulcer area

	GN	1-CS	F	BFGF				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
Robson 2000	67	24	15	75	19	15	100.0%	-8.00 [-23.49, 7.49]			
Total (95% CI)			15			15	100.0%	-8.00 [-23.49, 7.49]	•		
Heterogeneity. Not a Test for overall effect			0.31)						-100 -50 0 50 100 Favours BFGF Favours GM-CSF		

Figure 475: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus basic fibroblast growth factor (5.0½g/cm²) – mortality

	GM-C	SF	BFG	F		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Robson 2000	0	15	0	15		Not estimable	
Total (95% CI)		15		15		Not estimable	
Total events	0		0				
Heterogeneity: Not appropriate the Heterogeneity: N		able					0.01 0.1 1 10 100 Favours rGM-CSF 2.0 Favours rBFGF 5.0

I.2.7.32 Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²)

Figure 476: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – proportion of patients completely healed (after 1 year)

	GM-C	SF	GM-CSF	BFGF		Risk Ratio	Risk Ratio
Study or Subgroup	Events Total		Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
Payne 2001	8	14	9	9 13	100.0%	0.83 (0.46, 1.48	8]
Total (95% CI)		14		13	100.0%	0.83 [0.46, 1.48]	31
Total events	8		9				
Heterogeneity: Not ap	plicable						0.05 0.2 1 5 20
Test for overall effect: Z = 0.65 (P = 0			52)				0.05 0.2 1 5 20 Favours GM-CSF/BFGF Favours GM-CSF

Figure 477: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – proportion of patients worsened (after 1 year)

	GM-C	SF	GM-CSF	BFGF		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	1, 95% CI	
Payne 2001	2	14	1	13	100.0%	1.86 [0.19, 18.13]		_		
Total (95% CI)		14		13	100.0%	1.86 [0.19, 18.13]				
Total events	2		1							
Heterogeneity: Not as	plicable						0.001	01	10	1000
Test for overall effect	Z = 0.53	(P = 0.5)	59)					urs GM-CSF	Favours GM	

Figure 478: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – mean percentage reduction in ulcer area

	GN	I-CSI		GM-C	SF/BF	GF		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI
Robson 2000	67	24	15	68	21	16	100.0%	-1.00 [-16.92, 14.92	1 -
Total (95% CI)			15			16	100.0%	-1.00 [-16.92, 14.92]	. •
Heterogeneity: Not a Test for overall effect			0.90)						-100 -50 0 50 100

Figure 479: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – mortality

	GM-C	SF	GM-CSF	/BFGF		Peto Odds Ratio		Peto Od	ds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI		
Robson 2000	0	15	0	16		Not estimable					
Total (95% CI)		15		16		Not estimable					
Total events	0		0								
Heterogeneity: Not approperties and the Test for overall effect:		able).1	1 1	0	100
rest for overall effect.	ινοι αρριιο	abie					Favours r	GM-CSF 2.0	Favours rG	M-CSF	/rBFGF

1.2.7.33 Basic fibroblast growth factor (5.02g/cm²) versus placebo

Figure 480: Basic fibroblast growth factor (5.0½g/cm²) versus placebo – proportion of patients completely healed (after 1 year)

	BFG	F	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Payne 2001	10	14	10	13	100.0%	0.93 [0.59, 1.45]	_
Total (95% CI)		14		13	100.0%	0.93 [0.59, 1.45]	-
Total events	10		10				
Heterogeneity: Not as	pplicable						02 05 1 2 5
Test for overall effect	Z = 0.33	(P = 0.7)	74)				Favours placebo Favours BFGF

Figure 481: Basic fibroblast growth factor (5.02g/cm²) versus placebo – proportion of patients worsened (after 1 year)

	BFG	F	Place	bo		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Payne 2001	4	14	0	13	100.0%	8.85 [1.10, 71.20]	
Total (95% CI)		14		13	100.0%	8.85 [1.10, 71.20]	-
Total events	4		0				
Heterogeneity: Not as	pplicable						0.002 0.1 1 10 50
Test for overall effect	Z = 2.05	(P = 0.0)	(4)				Favours BGFG Favours placeb

Figure 482: Basic fibroblast growth factor (5.0½g/cm²) versus placebo – mean percentage reduction in ulcer area

	BFGF			Placebo				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Robson 2000	75	19	15	71	11	15	100.0%	4.00 [-7.11, 15.11]	
Total (95% CI)			15			15	100.0%	4.00 [-7.11, 15.11]	•
Heterogeneity: Not as	pplicable								-20-10 0 10 20
Test for overall effect	Z = 0.71	(P=	0.48)						Favours placebo Favours BGFG

Figure 483: Basic fibroblast growth factor (5.0½g/cm²) versus placebo – mortality

	BFG	F	Placel	bo		Peto Odds Ratio	Peto Oc	dds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fix	ed, 95% CI
Robson 2000	0	15	0	15		Not estimable		
Total (95% CI)		15		15		Not estimable		
Total events	0		0					
Heterogeneity: Not app	olicable						0.01 0.1	1 10 100
Test for overall effect:	Not applic	able						Favours placebo

I.2.7.34 Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²)

Figure 484: Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – proportion of patients completely healed (after 1 year)

	BFG	F	GM-CSF/BFGF		•	Risk Ratio	Risk Ratio
Study or Subgroup	Events Total		Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Payne 2001	10	14	9	13	100.0%	1.03 [0.63, 1.69	aj —
Total (95% CI)		14		13	100.0%	1.03 [0.63, 1.69	01
Total events	10		9				
Heterogeneity: Not as	pplicable						01 02 05 1 2 5 10
Test for overall effect	Z = 0.12	(P = 0.9)	30)			- 1	Favours GM-CSF/BFGF Favours BFGF

Figure 485: Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – proportion of patients worsened (after 1 year)




Figure 486: Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – mean percentage reduction in ulcer area




Figure 487: Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – mortality

	BFG	BFGF		GM-CSF/BFGF		Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl		Peto, Fix	ed, 95% C	1	
Robson 2000	0	15	0	16		Not estimable					
Total (95% CI)		15		16		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:		able					0.01 Fav	0.1 ours rBFGF 5.0	1 Favours	10 rGM-	100 CSF/rBFG

I.2.7.35 Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) versus placebo

Figure 488: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) and basic fibroblast growth factor (5.02g/cm²) versus placebo – proportion of patients completely healed (after 1 year)



Figure 489: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) versus placebo – proportion of patients worsened (after 1 year)

	GM-CSF/	BFGF	Place	bo		Peto Odds Ratio		Peto Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I P	eto, Fixed, 95% CI		
Payne 2001	1	13	0	13	100.0%	7.39 [0.15, 372.38]			
Total (95% CI)		13		13	100.0%	7.39 [0.15, 372.38]			
Total events	1		0							
Heterogeneity: Not as	pplicable						0.001	1 10 1000		
Test for overall effect	Z = 1.00 (8)	P = 0.32)					F/BFGF Favours placebo		

Figure 490: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) versus placebo – mean percentage reduction in ulcer area




Figure 491: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) versus placebo – mortality

_					•	•	
	GM-CSF/BFGF P					Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Robson 2000	0	16	0	15		Not estimable	
Total (95% CI)		16		15		Not estimable	
Total events	0		0				
Heterogeneity: Not app	licable						
Test for overall effect: N	Not applicat	ماد					0.01 0.1 1 10 100
rest for overall effect. I	voi applicat	,,,				Fav	ours rGM-CSE/rBEGE Favours placeho

I.2.7.36 Recombinant platelet-derived growth factor (100 g/g) versus placebo

Figure 492: Recombinant platelet-derived growth factor (1002g/g) versus placebo – proportion of patients completely healed

	PDGF-BE	100	Place	bo		Peto Odds Ratio		Peto Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix		ed, 95% CI	
Rees 1999	7	31	0	31	100.0%	9.19 [1.93, 43.75]		1111	_	
Total (95% CI)		31		31	100.0%	9.19 [1.93, 43.75]			-	
Total events	7		0							
Heterogeneity: Not a Test for overall effect		P = 0.00	5)				0.005 Fav	0.1 ours placebo	10 200 Favours PDGF-BB 100	

Figure 493: Recombinant platelet-derived growth factor (100½g/g) versus placebo – proportion of patients ≥ 90% healed

	PDGF-BE	100	Place	bo		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI
Rees 1999	18	31	9	31	100.0%	2.00 [1.07, 3.74]		_
Total (95% CI)		31		31	100.0%	2.00 [1.07, 3.74]		•
Total events	18		9					
Heterogeneity: Not as	pplicable						0.05 0.2	5 20
Test for overall effect	Z = 2.17 (8	P = 0.03)					Favours PDGF-BB 100

Figure 494: Recombinant platelet-derived growth factor (100½g/g) versus placebo – proportion of patients with osteomyelitis




Figure 495: Recombinant platelet-derived growth factor (100½g/g) versus placebo – proportion of patients with an infection




Figure 496: Recombinant platelet-derived growth factor (100½g/g) versus placebo – proportion of patients with adverse events other than osteomyelitis, infection and sepsis

	PDGF-BE	100	Place	bo		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	1	M-H, Fixe	d, 95% CI	
Rees 1999	2	31	2	31	100.0%	1.00 [0.15, 6.66]			
Total (95% CI)		31		31	100.0%	1.00 [0.15, 6.66	1		_	
Total events	2		2							
Heterogeneity: Not a							0.001	01	10	1000
Test for overall effect	Z = 0.00 (R)	P = 1.00)					DGF-BB 100		

Figure 497: Recombinant platelet-derived growth factor (1002g/g) versus placebo – mortality

	PDGF-BI	B 100	Place	bo		Peto Odds Ratio		Peto Od	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	P	eto, Fix	ed, 95% CI	
Rees 1999	0	31	0	31		Not estimable				
Total (95% CI)		31		31		Not estimable				
Total events	0		0							
Heterogeneity: Not ap	plicable						0.01 0.	1	1 10	100
Test for overall effect:	Not applica	ble						-	Favours pl	

I.2.7.37 Recombinant platelet-derived growth factor: 1002g/g versus 3002g/g alternated with placebo

Figure 498: Recombinant platelet-derived growth factor: 100@g/g versus 300@g/g alternated with placebo – proportion of patients completely healed

	PDGF-BB	100	PDGF-BB/pla	acebo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Rees 1999	7	31	6	32	100.0%	1.20 (0.46, 3.18	n —
Total (95% CI)		31		32	100.0%	1.20 [0.46, 3.18]	
Total events	7		6				
Heterogeneity: Not a	pplicable						0.01 0.1 10 100
Test for overall effect	Z = 0.37 (F	= 0.71)				Favours PDGF-BB/placebo Favours PDGF-BB 100

Figure 499: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g alternated with placebo – proportion of patients ≥ 90% healed

	PDGF-BE	3 100	PDGF-BB/pl	acebo		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixe	ed, 95% CI
Rees 1999	18	31	19	32	100.0%	0.98 (0.65, 1.48)	1 -	_
Total (95% CI)		31		32	100.0%	0.98 [0.65, 1.48]		
Total events	18		19					
Heterogeneity: Not as	pplicable						02 05	1 1 1
Test for overall effect	Z= 0.11 (P = 0.92)				Favours PDGF-BB/placebo	Favours PDGF-BB 100

Figure 500: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g alternated with placebo – proportion of patients with osteomyelitis

	PDGF-BE	3 100	PDGF-BB/pl	acebo		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI
Rees 1999	2	31	1 .	32	100.0%	2.06 [0.20, 21.63]		
Total (95% CI)		31		32	100.0%	2.06 [0.20, 21.63]		
Total events	2		1					
Heterogeneity: Not as	pplicable						0.001 0.1	1 10 1000
Test for overall effect	Z = 0.60 (P = 0.55)					Favours PDGF-BB/placebo

Figure 501: Recombinant platelet-derived growth factor: 100@g/g versus 300@g/g alternated with placebo – infection

	PDGF-B	B 100	PDGF-BB/p	lacebo		Peto Odds Ratio		Peto Od	lds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I	Peto, Fixe	ed, 95% CI		
Rees 1999	0	31	0	32		Not estimable					
Total (95% CI)		31		32		Not estimable					
Total events	0		0					1			
Heterogeneity: Not ap Test for overall effect:	•	ble						D.1 DGF-BB 100	1 10 Favours rPI	-	100 B 300

Figure 502: Recombinant platelet-derived growth factor: 100@g/g versus 300@g/g alternated with placebo – proportion of patients with sepsis

	PDGF-BE	3 100	PDGF-BB/pl	acebo		Peto Odds Ratio	Peto O	dds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
Rees 1999	0	31	1	32	100.0%	0.14 [0.00, 7.04]	-	
Total (95% CI)		31		32	100.0%	0.14 [0.00, 7.04]		
Total events	0		1					
Heterogeneity; Not as	pplicable						0.002 0.1	1 10 500
Test for overall effect	Z = 0.98 (P = 0.32)					Favours PDGF-BB/placeb

Figure 503: Recombinant platelet-derived growth factor: 100@g/g versus 300@g/g alternated with placebo – Proportion of patients with adverse events other than osteomyelitis, infection and sepsis

	PDGF-BI	B 100	PDGF-BB/p	lacebo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	2	31	3	32	100.0%	0.69 [0.12, 3.84]	
Total (95% CI)		31		32	100.0%	0.69 [0.12, 3.84]	
Total events	2		3				
Heterogeneity: Not appropriate the Test for overall effect:		= 0.67)					0.01

Figure 504: Recombinant platelet-derived growth factor: 100@g/g versus 300@g/g alternated with placebo – mortality

	PDGF-B	B 100	PDGF-BB/p	lacebo		Peto Odds Ratio		Peto O	dds Ratio		
Study or Subgroup	Events	Total	Events	Total \	Weight	Peto, Fixed, 95% C	l	Peto, Fix	ed, 95% CI		
Rees 1999	0	31	0	32		Not estimable					
Total (95% CI)		31		32		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:	•	ble					0.01 Favou	0.1 rs rPDGF-BB 100	1 10 Favours rPD) OGF-E	100 3B 300

I.2.7.38 Recombinant platelet-derived growth factor: 1002g/g versus 3002g/g

Figure 505: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g – proportion of patients completely healed

-	PDGF-B	B 100	PDGF-B	B 300		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	
Rees 1999	7	31	1	30	100.0%	6.77 [0.89, 51.80]	
Total (95% CI)		31		30	100.0%	6.77 [0.89, 51.80]	
Total events	7		1				
Heterogeneity: Not app		0.07\					0.001 0.1 1 10 1000
Test for overall effect:	Z = 1.84 (P	= 0.07)					Favours PDGF-BB 300 Favours PDGF-BB 100

Figure 506: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g – proportion of patients ≥ 90% healed

	PDGF-BE	100	PDGF-BE	3 300		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	18	31	12	30	100.0%	1.45 [0.85, 2.47]	-
Total (95% CI)		31		30	100.0%	1.45 [0.85, 2.47]	-
Total events	18		12				
Heterogeneity. Not as	pplicable						01 02 05 1 2 5 10
Test for overall effect	Z = 1.38 (F	P = 0.17)				Favours PDGF-BB 300 Favours PDGF-BB 100

Figure 507: Recombinant platelet-derived growth factor: 1002g/g versus 3002g/g – proportion of patients with osteomyelitis

	PDGF-BE	3 100	PDGF-BE	300		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Rees 1999	2	31	0	30	100.0%	7.40 [0.45, 121.11]	
Total (95% CI)		31		30	100.0%	7.40 [0.45, 121.11]	
Total events	2		0				
Heterogeneity: Not as	pplicable						0.002 0.1 1 10 500
Test for overall effect	Z= 1.40 (P = 0.16)				Favours PDGF-BB 100 Favours PDGF-BB 300

Figure 508: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g – proportion of patients with an infection

	PDGF-BE	100	PDGF-BE	300		Peto Odds Ratio	Peto Od	lds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI			
Rees 1999	0	31	1	30	100.0%	0.13 (0.00, 6.60)	_			
Total (95% CI)		31		30	100.0%	0.13 [0.00, 6.60]				
Total events	0		1							
Heterogeneity: Not as	pplicable						0.001 0.1	10 1000		
Test for overall effect	Z= 1.02 (F	= 0.31)					Favours PDGF-BB 300		

Figure 509: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g – proportion of patients with adverse events other than osteomyelitis, infection and sepsis

	PDGF-BI	3 100	PDGF-B	B 300		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Rees 1999	2	31	2	30	100.0%	0.97 [0.15, 6.44]	
Total (95% CI)		31		30	100.0%	0.97 [0.15, 6.44]	
Total events	2		2				
Heterogeneity: Not app Test for overall effect: 2		= 0.97)					0.01 0.1 1 10 100 Favours PDGF-BB 100 Favours PDGF-BB 300

Figure 510: Recombinant platelet-derived growth factor: 1002g/g versus 3002g/g – mortality

	PDGF-B	B 100	PDGF-B	B 300		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Rees 1999	0	31	0	30		Not estimable	
Total (95% CI)		31		30		Not estimable	,
Total events	0		0				
Heterogeneity: Not ap Test for overall effect:	•	ble					0.01 0.1 1 10 100 Favours rPDGF-BB 100 Favours rPDGF-BB 300
							1 avouis 11 Dai -DD 100 T avouis 11 Dai -DD 300

1.2.7.39 Recombinant platelet-derived growth factor (300 g/g) alternated with placebo versus placebo

Figure 511: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients completely healed




Figure 512: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients ≥ 90% healed

	PDGF-BB/placebo		Placebo			Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI		
Rees 1999	19	32	9	31	100.0%	2.05 [1.10, 3.80]		-		
Total (95% CI)		32		31	100.0%	2.05 [1.10, 3.80]		•		
Total events	19		9							
Heterogeneity. Not as	pplicable						0.05 0.2	200		
Test for overall effect	Z= 2.26 (P=	0.02)						Favours PDGF-BB/place		

Figure 513: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients with osteomyelitis




Figure 514: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients with an infection




Figure 515: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients with sepsis

	PDGF-BB/pl	Placebo			Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	ents Total		Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI			
Rees 1999	1	32	0	31	100.0%	7.16 [0.14, 361.11]		-		
Total (95% CI)		32		31	100.0%	7.16 [0.14, 361.11]				
Total events	1		0							
Heterogeneity: Not as	pplicable					0.0	02 0.1 1 10	500		
Test for overall effect	Z = 0.98 (P =	0.32)					PDGF-BB/placebo Favours placebo	500		

Figure 516: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients with adverse events other than osteomyelitis, infection and sepsis




Figure 517: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo − mortality

	PDGF-BB/p	Placel	bo	Peto Odds Ratio			Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C		Peto, Fi	xed, 95% CI		
Rees 1999	0	32	0	31		Not estimable					
Total (95% CI)		32		31		Not estimable					
Total events	0		0								
Heterogeneity: Not app	plicable						0.01	0.1	1 1		100
Test for overall effect:	Not applicable					Fa		DGF/placebo	Favours p) lacel	

1.2.7.40 Recombinant platelet-derived growth factor: 3002g/g alternated with placebo versus 3002g/g

Figure 518: Recombinant platelet-derived growth factor: 300½g/g alternated with placebo versus 300½g/g – proportion of patients completely healed




Figure 519: Recombinant platelet-derived growth factor: 300½g/g alternated with placebo versus 300½g/g – proportion of patients ≥ 90% healed

	PDGF-BB/pl	PDGF-BB 300		Risk Ratio		Risk Ratio	
Study or Subgroup	Events Total		Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	19	32	12	30	100.0%	1.48 [0.88, 2.51]	
Total (95% CI)		32		30	100.0%	1.48 [0.88, 2.51]	-
Total events	19		12				
Heterogeneity: Not as	pplicable						1 1 1 1 1
Test for overall effect	Z= 1.48 (P=	0.14)					Favours PDGF-BB 300 Favours PDGF-BB/placebo

Figure 520: Recombinant platelet-derived growth factor: 300½g/g alternated with placebo versus 300½g/g – proportion of patients with osteomyelitis

	PDGF-BB/placebo		PDGF-BE	3 300		Peto Odds Ratio	Peto	Odds Ratio	
Study or Subgroup	Events	Total	Events	Events Total		Peto, Fixed, 95% C	Peto,	Fixed, 95% CI	
Rees 1999	1	32	0	30	100.0%	6.94 [0.14, 350.54]	_		_
Total (95% CI)		32		30	100.0%	6.94 [0.14, 350.54]	_		
Total events	1		0						
Heterogeneity: Not as	opticable						0.001 0.1	10	1000
Test for overall effect	Z = 0.97 (P =	0.33)					Favours PDGF-BB/place		

Figure 521: Recombinant platelet-derived growth factor: 300½g/g alternated with placebo versus 300½g/g – proportion of patients with an infection




Figure 522: Recombinant platelet-derived growth factor: 300½g/g alternated with placebo versus 300½g/g – proportion of patients with sepsis




Figure 523: Recombinant platelet-derived growth factor: 300½g/g alternated with placebo versus 300½g/g – proportion of patients with adverse events other than osteomyelitis, infection and sepsis




Figure 524: Recombinant platelet-derived growth factor: 300@g/g alternated with placebo versus 300@g/g – mortality

	PDGF-BB/p	PDGF-BB 300			Peto Odds Ratio		Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ked, 95% CI	
Rees 1999	0	32	0	30		Not estimable				
Total (95% CI)		32		30		Not estimable				
Total events	0		0							
Heterogeneity: Not ap Test for overall effect:	•					Favoi	0.01 urs rP[0.1 OGF-BB/placebo	1 10 Favours place	100 ebo

I.2.7.41 Recombinant platelet-derived growth factor (3002g/g) versus placebo

Figure 525: Recombinant platelet-derived growth factor (300½g/g) versus placebo – proportion of patients completely healed

	PDGF-BE	3 300	Place	bo		Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	vents Total		Peto, Fixed, 95% CI	Peto, Fixed		ed, 95% CI	
Rees 1999	1	30	0	31	100.0%	7.64 [0.15, 385.21]	1.			
Total (95% CI)		30		31	100.0%	7.64 [0.15, 385.21]				
Total events	1		0							
Heterogeneity: Not as	plicable						0.001	0.1	10	1000
Test for overall effect	Z = 1.02 (6)	P = 0.31)					urs placebo		

Figure 526: Recombinant platelet-derived growth factor (300½g/g) versus placebo – proportion of patients ≥ 90% healed

	PDGF-BB 300		Placebo			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Events Total		M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	12	30	9	31	100.0%	1.38 [0.68, 2.78]	1
Total (95% CI)		30		31	100.0%	1.38 [0.68, 2.78]	•
Total events	12		9				11
Heterogeneity: Not as	plicable						0.01 0.1 10 100
Test for overall effect	Z = 0.89 (F	= 0.37)				Favours placebo Favours PDGF-BB 300

Figure 527: Recombinant platelet-derived growth factor (300½g/g) versus placebo – proportion of patients with osteomyelitis

	PDGF-BB	300	Place	bo	T in	Peto Odds Ratio		Peto Od	ds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Fixed, 95% CI		Peto, Fixed, 95% CI		
Rees 1999	0	30	1	31	100.0%	0.14 [0.00, 7.05	1 —				
Total (95% CI)		30		31	100.0%	0.14 [0.00, 7.05	1 -		_		
Total events	0		1								
Heterogeneity: Not as	pplicable						0.001	0.1	10	1000	
Test for overall effect	Z = 0.98 (F	= 0.33)					DGF-BB 300			

Figure 528: Recombinant platelet-derived growth factor (300⊡g/g) versus placebo − proportion of patients with an infection

	PDGF-BE	300	Place	bo		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixe	ed, 95% CI
Rees 1999	1	30	- 1	31	100.0%	1.03 [0.07, 15.78	1	
Total (95% CI)		30		31	100.0%	1.03 [0.07, 15.78	1	
Total events	1		- 1					
Heterogeneity: Not as	pplicable						0.01 0.1	10 100
Test for overall effect	Z = 0.02 (8	P = 0.98)				Favours PDGF-BB 300	

Figure 529: Recombinant platelet-derived growth factor (300⊡g/g) versus placebo − proportion of patients with sepsis

	PDGF-B	B 300	Place	bo		Peto Odds Ratio		Pet	o Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	<u> </u>	Peto	, Fixed	, 95% CI	
Rees 1999	0	30	0	31		Not estimable					
Total (95% CI)		30		31		Not estimable					
Total events	0		0								
Heterogeneity: Not ap	plicable						0.01	0.1	- ‡	10	100
Test for overall effect:	Not applica	ble				Fa		rPDGF-BB	300 F	avours pla	

Figure 530: Recombinant platelet-derived growth factor (300½g/g) versus placebo – proportion of patients with adverse events other than osteomyelitis, infection and sepsis




Figure 531: Recombinant platelet-derived growth factor (300⊡g/g) versus placebo −mortality

	PDGF-BB/p	lacebo	Placel	bo		Peto Odds Ratio			Peto Oc	lds Rat	io	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI			Peto, Fix	ed, 95%	% CI	
Rees 1999	0	32	0	31		Not estimable						
Total (95% CI)		32		31		Not estimable						
Total events	0		0									
Heterogeneity: Not ap	plicable						0.01		.1	 	10	100
Test for overall effect:	Not applicable					Fa		-	F/placebo	Favou	urs place	

I.2.7.42 Recombinant platelet-derived growth factor: 1.02g/g versus placebo

Figure 532: Recombinant platelet-derived growth factor: 1.02g/g versus placebo – proportion of people completely healed




Figure 533: Recombinant platelet-derived growth factor: 1.02g/g versus placebo – proportion of people with infection

	PDGF-B	B 1.0	Placel	bo		Risk Ratio		Risk Rat	io	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M	I-H, Fixed, 9	95% CI	
Robson 1992b	0	4	0	7		Not estimable				
Total (95% CI)		4		7		Not estimable				
Total events	0		0							
Heterogeneity: Not ap Test for overall effect:	•	ıble				F	0.01 0.1 avours PDGF		10 vours plac	100 ebo

Figure 534: Recombinant platelet-derived growth factor: 1.0 g/g versus placebo – mortality

	PDGF-B	B 1.0	Place	bo		Peto Odds Ratio		Peto	Odds R	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l	Peto, I	Fixed, 9	5% CI	
Robson 1992b	0	4	0	7		Not estimable					
Total (95% CI)		4		7		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:	•	able				Fa	0.01 avours r	0.1 PDGF-BB 1	.0 Fav	10 ours place	100 ebo

I.2.7.43 Recombinant platelet-derived growth factor-BB (1.02g/g) vs. recombinant platelet-derived growth factor-BB (10.02g/g)


Figure 535: Recombinant platelet-derived growth factor-BB (1.0½g/g) vs. recombinant platelet-derived growth factor-BB (10.0½g/g) – proportion of people with pressure ulcers completely healed

	PDGF-B	B 1.0	PDGF-BI	B 10.0		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Robson 1992b	0	4	0	4		Not estimable	
Total (95% CI)		4		4		Not estimable	
Total events	0		0				
Heterogeneity: Not approximately Test for overall effect:		ble					0.01

Figure 536: Recombinant platelet-derived growth factor-BB (1.0½g/g) vs. recombinant platelet-derived growth factor-BB (10.0½g/g) – proportion of people with an infection

	PDGF-B	B 1.0	PDGF-B	B 10.0		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fix	ed, 95% CI	
Robson 1992b	0	4	0	4		Not estimable				
Total (95% CI)		4		4		Not estimable				
Total events	0		0							
Heterogeneity: Not appropriate the control of the c	•	able					0.01 Favour	0.1 rs PDGF-BB 1.0	1 1 Favours PE	

Figure 537: Recombinant platelet-derived growth factor-BB (1.0½g/g) vs. recombinant platelet-derived growth factor-BB (10.0½g/g) - mortality



I.2.7.44 Recombinant platelet-derived growth factor: 1.02g/g versus 100.02g/g

Figure 538: Recombinant platelet-derived growth factor: 1.02g/g versus 100.02g/g – proportion of patients completely healed




Figure 539: Recombinant platelet-derived growth factor: 1.02g/g versus 100.02g/g – proportion of patients with infection

	PDGF-B	B 1.0	PDGF-BB	100.0		Peto Odds Ratio		Peto Od	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl		Peto, Fix	ed, 95% CI	
Robson 1992b	0	4	0	5		Not estimable				
Total (95% CI)		4		5		Not estimable				
Total events	0		0							
Heterogeneity: Not ap Test for overall effect:	•	ble					0.01 0 Favours rPI		t 1 1 10 Favours rPI	

Figure 540: Recombinant platelet-derived growth factor: 1.02g/g versus 100.02g/g – mortality

	PDGF-B	B 1.0	PDGF-BB	100.0		Peto Odds Ratio		Peto Oc	lds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C		Peto, Fix	ed, 95% CI		
Robson 1992b	0	4	0	5		Not estimable					
Total (95% CI)		4		5		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:	•	ıble					0.01 Favours	0.1 s rPDGF-BB 1.0	1 1 Favours rP	-	100 BB 100

I.2.7.45 Recombinant platelet-derived growth factor-BB (10.0□g/g) versus placebo

Figure 541: Recombinant platelet-derived growth factor-BB (10.02g/g) versus placebo – proportion of people with pressure ulcers completely healed

p p								-			
	PDGF-BE	3 10.0	Place	bo		Peto Odds Ratio		Peto	Odds F	latio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto,	Fixed, 9	5% CI	
Robson 1992b	0	4	0	7		Not estimable					
Total (95% CI)		4		7		Not estimable					
Total events	0		0								
Heterogeneity: Not app Test for overall effect: N		ole				_	0.01	0.1	1_	10	100
. ccc. c.bian onoci.i	.o. applious	0.0				Fav	vours rF	DGF-BB 10).U Fav	ours place	:bo

Figure 542: Recombinant platelet-derived growth factor-BB (10.02g/g) versus placebo – proportion of people with infection

	PDGF-BE	3 10.0	Place	bo		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ced, 95% CI	
Robson 1992b	0	4	0	7		Not estimable				
Total (95% CI)		4		7		Not estimable				
Total events	0		0							
Heterogeneity: Not ap	•	ala.					0.01	0.1	1 10	100
Test for overall effect:	пот аррпсат	ле				Fav	ours rP	DGF-BB 10.0	Favours place	ebo

Figure 543: Recombinant platelet-derived growth factor-BB (10.0⊡g/g) versus placebo – mortality

	PDGF-BE	3 10.0	Place	bo		Peto Odds Ratio		Peto O	dds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	red, 95% CI		
Robson 1992b	0	4	0	7		Not estimable					
Total (95% CI)		4		7		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:		ble				Fav	0.01 ours rP	0.1 DGF-BB 10.0		0 olace	100 bo

I.2.7.46 Recombinant platelet-derived growth factor: 10.02g/g versus 100.02g/g

Figure 544: Recombinant platelet-derived growth factor: 10.02g/g versus 100.02g/g – proportion of patients completely healed

	PDGF-BB	10.0	PDGF-BB	100.0		Peto Odds Ratio	Peto Oc	lds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
Robson 1992b	0	4	2	5	100.0%	0.13 [0.01, 2.52]		_
Total (95% CI)		4		5	100.0%	0.13 [0.01, 2.52]		-
Total events	0		2					
Heterogeneity: Not as	pplicable						0.002 0.1	10 500
Test for overall effect	Z = 1.35 (F	0.18)				Favours PDGF-BB 100.0	1 10 500 Favours PDGF-BB 10.0

Figure 545: Recombinant platelet-derived growth factor: 10.02g/g versus 100.02g/g – proportion of patients with infection

	PDGF-BI	3 10.0	PDGF-BB	100.0		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	ed, 95% CI	
Robson 1992b	0	4	0	5		Not estimable				
Total (95% CI)		4		5		Not estimable				
Total events	0		0							
Heterogeneity: Not ap Test for overall effect:	•	ble					0.01 Favours P	0.1 DGF-BB 10.0	1 1 Favours PD	

Figure 546: Recombinant platelet-derived growth factor: 10.02g/g versus 100.02g/g – mortality

	PDGF-BI	3 10.0	PDGF-BE	100.0		Risk Ratio		Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	ed, 95% CI		
Robson 1992b	0	4	0	5		Not estimable					
Total (95% CI)		4		5		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:	•	ble					0.01 0 Favours PD	H I.1 GF-BB 10.0		-	100 100.0

Figure 547: Recombinant platelet-derived growth factor (100.02g/g) versus placebo – proportion of patients completely healed




Figure 548: Recombinant platelet-derived growth factor (100.02g/g) versus placebo – mean percentage reduction in ulcer depth

	PDGF	PDGF-BB 100.0								PI	acebo	r		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI						
Robson 1992b	85.9	14.8	5	65.1	13.4	7	100.0%	20.80 [4.47, 37.13]							
Total (95% CI)			5			7	100.0%	20.80 [4.47, 37.13]	•						
Heterogeneity: Not as Test for overall effect			.01)						-100 -50 0 50 100 Favours placebo Favours PDGF-BB 100.						

Figure 549: Recombinant platelet-derived growth factor (100.0⊡g/g) versus placebo – mean percentage reduction in ulcer depth

	PDGF-BB 100.0			PI	Placebo Mean Diff			Mean Difference		Mean D	Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	ed, 95% CI		
Robson 1992b	93.6	8	5	78.2	11.2	7	100.0%	15.40 [4.54, 26.26]				-/-	
Total (95% CI)			5			7	100.0%	15.40 [4.54, 26.26]			-		
Heterogeneity: Not a Test for overall effect		(P = 0	005)						-50 Favour	-25 rs placebo	0 2 Favours	5 PDGI	50 F-BB 100.

Figure 550: Recombinant platelet-derived growth factor (100.0⊡g/g) versus placebo – proportion of people with infection

LT. St. Lat.	POGREB	100.0	Placel	00		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Robson 1992b	0	5	0	7		Not estimable	
Total (95% CI)		5		7		Not estimable	
Total e vents	0		0				
Heterogeneity: Not app	p koable					1	0.01 0.1 10
Test for overall effect.	Not applicab	le					outerPDGF-BB 100 Favour placebo

Figure 551: Recombinant platelet-derived growth factor (100.0⊡g/g) versus placebo – mortality

	PDGF-BB	100.0	Place	bo		Peto Odds Ratio		Peto (Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl		Peto, F	ixed, 95% CI	
Robson 1992b	0	5	0	7		Not estimable				
Total (95% CI)		5		7		Not estimable				
Total events	0		0							
Heterogeneity: Not app	plicable						0.01	0.1	1 10) 100
Test for overall effect:	Not applicab	le				Fa		PDGF-BB 10	0 Favours pl	

1.2.7.47 Basic fibroblast growth factor (different schedules and doses) versus placebo

Figure 552: Basic fibroblast growth factor (different schedules and doses) versus placebo – proportion of patients > 70% healed




Figure 553: Basic fibroblast growth factor (different schedules and doses) versus placebo – mortality

	BFG	F	Placel	bo		Peto Odds Ratio	Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI	
Robson 1992a	0	35	0	15		Not estimable			
Total (95% CI)		35		15		Not estimable			
Total events	0		0						
Heterogeneity: Not app Test for overall effect:		able					 0.1 ours BFGF	1 10 Favours p	100 lacebo

1.2.7.48 Interleukin 1-beta (0.01ug/cm²) vs. placebo

Figure 554: Interleukin 1-beta (0.012g/cm²) vs. placebo – proportion of people with pressure ulcers completely healed

	IL-1beta 0			bo		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixe	ed, 95% CI
Robson 1994	0	6	0	6		Not estimable		
Total (95% CI)		6		6		Not estimable		
Total events	0		0					
Heterogeneity: Not ap Test for overall effect:	•	ble					0.01 0.1 Favours IL-1beta	1 10 100 Favours placebo

Figure 555: Interleukin 1-beta (0.012g/cm²) vs. placebo – mortality

				bo					lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I	Peto, Fixe	ed, 95% CI	
Robson 1994	0	6	0	6		Not estimable				
Total (95% CI)		6		6		Not estimable				
Total events	0		0							
Heterogeneity: Not ap	plicable						0.01	0.1	 	100
Test for overall effect:	Not applica	able						rs rIL-1beta	Favours pla	

I.2.7.49 Interleukin 1-beta (0.012g/cm²) versus interleukin 1-beta (0.12g/cm²)

Figure 556: Interleukin 1-beta (0.012g/cm²) versus interleukin 1-beta (0.12g/cm²) – proportion of people with pressure ulcers completely healed





Figure 557: Interleukin 1-beta (0.012g/cm²) versus interleukin 1-beta (0.12g/cm²) – mortality



I.2.7.50 Interleukin 1-beta (0.012g/cm²) vs. interleukin 1-beta (1.02g/cm²) –

Figure 558: Interleukin 1-beta (0.012g/cm²) vs. interleukin 1-beta (1.02g/cm²) – proportion of people with pressure ulcers completely healed

	IL-1beta	0.01	IL-1beta	a 1.0		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	1	M-H, Fix	ed, 95% CI		
Robson 1994	0	6	0	6		Not estimable					
Total (95% CI)		6		6		Not estimable					
Total events	0		0								
Heterogeneity: Not app	olicable						0.01	0.1	1 1	0	100
Test for overall effect:	Not applica	ıble						L-1beta 0.01		-	

Figure 559: Interleukin 1-beta (0.012g/cm²) vs. interleukin 1-beta (1.02g/cm²) – mortality

	iL-ibela	0.01	IL-IDER	1 1.0		Pelo Odds nallo			Pelo Ot	aus natio	,	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	1		Peto, Fix	ed, 95%	CI	
Robson 1994	0	6	0	6		Not estimable						
Total (95% CI)		6		6		Not estimable						
Total events	0		0									
Heterogeneity: Not ap	plicable						0.01		-	<u> </u>	10	100
Test for overall effect:	Not applica	ıble					0.01 Favou	rs rIL-	1beta 0.01	Favours	10 s rIL-1be	100 eta 1.0

I.2.7.51 Interleukin 1-beta (0.12g/cm²) vs. placebo

Figure 560: Interleukin 1-beta (0.12g/cm²) vs. placebo – proportion of people with pressure ulcers completely healed

	IL-1beta	Place	bo		Risk Ratio			Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI		M-H, Fix	ed, 95% C	:1	
Robson 1994	0	6	0	6		Not estimable	е					
Total (95% CI)		6		6		Not estimable	е					
Total events	0		0									
Heterogeneity: Not ap	plicable						<u> </u>	.01	0.1	 	10	100
Test for overall effect:	Not applica	able					-		-1beta 0.1	-		

Figure 561: Interleukin 1-beta (0.12g/cm²) vs. placebo – mortality

	IL-1beta	0.1	Placel	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Robson 1994	0	6	0	6		Not estimable	
Total (95% CI)		6		6		Not estimable	
Total events	0		0				
Heterogeneity: Not app Test for overall effect:		able					0.01 0.1 1 10 100 Favours IL-1beta 0.1 Favours placebo

1.2.7.52 Interleukin 1-beta (0.12g/cm²) vs. interleukin 1-beta (1.02g/cm²)

Figure 562: Interleukin 1-beta (0.1½g/cm²) vs. interleukin 1-beta (1.0½g/cm²) – proportion of people with pressure ulcers completely healed

	IL-1beta	a 0.1	IL-1beta	a 1.0		Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI		
Robson 1994	0	6	0	6		Not estimable					
Total (95% CI)		6		6		Not estimable					
Total events	0		0								
Heterogeneity: Not app	plicable						0.01	0.1	1 1	n	100
Test for overall effect:	Not applica	able						IL-1beta 0.1		-	

Figure 563: Interleukin 1-beta (0.12g/cm²) vs. interleukin 1-beta (1.02g/cm²) – mortality

	IL-1beta 0.1		IL-1beta 1.0			Peto Odds Ratio		Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l	Peto, Fix	ed, 95% CI		
Robson 1994	0	6	0	6		Not estimable					
Total (95% CI)		6		6		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:	•	able).1 1beta 0.1	1 1 Favours II	0 1beta	100 1.0

1.2.7.53 Interleukin 1-beta (1.02g/cm²) vs. placebo

Figure 564: Interleukin 1-beta (1.02g/cm²) vs. placebo – proportion of people with pressure ulcers completely healed


	IL-1beta	1.0	Placel	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Robson 1994	0	6	0	6		Not estimable	
Total (95% CI)		6		6		Not estimable	
Total events Heterogeneity: Not app	0 olicable		0				
Test for overall effect:		able				F	0.01 0.1 1 10 100 Favours IL-1beta 1.0 Favours placebo

Figure 565: Interleukin 1-beta (1.02g/cm²) vs. placebo – mortality


	IL-1beta	a 1.0	Placel	bo		Risk Ratio			Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI		M-H, Fix	ed, 95%	CI	
Robson 1994	0	6	0	6		Not estimable)					
Total (95% CI)		6		6		Not estimable	•					
Total events	0		0									
Heterogeneity: Not app	olicable						0.0	1 (1	! 	10	100
Test for overall effect:	Not applica	able							1beta 1.0	Favour		

1.2.7.54 Chlorinated lime solution versus dextranomer

Figure 566: Chlorinated lime solution versus dextranomer – Time to healing (defined as granulation and < 25% of original ulcer area) (days)







1.2.8 Dressings

Figure 568: Figure 2. Hydrocolloid dressing versus gauze dressing – proportion of patients completely healed




Figure 569: Hydrocolloid dressing versus gauze dressing – proportion of ulcers completely healed (all stages – all sites)




Figure 570: Hydrocolloid dressing versus gauze dressing – proportion of ulcers completely healed (stage II – all sites)

	Hydroco	Moid	Gau			Risk Ratio	Diek	Ratio
Study or Subgroup	Events	Total			Weight	M-H, Random, 95% CI		lom, 95% CI
1.5.1 Patients with a	spinal co	rd injury	1					
Hollisaz 2004 Subtotal (95% CI)	12	18 18	3	19 19	40.2% 40.2%	4.22 [1.42, 12.54] 4.22 [1.42, 12.54]		-
Total events Heterogeneity: Not a Test for overall effect		P = 0.01	3					
1.5.2 General popula	tion							
Neill 1989 Subtotal (95% CI)	11	25 25	9	34 34	59.8% 59.8%	1.66 [0.81, 3.39] 1.66 [0.81, 3.39]		-
Total events	11		9					
Heterogeneity: Not a	plicable							
Test for overall effect	Z = 1.40 (P = 0.18	3)					
Total (95% CI)		43		53	100.0%	2.42 [0.97, 6.00]		-
Total events	23		12					
Heterogeneity: Tau ² =	0.23; Chi	= 2.03	df = 1 (F	= 0.15); P= 519	6	0.1 0.2 0.5	1 5 5 10
Test for overall effect	Z=1.90 (P = 0.08	5)				Favours gauze	
Test for subgroup dif	ferences: ($2hi^2 = 1$	97. df=1	(P = 0)	$(.16), I^2 = 1$	49.2%	i avonia gance	i avodia ilydrocol

Figure 571: Hydrocolloid dressing versus gauze dressing – proportion of ulcers completely healed (stage III – all sites)




Figure 572: Hydrocolloid dressing versus gauze dressing – proportion of ulcers completely healed (all stages - sacral)

	Hydrocolloid		Gauze		Peto Odds Ratio		Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95%	CI		
1.6.1 Gauze								-		
Hollisaz 2004 Subtotal (95% CI)	0	7	4	8	100.0% 100.0%	0.09 [0.01, 0.84] 0.09 [0.01, 0.84]				
Total events Heterogeneity: Not as Test for overall effect		P = 0,03	4							
		tot en ut	re a le ta				0.01 0.1 1 Favours gauze Favour	10 100 s hydrocolloid		
Test for subgroup dif	terences: (vot appi	icable							

Figure 573: Hydrocolloid dressing versus gauze dressing – proportion of ulcers improved

	Hydroco	biollo	Gauz	te		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI		
1.7.1 Gauze									
Hollisaz 2004 Subtotal (95% CI)	27	31 31	29	60 60	100.0% 100.0%	1.80 [1.34, 2.42] 1.80 [1.34, 2.42]			
Total events Heterogeneity: Not as Test for overall effect:		P < 0.00	29						
Test for subgroup dif	ferences: 1	Not app	licable				0.5 0.7 1 1.5 2 Favours gauze Favours by	drocolloi	

Figure 574: Hydrocolloid dressing versus gauze dressing – proportion of ulcers worsened (all stages)




Figure 575: Hydrocolloid dressing versus gauze dressing – proportion of ulcers worsened (stage II)

	Hydroco	biollo	Gau	ze		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
1.9.1 Gauze							
Neill 1989	7	25	11	34	100.0%	0.87 [0.39, 1.92]	
Subtotal (95% CI)		25		34	100.0%	0.87 [0.39, 1.92]	
Total events	7		11				
Heterogeneity: Not as	oplicable						
Test for overall effect	Z=0.36 (P = 0.72	2)				
							02 05 1 2 5
						E	avours hydrocolloid Favours gauze
Test for subgroup diff	ferences: N	Not app	icable				ivodis flydroconoid Favours gauze

Figure 576: Figure 10. Hydrocolloid dressing versus gauze dressing – proportion of ulcers worsened (stage III)

	Hydroco	olloid	Gau	ze		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
1.10.1 Gauze							
Neill 1989	7	17	4	11	100.0%	1.13 [0.43, 2.98]	
Subtotal (95% CI)		17		11	100.0%	1.13 [0.43, 2.98]	
Total events	7		4				
Heterogeneity: Not a	pplicable						
Test for overall effect	Z= 0.25 (P = 0.80	0)				
							02 05 1 2 5
						110	Favours hydrocolloid Favours gauze
Test for subgroup dif	ferences: N	Vot app	licable				Carrier identification () account and and

Figure 577: Hydrocolloid dressing versus gauze dressing – mean percentage reduction in ulcer area




Figure 578: Figure 12. Hydrocolloid dressing versus gauze dressing – mean percentage




Figure 579: Hydrocolloid dressing versus gauze dressing – mean healing speed (mm²/day)




Figure 580: Hydrocolloid dressing versus gauze dressing – proportion of patients with an infection




Figure 581: Hydrocolloid dressing versus gauze dressing – proportion of patients with hypergranulation




Figure 582: Hydrocolloid dressing versus gauze dressing – proportion of patients with skin irritation

mitati	011										
	Hydroco	biolic	Gau	ze	Peto Odds Ratio			Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	1	Peto, Fixe	ed, 95% CI		
1.25.1 Gauze											
Neill 1989	0	50	9	50	100.0%	0.11 [0.03, 0.44	1	_			
Subtotal (95% CI)		50		50	100.0%	0.11 [0.03, 0.44	i	-			
Total events	0		9								
Heterogeneity: Not a	pplicable										
Test for overall effect	Z=3.13 (P = 0.00	12)								
							0.005	0.1	10	200	
							-,	hydrocolloid	/		
							dionis	nj di ocomora	i divuis ga	ULLU	

Figure 583: Hydrocolloid dressing versus gauze dressing – proportion of patients with pain at dressing removal




Figure 584: Figure 18. Hydrocolloid dressing versus gauze dressing – proportion of patients with discomfort

	Hydroco	lloid	Gauz	e		Peto Odds Ratio	Peto O	dds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
1.28.1 Gauze								
Chang 1998 Subtotal (95% CI)	0	17	9	17 17	100.0% 100.0%	0.07 [0.02, 0.32] 0.07 [0.02, 0.32]		
Total events Heterogeneity: Not as Test for overall effect.		P = 0.00	9 (106)					
Test for subaroup dif	ferences: N		licable				0.01 0.1 Favours hydrocolloid	1 10 100 Favours gauze

Figure 585: Hydrocolloid dressing versus gauze dressing - mortality

	Hydrocolloid		Gauze		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95%	CI M-H, Fixed, 95% CI
Kordestani 2008	0	33	10	52	65.6%	0.07 [0.00, 1.23] ←
Matzen 1999	2	17	1	15	8.5%	1.76 [0.18, 17.56] -
Xakellis 1992	0	18	3	21	25.9%	0.17 [0.01, 3.00	ı] • • • • • • • • • • • • • • • • • • •
Total (95% CI)		68		88	100.0%	0.24 [0.07, 0.89	
Total events	2		14				
Heterogeneity: Chi ² = 3	3.62, df = 2	(P = 0.	16); I ² = 4	5%			0.01 0.1 1 10 100
Test for overall effect:	Z = 2.13 (P	r = 0.03)			I	Favours hydrocolloid Favours gauze

Figure 586: Hydrocolloid dressing versus foam dressing – proportion of patients completely healed

	Hydroco	biolloid	Foar	m		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
2.1.2 Foam							
Bale 2005	5	9	7	12	25.0%	0.95 [0.45, 2.03]	-
Seeley 1999	5	20	8	20	33.3%	1.00 [0.47, 2.14]	
Thomas 1997 Subtotal (95% CI)	16	48 77	10	48 80	41.7% 100.0%	1.60 [0.81, 3.16] 1.24 [0.81, 1.90]	
Total events	29		25				
Heterogenetty: Chi*= Test for overall effect				0%			
To the country of the country of			0 - 7.1				0.5 0.7 1 1.5 2 Favours foam Favours hydrocolloid


Test for subgroup differences: Not applicable

Figure 587: Hydrocolloid dressing versus foam dressing – proportion of patients improved

	Hydroco	biollo	Foar	m		Risk Ratio		Risk Rat	io	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 9	5% CI	
2.2.1 Foam										
Thomas 1997 Subtotal (95% CI)	39	48 48	39	48 48	100.0% 100.0%	1.00 [0.83, 1.21 1.00 [0.83, 1.21				
Total events Heterogeneity: Not a Test for overall effect	CONTRACTOR	P = 1.00	39 D							
							0.5	0.7	1.5	2
T1 (124 244	ta a la ta				Favours	hydrocolloid Fa	vours roam	

Test for subgroup differences: Not applicable

Figure 588: Hydrocolloid dressing versus foam dressing – proportion of patients not changed



Test for subgroup differences: Not applicable

Figure 589: Hydrocolloid dressing versus foam dressing – proportion of patients worsened




Figure 590: Hydrocolloid dressing versus foam dressing – mean reduction in ulcer area

	Hydrocolloid			Foam				Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
2.5.2 Foam										
Seeley 1999 Subtotal (95% CI)	52	6.06	19 19	50	6.06	20 20	100.0%	2.00 [-1.81, 5.81] 2.00 [-1.81, 5.81]		
Heterogenathr. Not ap Test for overall affect:			,3m							
									-4 -2 0 2 4 Favours foam Favours hydrocollo	


Test for subgroup differences: Not applicable

Figure 591: Hydrocolloid dressing versus foam dressing – proportion of patients with bleeding

	Hydroco	biolloid	Foar	n		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (Cl Peto, Fixed, 95% Cl
2.7.1 Foam							
Thomas 1997 Subtotal (95% CI)	2	49 49	0	50 50	100.0% 100.0%	7.70 [0.47, 124.89 7.70 [0.47, 124.89	· ·
Total events Heterogeneity: Not as Test for overall effect:	A Committee of the Comm	P = 0.15	0				
							too de la col
Test for subgroup dif	forances: t	lat ann	licable				0.005 0.1 1 10 200 Favours hydrocolloid Favours foam

Test for subgroup differences: Not applicable

Figure 592: Hydrocolloid dressing versus foam dressing – proportion of patients with maceration



147

Figure 593: Hydrocolloid dressing versus foam dressing – proportion of patients with inflammation or maceration

	Hydroco	lloid	Foar	m		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
2.9.1 Foam							
Seeley 1999 Subtotal (95% CI)	6	19 19	12	20 20	100.0% 100.0%	0.53 [0.25, 1.12 0.53 [0.25, 1.12	
Total events Heterogeneity: Not a Test for overall effect		P = 0.09	12				
Test for subgroup dif	Yerences: N	Vot ann	licable				0.01 0.1 1 10 100 Favours hydrocolloid Favours foam

Figure 594: Figure 27. Hydrocolloid dressing versus foam dressing – mean pain score at end of treatment

	Hydr	Hydrocolloid			Foam			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
2.10.1 Foam									
Seeley 1999 Subtotal (95% CI)	0.47	0.9	19	0.15	0,8	20 20	100.0%	0.32 [-0.22, 0.86] 0.32 [-0.22, 0.86]	-
Haterogeneity. Not ap Teat for overall effect			0.24)						
									-1 -0.5 0 0.5 1
Test for subgroup dif	ferences	Nota	applica	ble				F	avours hydrocolloid Favours foam

Figure 595: Hydrocolloid dressing versus foam dressing – mean odour score at end of treatment




Figure 596: Hydrocolloid dressing versus foam dressing – proportion of patients with adverse events (unknown if dressing related)

	Hydroco	lloid	Foar	m		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Bale1997	2	31	3	29	38.3%	0.62 [0.11, 3.47]	
Seeley 1999	3	20	5	20	61.7%	0.60 [0.17, 2.18]	
Total (95% CI)		51		49	100.0%	0.61 [0.22, 1.71]	•
Total events	5		8				
Heterogeneity: Chi ² =	0.00, df=	1 (P = 0)	.97); 12=	0%			0.01 0.1 1 10 100
Test for overall effect	Z = 0.94 (P = 0.35	5)			0	Favours hydrocolloid Favours foam

Figure 597: <Insert graphic title here>

<Click here and insert picture with the Graphic tools on the Toolbar Ribbon>

Figure 598: Hydrocolloid dressing versus foam dressing- mortality

	Hydroco	lloid	Foar	n		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI M-H, Fixed, 95% CI
Bale1997	2	31	6	29	100.0%	0.31 [0.07, 1.42	
Total (95% CI)		31		29	100.0%	0.31 [0.07, 1.42]	
Total events	2		6				
Heterogeneity: Not appropriate to the Test for overall effect:		= 0.13))			F	0.01 0.1 1 10 100 avours hydrocolloid Favours foam

Figure 599: Hydrocolloid dressing versus polyurethane dressing – proportion of patients completely healed

	Hydroco	biollo	Polyuret	hane		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Events Total		M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
3.1.3 Polyurethane							
Banks 1994a	11	12	10	10	27.0%	0.93 [0.73, 1.17]	
Banks 1994b	10	10	12	18	21.8%	1.45 [1.02, 2.08]	
Brown-Etris 2008 Subtotal (95% CI)	22	37 59	21	35 63	51.2% 100.0%	0.99 [0.68, 1.45] 1.07 [0.87, 1.33]	•
Total events Heterogenalty: Chr= Test for overall effect.				10%			
a wood look or house of the war			,				0.5 0.7 1 1.5 2
Test for subgroup dif	ferences: f	Vot app	licable				Favours polyurethane Favours hydrocolloi

Figure 600: Hydrocolloid dressing versus polyurethane dressing – proportion of patients improved

	Hydroco	biollo	Polyuret	hane		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	vents Total		M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
3.2.3 Polyurethane							
Banks 1994b Subtotal (95% CI)	10	10 10	18	18 18	100.0% 100.0%	1.00 [0.86, 1.16] 1.00 [0.86, 1.16]	
Total events Heterogeneity: Not as Test for overall effect:		P=1.00	18				
							0.5 0.7 1 1.5 2
Test for subgroup diff	ferences: N	Not app	licable				Favours hydrocolloid Favours polyurethane

Figure 601: Hydrocolloid dressing versus polyurethane dressing – linear healing rate (cm/week)




Figure 602: Hydrocolloid dressing versus polyurethane dressing - mean odour score Hydrocolloid Polyurethane Mean Difference Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI IV, Fixed, 95% CI 3.6.1 Polyurethane Brown-Etris 2008 4.8 0.39 5 0.14 35 100.0% -0.20 [-0.33, -0.07] 37 Subtotal (95% CI) 37 35 100.0% -0.20 [-0.33, -0.07] Heterogeneity: Not applicable Tast for overall effect Z = 2.93 (P = 0.003) -0.2 -0.1 0 0.1 0.2

Favours polyurethane Favours hydrocolloid




Figure 604: Hydrocolloid dressing versus polyurethane dressing – mortality											
	Hydroco	Hydrocolloid F		hane		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI				
Banks 1994b	2	20	1	20	100.0%	2.00 [0.20, 20.33]					
Total (95% CI)		20		20	100.0%	2.00 [0.20, 20.33]					
Total events	2		1								
Heterogeneity: Not a Test for overall effect		= 0.56))				0.01 0.1 1 10 100 Favours hydrocolloid Favours polyurethane				

Figure 605: Hydrocolloid dressing versus collagenase ointment – proportion of patients completely healed





Figure 606: Hydrocolloid dressing versus collagenase ointment - mean percentage reduction



Hydrocolloid dressing versus collagenase ointment – mean cm² reduction in ulcer Figure 607: area

Favours collagen Favours hydrocolloid

arca									
	Hydr	ocollo	bid	Co	ollager	1		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
4.4.3 Collagen									
Burgos 2000a	8.2	9.8	19	9.1	12.7	18	100.0%	-2.90 [-10.24, 4.44]	
Subtotal (95% CI)			19			18	100.0%	-2.90 [-10.24, 4.44]	
Heterogeneity: Not ap Test for overall effect			0.44)						
									-10 -5 0 5 10
Test for subgroup dif	ferences	Nota	applica	ble					Favours collagen Favours hydrocolloid

Figure 608: Hydrocolloid dressing versus collagenase ointment - mean time to healing (weeks)

	Hydr	ocollo	bid	Collagen			Mean Difference		Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Rando	om, 95% CI		
Müller 2001	14	4.6	11	10	4.6	12	100.0%	4.00 [0.24, 7.76]				
Total (95% CI)			11			12	100.0%	4.00 [0.24, 7.76]		-		
Heterogeneity: Not a Test for overall effect			0.04)						-4 -2 Favours hydrocolloid	0 2 4 Favours collager		

Figure 609: Hydrocolloid dressing versus collagenase ointment - proportion of Figure 39. patients with adverse events

	Hydrocolloid		Collagen			Risk Ratio	Risk Ratio			
Study or Subgroup	Events Total		Events Total		Weight	M-H, Fixed, 95% CI		M-H, Fixed, 959	% CI	
Burgos 2000a	2	19	1	18	100.0%	1.89 (0.19, 19.13)		_	_	
Total (95% CI)		19		18	100.0%	1.89 [0.19, 19.13]		-	_	
Total events	2		1							
Heterogeneity: Not as	pplicable						0.002	04	10	500
Test for overall effect	P = 0.59	3)					hydrocolloid Favo	10		

Figure 610: Hydrocolloid dressing versus collagenase ointment –mortality

	Hydroco	Collag	jen		Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	l	M-H, Fixe	ed, 95% C	1	
Burgos 2000a	1	19	3	18	100.0%	0.32 [0.04, 2.76]					
Total (95% CI)		19		18	100.0%	0.32 [0.04, 2.76]	-				
Total events	1		3								
Heterogeneity: Not ap	plicable						0.01 0	.1	 	10	100
Test for overall effect: $Z = 1.04 (P = 0.30)$								/drocolloid	Favours		

Figure 611: Hydrocolloid dressing versus collagen dressing – proportion of patients completely healed

ilealet	a .						
	Hydroco	Hydrocolloid		Collagen		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Graumlich 2003	15	30	18	35	100.0%	0.97 [0.60, 1.57]	
Total (95% CI)		30		35	100.0%	0.97 [0.60, 1.57]	-
Total events Heterogeneity: Not ap			18				0.2 0.5 1 2 5
Test for overall effect	Z = 0.11 (P = 0.91)				Favours collagen Favours hydrocolloid

Figure 612: Hydrocolloid dressing versus collagen dressing – mean percentage reduction in ulcer area

	Hyd	rocollo	id	C	ollagen			Mean Difference		Me	an Diffe	erence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed, 9	95% CI	
Graumlich 2003	9	73.98	30	33	73.98	35	100.0%	-24.00 [-60.08, 12.08]		_			
Total (95% CI)			30			35	100.0%	-24.00 [-60.08, 12.08]	1				
Heterogeneity: Not ap Test for overall effect:			19)						-100 Fave	-50 ours colla	0 igen F	50 avours hy	100 drocolloi

Figure 613: Hydrocolloid dressing versus collagen dressing – mean speed of healing (mm²/day)

	Hydro	ocollo	bid	Col	lage	n		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Graumlich 2003	6	16	35	6	19	35	100.0%	0.00 [-8.23, 8.23]	-
Total (95% CI)			35			35	100.0%	0.00 [-8.23, 8.23]	•
Heterogeneity: Not ag Test for overall effect:			(00)						-20 -10 0 10 20 Favours collagen Favours hydrocolloid

Figure 614: Figure 43. Hydrocolloid dressing versus collagen dressing – mean time to healing (weeks)

	Hydi	rocollo	bid	Co	llager	1		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Random, 95% CI
Graumlich 2003	6	2.68	30	5	2.91	35	100.0%	1.00 [-0.36, 2.36]	-
Total (95% CI)			30			35	100.0%	1.00 [-0.36, 2.36]	•
Heterogeneity: Not ap									-4 -5 0 5 4
Test for overall effect	Z = 1.44	(P=0	0.15)						Favours hydrocolloid Favours collagen

Figure 615: Hydrocolloid dressing versus collagen dressing – proportion of people with adverse events

	Hydroco	olloid	Collag	en		Risk Ratio				Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI		M-I	H, Fixe	ed, 959	% CI	
Graumlich 2003	0	30	0	35		Not estimable	9						
Total (95% CI)		30		35		Not estimable)						
Total events	0		0										
Heterogeneity: Not ap Test for overall effect:	•	able					-	.002 vours hyd	0. Iroc		-	10 urs coll	500 agen

Figure 616: Hydrocolloid dressing versus collagen dressing – mortality

	Hydroco	lloid	Collag	jen		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI M-H, Fixed, 95% CI
Graumlich 2003	2	30	3	35	100.0%	0.78 [0.14, 4.35]	1 —
Total (95% CI)		30		35	100.0%	0.78 [0.14, 4.35]	
Total events	2		3				
Heterogeneity: Not app							0.01 0.1 1 10 100
Test for overall effect:	Z = 0.29 (P)	r = 0.77					Favours hydrocolloid Favours collagen

Figure 617: Figure 44. Hydrocolloid dressing versus hydrogel dressing – proportion of patients completely healed

	Hydroco	lloid	Hydro	gel		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
5.1.5 Hydrogel							
Motta 1999	2	5	2	5	100.0%	1.00 [0.22, 4.56]	
Subtotal (95% CI)		5		5	100.0%	1.00 [0.22, 4.56]	
Total events	2		2				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.00 (P	= 1.00)					
							0.2 0.5 1 2 5
							* *
							Favours hydrogel Favours hydrocollo

Figure 618: Hydrocolloid dressing versus hydrogel dressing – proportion of ulcers completely healed




Figure 619: Hydrocolloid dressing versus hydrogel dressing – proportion of ulcers not changed

	Hydroco	lloid	Hydro	gel		Risk Ratio		R	isk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H,	Fixed, 95°	% CI	
5.3.1 Hydrogel											
Darkovich 1990 Subtotal (95% CI)	8	67 67	5	62 62	100.0% 100.0 %	1.48 [0.51, 4.28] 1.48 [0.51, 4.28]				- -	
Total events Heterogeneity: Not ap Test for overall effect:		° = 0.47)	5								
							0.01	0.1	1 nid Favo	10	100

Figure 620: Hydrocolloid dressing versus hydrogel dressing – proportion of ulcers worsened

	Hydroco	lloid	Hydro	gel		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95%	CI	M-H, Fix	ed, 95% CI	
5.4.2 Hydrogel										
Darkovich 1990 Subtotal (95% CI)	7	67 67	1	62 62	100.0% 100.0 %	6.48 [0.82, 51.16 6.48 [0.82, 51.16]				— >
Total events	7	01	1	02	100.0 /8	0.40 [0.02, 31.10]	J			
Heterogeneity: Not ap	plicable									
Test for overall effect:	Z = 1.77 (P	r = 0.08								
								1		
							0.01	0.1	1 10	100
							Favours	hydrocolloid	Favours hydi	oael

Figure 621: Hydrocolloid dressing versus hydrogel dressing – mean percentage reduction in ulcer area (stage II)

w	u. cu ,	, , , , , ,	,~,										
	Hyd	rocoll	oid	Hy	droge	el		Mean Difference		Mean Di	fference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	l	IV, Fixed	d, 95% CI		
5.6.1 Hydrogel													
Darkovich 1990	34	47.7	36	64	47.7	35	100.0%	-30.00 [-52.19, -7.81]	_	-			
Subtotal (95% CI)			36			35	100.0%	-30.00 [-52.19, -7.81]	4				
Heterogeneity: Not ap	plicable												
Test for overall effect:	Z = 2.65	(P = 0	(800.0										
									100 50	$\overline{}$			
									-100 -50			50	100
									Favours	hydrogel	Favours	nydroc	colloid

Figure 622: Hydrocolloid dressing versus hydrogel dressing – mean healing rate (cm/day)




Figure 623: Hydrocolloid dressing versus hydrogel dressing – mortality (all-cause)

	Hydroco	lloid	Hydro	gel		Peto Odds Ratio	Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fix	red, 95% CI	
Motta 1999	0	5	0	5		Not estimable	•		
Total (95% CI)		5		5		Not estimable			
Total events	0		0						
Heterogeneity: Not app							0.01 0.1	1 10	100
Test for overall effect:	Not applica	ıble					Favours hydrocolloid		

Figure 624: Hydrocolloid dressing versus impregnated gauze dressing – proportion of patients completely healed

	Hydroco	lloid	Impregnated	gauze		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95%	CI	M-H, Fix	ed, 95% CI		
6.1.6 Impregnated ga	uze										
Winter 1990 Subtotal (95% CI)	5	6 6	3	-	100.0% 100.0%	1.39 [0.62, 3.09 1.39 [0.62, 3.09					
Total events Heterogeneity: Not ap	5 plicable		3								
Test for overall effect:	Z = 0.80 (P	= 0.42)								
						ı	0.2	0.5 pregnated gauze	1 Favours l	2 nydrocolloid	5

Figure 625: Hydrocolloid dressing versus impregnated gauze dressing – proportion of patients improved

	Hydroco	olloid	Impregnated	gauze		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95% CI	
6.2.2 Impregnated ga	auze							_		
Winter 1990 Subtotal (95% CI)	6	6 6	5	-	100.0% 100.0%	1.00 [0.73, 1.37] 1.00 [0.73, 1.37]				
Total events Heterogeneity: Not ap	6 plicable	·	5		1001070					
Test for overall effect:	•	P = 1.00)							
						-	0.5	0.7	1 1.5	2
							Favours	hydrocolloid	Favours impre	egnated gauz

Test for subgroup differences: Not applicable

Figure 626: Hydrocolloid dressing versus poly-hema dressing – proportion of patients completely healed




Figure 627: Hydrocolloid dressing versus poly-hema dressing – absolute rate of healing (cm²/week)

	Hyd	drocollo	oid	Po	ly-hem	a		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
7.3.1 Poly-hema									
Brod 1990 Subtotal (95% CI)	0.1	0.085	16 16	0.18	0.085	27 27		-0.08 [-0.13, -0.03] -0.08 [-0.13, -0.03]	
Heterogeneity: Not as	plicable								
Test for overall effect	: Z = 2.98	B (P = 0.	003)						
									-0.2 -0.1 0 0.1 0.2
									Favours poly-hema Favours hydrocollo

Figure 628: Hydrocolloid dressing versus poly-hema dressing – proportion of patients with adverse events

	Hydroco	lloid	Poly-he	ema		Peto Odds Ratio		Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	l	Peto, Fix	ed, 95% CI	
7.4.1 Poly-hema										
Brod 1990 Subtotal (95% CI)	1	16 16	0	27 27	100.0% 100.0 %	14.69 [0.25, 847.55] 14.69 [0.25, 847.55]				
Total events Heterogeneity: Not ap Test for overall effect:	•	= 0.19)	0							
							0.002 Favours I	0.1	1 10 Favours poly	500 -hema

Test for subgroup differences: Not applicable

Figure 629: Hydrocolloid dressing versus poly-hema dressing – mortality

	Hydroco	lloid	Poly-he	ema		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	ı	M-H, Fix	ed, 95% CI		
Brod 1990	1	16	2	27	100.0%	0.84 [0.08, 8.58]					
Total (95% CI)		16		27	100.0%	0.84 [0.08, 8.58]					
Total events	1		2								
Heterogeneity: Not ap	plicable						0.01	0.1	 	0	100
Test for overall effect:	Z = 0.14 (P	r = 0.89)					hydrocolloid	Favours p	-	

Figure 630: Hydrocolloid dressing versus co-polymer (amino acid) dressing – proportion of patients completely healed




Figure 631: Hydrocolloid dressing versus co-polymer (amino acid) dressing – proportion of patients with an infection

-	Hydroco	lloid	Co-poly	/mer		Risk Ratio		Risl	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H, Fix	red, 95% C	ا(
8.3.3 Copolymer (am	ino acid)							_			
Hondé 1994 Subtotal (95% CI)	6	88 88	6	80 80	100.0% 100.0 %	0.91 [0.31, 2.70] 0.91 [0.31, 2.70]					
Total events Heterogeneity: Not ap Test for overall effect:	•	= 0.86)	6								
							0.01 Favour	0.1	1 Favours	10 co-po	100 olymer

Figure 632: Hydrocolloid dressing versus phenytoin cream – proportion of patients completely healed

	Hydroco	olloid	Pheny	toin		Risk Ratio		Ris	k Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	xed, 95% CI	
9.1.9 Phenytoin crea	ım									
Hollisaz 2004 Subtotal (95% CI)	20	28 28	8	27 27	100.0%	2.41 [1.29, 4.51] 2.41 [1.29, 4.51]				_
Total events Heterogeneity: Not a Test for overall effect		P = 0.00	8 (6)							
							0.2 Favo	0.5 urs phenytoii	1 2 n Favours hydro	5 ocolloid
Test for subgroup dif	ferences: I	Not app	licable					No. Same	A STATE OF THE PARTY OF THE PAR	

Figure 633: Hydrocolloid dressing versus phenytoin cream – proportion of ulcers completely healed (all stages – all sites)

	. (.D	a o	٠,					
	Hydroco	bioll	Phenytoin			Risk Ratio	Risk Ratio		
Study or Subgroup	Events Tota		Events	Events Total		M-H, Fixed, 95% CI	M-H, Fixed, 95% CI		
9.2.3 Phenytoin crea	m								
Hollisaz 2004 Subtotal (95% CI)	23	31 31	12	30 30	100.0% 100.0%	1.85 [1.14, 3.01] 1.85 [1.14, 3.01]			
Total events Heterogeneity: Not ap Test for overall effect:		P = 0.01	12						
Test for subgroup diff	ferences: N	Not app	licable				0.01 0.1 10 10 Favours phenytoin Favours hydrocolloi		

Figure 634: Hydrocolloid dressing versus phenytoin cream – proportion of ulcers improved

	Experim	ental	Cont	lor		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI
9.6.3 Phenytoin crea	m							
Hollisaz 2004 Subtotal (95% CI)	27	31 31	16	30 30	100.0% 100.0%	1.63 [1.14, 2.34] 1.63 [1.14, 2.34]		-
Total events Heterogeneity: Not a Test for overall effect		P = 0,00	16					
Test for subgroup dif	ferences: 1	Not appl	icable				0.5 0.7 Favours control	1 1.5 2 Favours experimenta

Figure 635: Hydrocolloid dressing versus phenytoin cream – proportion of ulcers worsened





Figure 636: Hydrocolloid dressing versus phenytoin cream – mortality (all-cause)

	Hydroco	lloid	Contr	ol		Peto Odds Ratio		Peto 0	Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	i .	Peto, F	ixed, 95% CI	
Hollisaz 2004	0	28	0	28		Not estimable	•			
Total (95% CI)		28		28		Not estimable	•			
Total events	0		0							
Heterogeneity: Not app		le Le					0.01	0.1	1 10	100
Test for overall effect:	Not applica	bie					Favour	s hydrocolloid	d Favours phe	nytoin

Figure 637: Hydrocolloid dressing versus alginate dressing – proportion of patients 40% healed

	Hydroco	lloid	Algina	ate		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
10.1.1 Alginate							
Belmin 2002 Subtotal (95% CI)	31	53 53	43	57 57	100.0% 100.0%	0.78 [0.59, 1.02] 0.78 [0.59, 1.02]	
Total events Heterogeneity: Not app	31 olicable		43			• / •	Ĭ
Test for overall effect:	Z = 1.84 (P	r = 0.07					
Total (95% CI)		53		57	100.0%	0.78 [0.59, 1.02]	•
Total events Heterogeneity: Not app Test for overall effect: 7 Test for subgroup diffe	Z = 1.84 (P	,					0.1 0.2 0.5 1 2 5 10 Favours alginate Favours hydrocolloid

Figure 638: Hydrocolloid dressing versus alginate dressing – mean percentage reduction in ulcer area



158

Figure 639: Hydrocolloid dressing versus alginate dressing - mean cm² reduction in ulcer area Hydrocolloid Alginate Mean Difference **Mean Difference** Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI IV, Fixed, 95% CI Study or Subgroup 10.3.2 Alginate Belmin 2002 5.2 7.2 9.7 7.1 57 100.0% -4.50 [-7.17, -1.83] 53 Subtotal (95% CI) 53 57 100.0% -4.50 [-7.17, -1.83] Heterogeneity: Not applicable Test for overall effect: Z = 3.30 (P = 0.0010)

-10

Favours alginate Favours hydrocolloid

Test for subgroup differences: Not applicable

Figure 640: Hydrocolloid dressing versus alginate dressing – proportion of patients with an infection

	Hydroco	lloid	Algina	ate		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (CI Peto, Fixed, 95% CI
10.4.2 Alginate							
Belmin 2002 Subtotal (95% CI)	0	53 53	1	57 57	100.0% 100.0%	0.15 [0.00, 7.34 0.15 [0.00, 7.34]	
Total events	0		1				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.96 (P)	= 0.33)					
							0.001 0.1 1 10 1000
							Favours hydrocolloid Favours alginate

Figure 641: Hydrocolloid dressing versus alginate dressing – proportion of patients with skin irritation

	Hydroco	biollo	Algina	ate		Peto Odds Ratio		Peto Oc	ds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C		Peto, Fix	ed, 95% CI	
10.5.2 Alginate										
Belmin 2002 Subtotal (95% CI)	0	53 53	2	57 57	100.0% 100.0%	0.14 [0.01, 2.31] 0.14 [0.01, 2.31]		-		
Total events Heterogeneity: Not a Test for overall effect		P = 0.17	7)				-			1
							0.001 Favours	0.1 hydrocolloid	1 10 Favours al	1000 Iginate

Figure 642: Hydrocolloid dressing versus alginate dressing – proportion of patients with hypergranulation

	Hydroco	lloid	Algina	ate		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95%	CI M-H, Fixed, 95% CI
10.6.3 Alginate							
Belmin 2002	5	53	1	57	100.0%	5.38 [0.65, 44.54	4]
Subtotal (95% CI)		53		57	100.0%	5.38 [0.65, 44.54]	
Total events	5		1				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.56 (P	= 0.12)					
							0.01 0.1 1 10 100
							Favours hydrocolloid Favours alginate

Figure 643: Figure 67. Hydrocolloid dressing versus alginate dressing – proportion of patients with maceration

	Hydroco	lloid	Algina	ate	Peto Odds Ratio			Peto Odds Ratio			
Study or Subgroup	Events Total		Events Total		Weight	Peto, Fixed, 95% (CI	Peto, Fixed, 95% CI			
10.7.2 Alginate											
Belmin 2002 Subtotal (95% CI)	0	53 53	1	57 57	100.0% 100.0 %	0.15 [0.00, 7.34 0.15 [0.00, 7.34]		-			
Total events Heterogeneity: Not ap	•	0.00	1								
Test for overall effect:	Z = 0.96 (P)	= 0.33)									
							0.002 Favours	0.1 hvdrocolloid	1 10 Favours alo	500 inate	

Figure 644: Hydrocolloid dressing versus alginate dressing – proportion of patients with bleeding

	Hydroco	Hydrocolloid				Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events Total		Weight	Peto, Fixed, 95% (CI Peto, Fixed, 95% CI
10.8.2 Alginate							<u></u>
Belmin 2002	0	53	1	57	100.0%	0.15 [0.00, 7.34	
Subtotal (95% CI)		53		57	100.0%	0.15 [0.00, 7.34]	
Total events	0		1				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.96 (P)	= 0.33)					
							0.001 0.1 1 10 1000
							Favours hydrocolloid Favours alginate

Figure 645: Hydrocolloid dressing versus alginate dressing – incidence of pain at dressing removal

	Hydroco	Hydrocolloid		Alginate		Risk Ratio	R	isk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, I	ixed, 95% CI	
Belmin 2002	411	1314	316	887	100.0%	0.88 [0.78, 0.99]	1		
Total (95% CI)		1314		887	100.0%	0.88 [0.78, 0.99]	· •	>	
Total events	411		316						
Heterogeneity: Not as	oplicable						0.5 0.7	1 1	- 1
Test for overall effect	Z = 2.14 (P = 0.03	1)				Favours hydrocoll	oid Favours alg	inate 2

Figure 646: Hydrocolloid dressing versus alginate dressing – incidence of strong odour at dressing removal

	Hydroco	biolic	Algina	ate		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	d, 95% CI	
Belmin 2002	173	1314	178	887	100.0%	0.66 [0.54, 0.79]				
Total (95% CI)		1314		887	100.0%	0.66 [0.54, 0.79]		•		
Total events	173		178							
Heterogeneity: Not as	plicable						0.2	015	1	<u> </u>
Test for overall effect	Z = 4.32 (P < 0.00	001)				Favours h	0.5 1 hydrocolloid	Favours al	ginate

Figure 647: Hydrocolloid dressing versus alginate dressing – incidence of mild odour at dressing removal

	Hydroco	biolic	Algina	ite		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95% CI	
Belmin 2002	382	1314	361	887	100.0%	0.71 [0.64, 0.80]				
Total (95% CI)		1314		887	100.0%	0.71 [0.64, 0.80]				
Total events Heterogeneity: Not as	382 oplicable		361					0.7	1 15 1	
Test for overall effect	Z = 5.69 (P < 0.00	001)				Favours h		Favours alginate	

Figure 648: Hydrocolloid dressing versus alginate dressing -mortality

	Hydroco	lloid	Algina	ate		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI M-H, Fixed, 95% CI
Belmin 2002	11	57	8	53	100.0%	1.28 [0.56, 2.93]	
Total (95% CI)		57		53	100.0%	1.28 [0.56, 2.93]	1 🔷
Total events	11		8				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.58 (P	= 0.56)					Favours hydrocolloid Favours alginate

Figure 649: Hydrocolloid dressing versus charcoal dressing – proportion of patients worsened

	Hydroco	olloid	Charc	oal		Peto Odds Ratio		Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Cl	Peto, Fix	ed, 95% CI	
11.1.2 Charcoal										
Kerihuel 2010 Subtotal (95% CI)	1	30 30	0	29 29	100.0% 100.0%	7.15 [0.14, 360.38] 7.15 [0.14, 360.38]				
Total events Heterogeneity: Not ap Test for overall effect:	•	P = 0.33)	0							
							0.002 Favours h	0.1	1 10 Favours cha	500

Figure 650: Hydrocolloid dressing versus charcoal dressing – proportion of patients with maceration

	Hydroco	lloid	Charc	oal		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (Cl Peto, Fixed, 95% Cl
11.4.3 Charcoal							
Kerihuel 2010 Subtotal (95% CI)	2	30 30	0	29 29	100.0% 100.0 %	7.40 [0.45, 121.22 7.40 [0.45, 121.22]	
Total events	2		0				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.40 (P	9 = 0.16)					
							0.002 0.1 1 10 500
							Favours hydrocolloid Favours charcoal

Figure 651: Hydrocolloid dressing versus charcoal dressing – proportion of patients with an infection

	Hydroco	lloid	Charc	oal		Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI	M-H, Fix	ed, 95% CI		
11.5.4 Charcoal											
Kerihuel 2010	2	30	1	29	100.0%	1.93 [0.19, 20.18]				_	
Subtotal (95% CI)		30		29	100.0%	1.93 [0.19, 20.18]				-	
Total events	2		1								
Heterogeneity: Not ap	plicable										
Test for overall effect:	Z = 0.55 (P	0.58	1								
							0.01	0.1	 	100	
								hydrocolloid			

Figure 652: Hydrocolloid dressing versus charcoal dressing – proportion of patients with hypergranulation

	Hydroco	lloid	Chaco	oal		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95%	Cl Peto, Fixed, 95% Cl
11.6.4 Charcoal							
Kerihuel 2010 Subtotal (95% CI)	1	30 30	0	29 29	100.0% 100.0%	7.15 [0.14, 360.38 7.15 [0.14, 360.38]	
Total events Heterogeneity: Not ap	1 plicable		0				
Test for overall effect:	Z = 0.98 (P	= 0.33)					
							0.001 0.1 1 10 1000 Favours hydrocolloid Favours charcoal

Figure 653: Hydrocolloid dressing versus charcoal dressing – proportion of patients with skin irritation and eczema

	Hydroco	lloid	Charcoal			Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events Total		Weight	Peto, Fixed, 95% (Peto, Fixed, 95% CI
11.7.3 Charcoal							
Kerihuel 2010 Subtotal (95% CI)	1	30 30	0	29 29	100.0% 100.0 %	7.15 [0.14, 360.38]	
Total events	1		0	_0	1001070		
Heterogeneity: Not app	olicable						
Test for overall effect: 2	Z = 0.98 (P)	= 0.33					
							0.002 0.1 1 10 500 Favours hydrocolloid Favours charcoal

Figure 654: Hydrocolloid dressing versus charcoal dressing – proportion of patients with bleeding

	Hydroco	lloid	Charcoal			Peto Odds Ratio		Peto Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (CI	Peto, Fix	ed, 95% CI	
11.8.3 Charcoal										
Kerihuel 2010 Subtotal (95% CI)	0	30 30	0	29 29		Not estimable Not estimable				
Total events	0		0							
Heterogeneity: Not ap	plicable									
Test for overall effect:	Not applica	ıble								
							0.01	0.1	1 10	100
							Favours	hvdrocolloid	Favours cha	rcoal

Figure 655: Hydrocolloid dressing versus charcoal dressing – proportion of patients with pruritus

	Hydroco	lloid	Charc	oal		Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (Peto, Fixed, 95% CI			
11.9.1 Charcoal							<u></u>			
Kerihuel 2010	0	30	1	29	100.0%	0.13 [0.00, 6.59]				
Subtotal (95% CI)		30		29	100.0%	0.13 [0.00, 6.59]				
Total events	0		1							
Heterogeneity: Not ap	plicable									
Test for overall effect:	Z = 1.02 (P	= 0.31)								
							0.001 0.1 1 10 1000			
							Favours hydrocolloid Favours charcoal			

Test for subgroup differences: Not applicable

Figure 656: Hydrocolloid dressing versus charcoal dressing – proportion of patients with wound pain

	Hydroco	lloid	Charc	oal		Peto Odds Ratio		Peto Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (CI	Peto, Fix	red, 95% CI	
11.10.1 Charcoal										
Kerihuel 2010 Subtotal (95% CI)	0	30 30	0	29 29		Not estimable Not estimable				
Total events Heterogeneity: Not ap Test for overall effect:	•	ıble	0							
T-11 (1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1							0.01 Favours	0.1 hydrocolloid	1 10 Favours cha	100 arcoal

Figure 657: Hydrocolloid dressing versus charcoal dressing – proportion of patients with pain at dressing removal

	Hydroco	lloid	Charc	oal	Risk Ratio			Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI	M-H, Fi	xed, 95%	6 CI	
11.11.2 Charcoal											
Kerihuel 2010 Subtotal (95% CI)	19	30 30	19	29 29	100.0% 100.0%	0.97 [0.66, 1.41] 0.97 [0.66, 1.41]		-	•		
Total events Heterogeneity: Not ap Test for overall effect:	•	= 0.86)	19								
							0.05 Favours	0.2	1 1 Favou	5 urs chai	20 rcoal

Figure 658: Hydrocolloid dressing versus charcoal dressing – mortality (all-cause)

	Hydroco	lloid	Contr	ol	Risk Ratio			Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI	M-H, F	xed, 9	5% CI	
Kerihuel 2010	2	31	1	29	100.0%	1.87 [0.18, 19.55]					
Total (95% CI)		31		29	100.0%	1.87 [0.18, 19.55]					
Total events	2		1								
Heterogeneity: Not app	olicable						0.01	0.1	+	10	100
Test for overall effect:	Z = 0.52 (P						u.i s hvdrocolloi	ı d Fav	ours char		

Figure 659: Figure 79. Hydrocolloid dressing versus phenytoin ointment – mean time to healing (days)

iicai	B /~	,,,,,											
	Hyd	rocolle	oid	Phenytoin ointment				Mean Difference	Mean	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV, Fix	ced, 95% CI			
12.1.1 Phenytoin oin	tment												
Rhodes 2001 Subtotal (95% CI)	51.8	19.6	13 13	35.3	14.3	15 15	100.0% 100.0%	16.50 [3.62, 29.38] 16.50 [3.62, 29.38]					
Heterogeneity: Not ap Test for overall effect:	•	(P = 0).01)										
									-100 -50	0 5			

Figure 660: Hydrocolloid dressing versus phenytoin ointment – proportion of people with adverse events




Figure 661: Hydrocolloid dressing versus phenytoin ointment -mortality

Hydrocolloid			Phenytoin oi	ntment		Risk Ratio	Risk Ratio	C
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI M-H, Fixed, 95	5% CI
Rhodes 2001	2	16	2	18	100.0%	1.13 [0.18, 7.09]]	
Total (95% CI)		16		18	100.0%	1.13 [0.18, 7.09]		
Total events	2		2					
Heterogeneity: Not ap	plicable						0.01 0.1 1	10 100
Test for overall effect:	Z = 0.13 (F	P = 0.90)					ours phenytoin

Figure 662: Hydrocolloid dressing versus antibiotic ointment – mean time to healing (days)




Figure 663: Hydrocolloid dressing versus antibiotic ointment – proportion of people with adverse events

	Hydroco	lloid	Antibiotic		Peto Odds Ratio			Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (CI	Peto, Fix	ed, 95% CI		
13.2.5 Antibiotic oint	ment										
Rhodes 2001 Subtotal (95% CI)	0	13 13	0	11 11		Not estimable Not estimable					
Total events Heterogeneity: Not ap Test for overall effect:	•	ıble	0								
							0.002 Favours h	0.1 nydrocolloid	1 10 Favours an	500 tibiotic	

Figure 664: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients completely healed

	Triangular		Oval		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
Day 1995	17	47	11	49	100.0%	1.61 [0.85, 3.07]	
Total (95% CI)		47		49	100.0%	1.61 [0.85, 3.07]	•
Total events	17		11				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.45 (F	P = 0.15	5)				Favours triangular Favours oval

Figure 665: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients improved

	Triang	ular	Ova	I		Risk Ratio		Ris	k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fi	xed, 95% (CI	
Day 1995	41	47	31	49	100.0%	1.38 [1.08, 1.75]					
Total (95% CI)		47		49	100.0%	1.38 [1.08, 1.75]			♦		
Total events	41		31								
Heterogeneity: Not ap	plicable						0.01	0.1	+ -	0	100
Test for overall effect:	Z = 2.63 (I	P = 0.00	09)					• • •	ı Favours	-	

Figure 666: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients not changed

	Triangu	ılar	Ova	I		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (CI M-H, Fixed, 95% CI	
Day 1995	4	47	3	49	100.0%	1.39 [0.33, 5.88]	l —	
Total (95% CI)		47		49	100.0%	1.39 [0.33, 5.88]	•	
Total events	4		3					
Heterogeneity: Not ap	plicable						0.01 0.1 1 10	100
Test for overall effect:	Z = 0.45 (F	o = 0.6	5)				Favours triangular Favours ov	

Figure 667: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients worsened

	Triange	ular	Ova	d		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Day 1995	2	47	15	49	100.0%	0.14 [0.03, 0.58]	-
Total (95% CI)		47		49	100.0%	0.14 [0.03, 0.58]	•
Total events	2		15				
Heterogeneity: Not as	plicable						0.002 0.1 1 10 500
Test for overall effect	Z = 2.72	(P = 0.0)	106)				Favours triangular Favours oval

Figure 668: Hydrocolloid dressing: triangular shape versus oval shape – mean percentage reduction in ulcer length

	Triangular Oval					Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI
Day 1995	32	34.15	47	17	34.15	49	100.0%	15.00 [1.33, 28.67]	-
Total (95% CI)			47			49	100.0%	15.00 [1.33, 28.67]	•
Heterogeneity: Not ap Test for overall effect:	•		03)						-100 -50 0 50 100 Favours triangular Favours oval

Figure 669: Hydrocolloid dressing: triangular shape versus oval shape – mean pain at dressing change

	Tria	ngul	ar		Oval			Mean Difference		Mea	n Diff	ference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	1	IV, F	ixed	, 95% CI	
Day 1995	2.1	2.1	47	4.3	1.75	49	100.0%	-2.20 [-2.97, -1.43]					
Total (95% CI)			47			49	100.0%	-2.20 [-2.97, -1.43]		•			
Heterogeneity: Not app Test for overall effect:	•	(P <	0.0000	1)					-10 Favo	-5 ours triangu	0 lar	5 Favours ova	10 al

Figure 670: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients with ulcer pain

	Triang	ular	Ova	I		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
Day 1995	8	47	15	49	100.0%	0.56 [0.26, 1.19]	1 -
Total (95% CI)		47		49	100.0%	0.56 [0.26, 1.19]	•
Total events	8		15				
Heterogeneity: Not app	plicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 1.52 (I	P = 0.13	3)				Favours triangular Favours oval

Figure 671: Hydrocolloid dressing: triangular shape versus oval shape – proportion of patients with adverse events

	Triangu	ılar	Ova	l		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Day 1995	0	47	4	49	100.0%	0.13 [0.02, 0.97]	
Total (95% CI)		47		49	100.0%	0.13 [0.02, 0.97]	
Total events	0		4				
Heterogeneity: Not app	olicable						0.002 0.1 1 10 500
Test for overall effect:	Z = 1.99 (F	o = 0.05	5)				Favours triangular Favours oval

Figure 672: Hydrocolloid dressing: SignaDress® versus Comfeel®Plus – proportion of patients completely healed

•	•						
	SingaD	ress	Comfee	IPlus		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Seaman 2000	6	17	1	18	100.0%	6.35 [0.85, 47.44]	
Total (95% CI)		17		18	100.0%	6.35 [0.85, 47.44]	
Total events	6		1				
Heterogeneity: Not ap Test for overall effect:	•	P = 0.0	7)				0.002 0.1 1 10 500 Favours ComfeelPlus Favours SingaDress

Figure 673: Hydrocolloid dressing: SignaDress® versus Comfeel®Plus – proportion of people with adverse events

	SingaDi	ress	Comfeel	Plus		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fix	ed, 95% CI
Seaman 2000	0	17	0	18		Not estimable		
Total (95% CI)		17		18		Not estimable		
Total events	0		0					
Heterogeneity: Not appropriate the control of the c		able					0.01 0.1 Favours SingaDress	1 10 100 Favours ComfeelPlus

Figure 674: Gauze dressing versus foam dressing – proportion of patients completely healed




Figure 675:	Gauze ares	ssing v	versus t	oam	aressing	g –mortality	
	Gauz	e	Foan	n		Risk Ratio	Risk Ratio
Study or Subgrou	up Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Kraft 1993	2	14	0	24	12.3%	8.33 [0.43, 162.13]	<u></u>
Payne 2009	2	16	3	20	87.7%	0.83 [0.16, 4.40]	
Total (95% CI)		30		44	100.0%	1.76 [0.49, 6.34]	
Total events	4		3				
Heterogeneity: Chi	$i^2 = 1.83$, df =	1 (P = 0	0.18); I ² =	45%			0.01 0.1 1 10 100
Test for overall effe	ect: Z = 0.86 (P = 0.39	9)				0.01 0.1 1 10 100 Favours gauze Favours foam

Figure 676: Figure 90. Gauze dressing versus polyurethane dressing – proportion of ulcers completely healed (all stages)

	Gauz	e	Polyuret	thane	•	Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% (CI	Peto, Fix	ed, 95% CI	
15.1.2 Polyurethane										
Olekse 1986	0	10	1	9	11.4%	0.12 [0.00, 6.14	4]		_	
Sebern 1989	0	12	14	22	88.6%	0.08 [0.02, 0.32	2]	-		
Subtotal (95% CI)		22		31	100.0%	0.08 [0.02, 0.31	1]	•		
Total events	0		15							
Hotarogenetty, Chi*=	0.04, df=	1 (P=	0.E4); F=	0%						
Test for overall effect.	Z=3.70	P=0.0	1002)							
							0.002	0.1	1 10	500
								olyurethane		

Figure 677: Gauze dressing versus polyurethane dressing – proportion of ulcers completely healed (stage II)

	Gauz	e	Polyuret	hane		Peto Odds Ratio	Peto Od	ds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixe	ed, 95% CI
5.2.2 Polyurethane								
Sebern 1989 Subtotal (95% CI)	0	12 12	14	22 22	100.0% 100.0%	0.08 [0.02, 0.32] 0.08 [0.02, 0.32]		
otal events leterogeneity: Not app est for overall effect: Z		(P = 0,0	14				0.001 01	10 1000

Figure 678: Gauze dressing versus polyurethane dressing – proportion of ulcers worsened

	Gauz	ze	Polyuret	hane		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
15.3.2 Polyurethane							
Olekse 1986	2	10	1	9	33.2%	1.80 [0.19, 16.66]	-
Sebern 1989 Subtotal (95% CI)	7	12	3	22 31	66.8% 100.0%	4.28 [1.35, 13.58] 3.46 [1.26, 9.49]	
Total events Helerogenetly, Chf*= Test for overall effect:			4.5	0%			
							0.002 0.1 1 10 500
Test for subgroup diff	ferences:	Not ap	plicable				Favours gauze Favours polyurethan

Figure 679: Gauze dressing versus polyurethane dressing – proportion of ulcers decreased in ulcer stage (stage II)




Figure 680: Gauze dressing versus polyurethane dressing – proportion of ulcers increased in ulcer stage (stage II)

	Gauz	te	Polyuret	hane		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
15.5.1 Polyurethane							
Sebern 1989 Subtotal (95% CI)	5	12 12	1	22 22	100.0% 100.0%		-
Total events Heterogeneity: Not as Test for overall effect:	Act Control of	(P = 0.0	1 (3)				
Test for subgroup diff	foronces:	Not an	nlicable				0.001 0.1 1 10 1000 Favours gauze Favours polyurethan

Figure 681: Gauze dressing versus polyurethane dressing – proportion of patients with maceration

	Gauz	te	Polyuret	hane		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
15.9.1 Polyurethane							
Sebern 1989 Subtotal (95% CI)	10	12 12	17	22 22	100.0%	1.08 [0.77, 1.51] 1.08 [0.77, 1.51]	-
Total events Heterogeneity: Not ap Test for overall effect:	WO. O. ST. W. D.	(P = 0.6	17				
Test for subgroup diff	'oronooo'	Noton	nlicable			. 7	0.5 0.7 1 1.5 2 Favours gauze Favours polyurethane

Figure 682: Gauze dressing versus hydrogel – proportion of patients completely healed


	Gauz	e	Hydro	gel		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
16.1.3 Hydrogel							
Thomas 1998 Subtotal (95% CI)	9	14	10	16 16	100.0% 100.0%	1.03 [0.60, 1.77] 1.03 [0.60, 1.77]	
Total events Heterogeneity: Not a Test for overall effect		(P = 0.9	10				
							0.05 0.2 1 5 20
Test for subgroup dif	Yerences:	Not ap	plicable				Favours hydrogel Favours gauze

The state of the s

Figure 683: Gauze dressing versus hydrogel – proportion of patients worsened

	Gauze Hydrogel				•	Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, F	ixed, 95	5% CI	
Thomas 1998	1	19	1	22	100.0%	1.16 [0.08, 17.28]				_	
Total (95% CI)		19		22	100.0%	1.16 [0.08, 17.28]			-		
Total events	1		1								
Heterogeneity: Not as	oplicable						0.001	0.1	1	10	1000
Test for overall effect	Z = 0.11	(P = 0.9)	32)					urs gau	ze Fav		107.50

Figure 684: Gauze dressing versus hydrogel – mean percentage reduction in ulcer area



170

Figure 685: Gauze dressing versus hydrogel – mean healing rate (cm²/day)




Figure 686: Gauze dressing versus hydrogel – mean time to healing (weeks)

	G	Gauze			Hydrogel			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Thomas 1998	5.2	2.4	14	5.3	2.3	16	100.0%	-0.10 [-1.79, 1.59]	
Total (95% CI)			14			16	100.0%	-0.10 [-1.79, 1.59]	-
Heterogeneity: Not ap	Carrent Andrews		0.041						-4 -2 0 2 4
Test for overall effect	Z=0.12	(P=	0.91)						Favours gauze Favours hydrogel

Figure 687: Gauze dressing versus hydrogel – mortality

	Gauz	e	Hydro	gel		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Thomas 1998	2	14	4	16	100.0%	0.57 [0.12, 2.66]	
Total (95% CI)		14		16	100.0%	0.57 [0.12, 2.66]	
Total events	2		4				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.71 (I	P = 0.48	8)				Favours gauze Favours hydrogel

Figure 688: Gauze dressing versus dextranomer – proportion of ulcers improved




Figure 689: Gauze dressing versus dextranomer – proportion of people with adverse events

	Gauz	e	Dextrand	omer		Peto Odds Ratio		Pete	Odds R	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I	Peto,	Fixed, 9	5% CI	
17.3.1 Dextranomer											
Ljungberg 2009 Subtotal (95% Cl)	0	15 15	0	15 15		Not estimable Not estimable					
Total events Heterogeneity: Not app Test for overall effect: N		able	0				-				———
							0.01	0.1	1	10	100
							Fa	avours da	uze Fav	ours dex	tranome

Figure 690: Gauze dressing versus phenytoin cream – proportion of patients completely healed




Figure 691: Gauze dressing versus phenytoin cream – proportion of ulcers completely healed (all stages – all sites)

	Gauz	e	Pheny	toin		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
18.2.1 Phenytoin cre	am						
Hollisaz 2004 Subtotal (95% CI)	8	30 30	12	30 30	100.0% 100.0%	0.67 [0.32, 1.39] 0.67 [0.32, 1.39]	
Total events Heterogeneity: Not as Test for overall effect:	CALL THE STATE OF	P = 0.2	12				
							0.01 0.1 1 10 100 Enveyor phenidein Enveyor cours
Test for subgroup diff	ferences:	Not ap	olicable				Favours phenytoin Favours gauze

Figure 692: Gauze dressing versus phenytoin cream – proportion of ulcers improved

	Gauz	ze	Pheny	toin		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
18.6.2 Phenytoin cre	am						
Hollisaz 2004 Subtotal (95% CI)	13	30 30	16	30 30	100.0% 100.0%	0.81 [0.48, 1.38] 0.81 [0.48, 1.38]	
Total events Heterogeneity: Not ap Test for overall effect		(P = 0.4	16				
							0.1 0.2 0.5 1 2 5 10
Test for subgroup dif	forences:	Not an	nlicable				Favours phenytoin Favours gauze

Figure 693: Gauze dressing versus phenytoin cream – proportion of ulcers worsened




Figure 694: Gauze dressing versus phenytoin cream – mortality (all-cause)




Figure 695: Foam dressing versus skin replacement - proportion of patients completely healed




Figure 696: Foam dressing versus skin replacement – proportion of patients with an infection




Figure 697: Foam dressing versus skin replacement – proportion of people with adverse events

	Foar	n	Skin remplac	ement		Peto Odds Ratio		Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
19.7.1 Skin replacem	nent									
Payne 2004 Subtotal (95% CI)	0	16 16	0	18 18		Not estimable Not estimable				
Total events	0		0							
Heterogeneity: Not ap Test for overall effect:	•	able								
Tool for a long of W		- 1 I'	la la				0.01	0.1 Favours foam		0 100 kin remplacen

Figure 698: Foam dressing versus antibiotic ointment – proportion of patients completely healed



Figure 699: Foam dressing: Allevyn® versus Biatain® – proportion of patients completely healed

	Allev	/n	Biatia	an		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI
Amoine 2005	11	14	5	18	100.0%	2.83 [1.28, 6.25]		-
Total (95% CI)		14		18	100.0%	2.83 [1.28, 6.25]		•
Total events	11		5					
Heterogeneity: Not as	plicable						0.01 0.1 1	10 100
Test for overall effect	Z = 2.57	(P = 0.0)	11)				Favours Biatian	

Figure 700: Foam dressing: Allevyn® versus Biatain® – mean comfort score at dressing removal

	Allevyn			Biatian				Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI			
Amoine 2005	1.84	0.26	14	2.11	0.26	18	100.0%	-0.27 [-0.45, -0.09]				
Total (95% CI)			14			18	100.0%	-0.27 [-0.45, -0.09]	•			
Heterogeneity: Not a Test for overall effect			0.004)						-0.5 -0.25 0 0.25 0.5 Favours Allevyn Favours Biatian			

Figure 701: Foam dressing: Allevyn® versus Biatain® – proportion of patients with dressing related adverse events

	Allev	/n	Biatia	an		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI
Amoine 2005	1	14	4	18	100.0%	0.32 [0.04, 2.57]		
Total (95% CI)		14		18	100.0%	0.32 [0.04, 2.57]	•	-
Total events	1		4					
Heterogeneity: Not as	plicable						0.001 0.1	10 1000
Test for overall effect	Z = 1.07	(P = 0.2)	28)					Favours Biatian

Figure 702: Foam dressing: Allevyn® versus Biatain® – mortality

	Allev	yn	Biatia	an		Peto Odds Ratio	Peto Od	ds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
Amoine 2005	0	14	1	18	100.0%	0.17 [0.00, 8.79]	←	
Total (95% CI)		14		18	100.0%	0.17 [0.00, 8.79]		
Total events	0		1					
Heterogeneity: Not app	olicable						0.01 0.1	10 100
Test for overall effect:	Z = 0.88 (I	P = 0.38	B)				0.01 0.1 Favours Allevyn	1 10 100 Favours Biatain

Figure 703: Foam dressing: Mepilex® versus Tielle® – proportion of patients completely healed

	Mepil	ex	Tiell	e		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Meaume 2003	8	18	10	20	100.0%	0.89 [0.45, 1.75]	-
Total (95% CI)		18		20	100.0%	0.89 [0.45, 1.75]	•
Total events Heterogeneity: Not as	8 oplicable		10				to 10 100
Test for overall effect	Z= 0.34	(P = 0.7)	'3)				0.01 0.1 1 10 100 Favours Tielle Favours Mepilex

Figure 704: Foam dressing: Mepilex® versus Tielle® – proportion of patients improved

	Mepil	ex	Tiell	e		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C1		M-H, Fixe	ed, 95%	CI	
Meaume 2003	15	18	19	20	100.0%	0.88 [0.70, 1.10]		-			
Total (95% CI)		18		20	100.0%	0.88 [0.70, 1.10]		•	-		
Total events	15		19								
Heterogeneity: Not a	pplicable						0.5	0.7	1	-	-
Test for overall effect	: Z= 1.12	(P = 0.2)	26)					irs control	Favou	rs ex	z perimenta

Figure 705: Foam dressing: Mepilex® versus Tielle® – proportion of patients worsened

	Mepilex		Tielle			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Meaume 2003	2	18	1	20	100.0%	2.22 [0.22, 22.49]	
Total (95% CI)		18		20	100.0%	2.22 [0.22, 22.49]	
Total events	2		1				
Heterogeneity: Not ap	plicable						0.01 0.1 1 10 100
Test for overall effect	Z = 0.68	P = 0.5	50)				Favours Mepilex Favours Tielle

Figure 706: Foam dressing: Mepilex® versus Tielle® – proportion of patients with maceration

	Mepil	ex	Hell	e		Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events Total		Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI			
Meaume 2003	0	18	3	20	100.0%	0.13 [0.01, 1.38]	-			
Total (95% CI)		18		20	100.0%	0.13 [0.01, 1.38]				
Total events	0		3							
Heterogeneity: Not as	pplicable						0.001 0.1 10 1000			
Test for overall effect:	Z = 1.69	(P = 0.0)	19)				Favours Mepilex Favours Tielle			

Figure 707: Foam dressing: Mepilex® versus Tielle® – proportion of patients reporting odour

	Mepilex		Tielle			Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI			
Meaume 2003	0	18	3	20	100.0%	0.13 [0.01, 1.38]				
Total (95% CI)		18		20	100.0%	0.13 [0.01, 1.38]				
Total events	0		3							
Heterogeneity: Not as	oplicable						0.001 0.1 1 10	1000		
Test for overall effect: $Z = 1.69$ (P = 0.09)		19)				Favours Mepilex Favours Ti	1,000			

Figure 708: Foam dressing: Mepilex® versus Tielle® – proportion of patients with adverse events

	Mepil	ex	Tielle			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Meaume 2003	1	18	3	20	100.0%	0.37 [0.04, 3.25]	
Total (95% CI)		18		20	100.0%	0.37 [0.04, 3.25]	-
Total events	1		3				
Heterogeneity: Not ap	plicable						0.001 0.1 1 10 1000
Test for overall effect:	Z = 0.90	(P = 0.3)	17)				0.001 0.1 1 10 1000 Favours Mepilex Favours Tielle

Figure 709: Foam dressing: Mepilex® versus Tielle® – mortality

					•						
	Mepil	ex	Tielle		Risk Ratio			Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fi	xed, 95% C	<u> </u>	
Meaume 2003	1	18	1	20	100.0%	1.11 [0.07, 16.49]				_	
Total (95% CI)		18		20	100.0%	1.11 [0.07, 16.49]				_	
Total events	1		1								
Heterogeneity: Not app	plicable						0.01	0.1	1 1		100
Test for overall effect:	Z = 0.08 (P = 0.9	4)					urs mepile		-	

<Insert Note here>

Figure 710: Hydrogel dressing versus foam dressing – proportion of ulcers completely healed (all stages)




Figure 711: Hydrogel dressing versus foam dressing – proportion of ulcers improved (all stages)



Figure 712: Hydrogel dressing versus foam dressing – mean rate of healing of healed ulcers (cm²/dav) (grade II)

	Hydrogel			Foam				Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI			
21.7.1 Foam												
Sopata 2002	0.67	0.37	6	1.23	1.33	6	100.0%	-0.56 [-1.66, 0.54]	-			
Subtotal (95% CI)			6			6	100.0%	-0.56 [-1.66, 0.54]	-			
Heterogeneity, Not as Test for overall effect			0.32)									
									-4 -2 0 2 4			
Test for subgroup dif	ferences	· Not a	nnlical	hle					Favours foam Favours hydroge			

Figure 713: Hydrogel dressing versus foam dressing – mean rate of healing of healed ulcers (cm²/day) (grade III)




Figure 714: Hydrogel dressing versus foam dressing – mean rate of healing of improved ulcers (cm²/day) (grade III)




Figure 715: Hydrogel dressing versus foam dressing – mortality

	gel	Foar	n		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixe	ed, 95% CI		
Sopata 2002	3	17	2	17	100.0%	1.50 [0.29, 7.87]				
Total (95% CI)		17		17	100.0%	1.50 [0.29, 7.87]				
Total events	3		2							
Heterogeneity: Not app	plicable						0.01 0.1	 	100	
Test for overall effect:	Z = 0.48 (F	P = 0.63	3)					1 10 Favours foa		

Figure 716: Hydrogel dressing versus dextranomer – proportion of patients reporting pain at dressing application

	Hydro	gel	Dextran	omer		Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ked, 95% CI	
22.2.1 Dextranomer										
Colin 1996 Subtotal (95% CI)	0	67 67	1	68 68	100.0% 100.0%	0.14 [0.00, 6.92] 0.14 [0.00, 6.92]				
Total events Heterogeneity: Not ap Test for overall effect:	And the second	(P = 0.3	1 (32)							
Test for subgroup diff	erences:	Not ap	plicable				0.001 Favour	0.1 rs hydroge	1 10 Favours de	1000 extranomer

Figure 717: Hydrogel dressing versus dextranomer –mortality

	Hydro	gel	Dextrand	omer		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	ed, 95% C	<u> </u>	
Colin 1996	2	67	2	68	100.0%	1.01 [0.15, 7.00]					
Total (95% CI)		67		68	100.0%	1.01 [0.15, 7.00]					
Total events	2		2								
Heterogeneity: Not app Test for overall effect: 2	P = 0.9	9)).1 s hydrogel		0 dext	100 ranomer	

Figure 718: Hydrogel, foam dressing or transparent film versus different types of dressing – proportion of patients completely healed




Figure 719: Hydrogel, foam dressing or transparent film dressing versus different types of dressing – proportion of patients reporting the application of the dressing as comfortable




Figure 720: Hydrogel, foam dressing or transparent film dressing versus different types of dressing – proportion of patients reporting discomfort at dressing removal

	Hydrogel Differen			Different types Peto C			Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fi	xed, 95% CI	
Small 2002	0	14	1	7	100.0%	0.05 [0.00, 3.18]	+			
Total (95% CI)		14		7	100.0%	0.05 [0.00, 3.18]			-	
Total events	0		1							
Heterogeneity: Not as	pplicable						0.004	0.1	1 10	1000
Test for overall effect	Z=1.41	(P = 0.1)	6)				0.001 Fav	ours hydroge	1 10 el Favour diffe	

Figure 721: Hydrogel, foam dressing or transparent film dressing versus different types of dressing – proportion of people with adverse events

	Hydrog	gel	Different	types	Peto Odds Ratio			Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C		Peto, Fixed, 95% CI				
23.3.1 Different type	of dressin	gs										
Small 2002 Subtotal (95% CI)	0	28 28	0	30 30		Not estimable Not estimable						
Total events	0		0									
Heterogeneity: Not ap	plicable											
Test for overall effect:	Not applica	able										
							0.01	0.1	i	10	100	
Test for subgroup diffe	erences: No	ot appli	icable				Fav	ours hydro	gel Favo	ours differ	rent types	

Figure 722: Hydrogel, foam dressing or transparent film dressing versus different types of dressing – mortality

	Hydrogel		Different types			Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95% CI	
Small 2002	3	28	7	30	100.0%	0.46 [0.13, 1.60]			\vdash	
Total (95% CI)		28		30	100.0%	0.46 [0.13, 1.60]			-	
Total events Heterogeneity: Not ap	3 plicable		7				0.01	0.1	1 10	100
Test for overall effect:	Z = 1.22 (P = 0.2	2)					urs hydrogel	Favours di	fferent types

Figure 723: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with intermittent ulcer pain

	Sterig	jel	Intras	ite		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI		
Bale 1998	13	24	16	23	100.0%	0.78 [0.49, 1.23]	-		
Total (95% CI)		24		23	100.0%	0.78 [0.49, 1.23]	•		
Total events	13		16						
Heterogeneity: Not as	plicable						01 02 05 1 2 5 10		
Test for overall effect	(P = 0.2)	28)				0.1 0.2 0.5 1 2 5 10 Favours sterigel Favours intrasite			

Figure 724: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with continuous ulcer pain

	Sterig	Intras	Intrasite		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI		
Bale 1998	1	24	2	23	100.0%	0.48 [0.05, 4.93]			
Total (95% CI)		24		23	100.0%	0.48 [0.05, 4.93]	-		
Total events	1		2						
Heterogeneity: Not as	oplicable						0.002 0.1 1 10 500		
Test for overall effect	Z = 0.62	(P = 0.5)	(4)				0.002 0.1 1 10 500 Favours sterigel Favours intrasite		

Figure 725: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with slight pain at dressing removal

	Sterig	jel	Intrasite			Risk Ratio	Risk Ratio			
Study or Subgroup	Events Tota		Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI			
Bale 1998	5	22	6	20	100.0%	0.76 [0.27, 2.10]				
Total (95% CI)		22		20	100.0%	0.76 [0.27, 2.10]	•			
Total events	5		6							
Heterogeneity: Not as	oplicable						0.01 0.1 1 10 100			
Test for overall effect	Z = 0.53	(P = 0.5)	59)				0.01 0.1 1 10 100 Favours sterigel Favours intrasite			

Figure 726: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with severe pain at dressing removal

	Sterigel		Intrasite			Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Events Total		Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Bale 1998	0	22	1	20	100.0%	0.12 [0.00, 6.20]	
Total (95% CI)		22		20	100.0%	0.12 [0.00, 6.20]	
Total events	0		1				
Heterogeneity: Not as						0.001 0.1 1 10 1000	
Test for overall effect: Z = 1.05 (P = 0.29)			29)				Favours sterigel Favours intrasite

Figure 727: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with discomfort

	Sterig	el	Intras	ite		Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI			
Bale 1998	0	22	1	20	100.0%	0.12 [0.00, 6.20]				
Total (95% CI)		22		20	100.0%	0.12 [0.00, 6.20]				
Total events	0		1							
Heterogeneity: Not as	plicable						0.001 0.1 1 10 1000			
Test for overall effect:	Z=1.05	P = 0.2	29)				Favours sterigel Favours intrasite			

Figure 728: Hydrogel dressing: Sterigel® versus Intrasite® – proportion of patients with maceration

	Sterig	jel	Intrasite			Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI			
Bale 1998	8	21	9	17	100.0%	0.72 [0.36, 1.46]	-			
Total (95% CI)		21		17	100.0%	0.72 [0.36, 1.46]	•			
Total events	8		9				4.0			
Heterogeneity: Not as	plicable						0.02 0.1 1 10 50			
Test for overall effect	Z = 0.91	(P = 0.3)	86)				0.02 0.1 1 10 50 Favours sterigel Favours intrasite			

Figure 729: Hydrogel dressing: Sterigel® versus Intrasite® – mortality (all-cause)

	Sterige	el .	Intras	ite		Risk Ratio	Risk Ratio
Study or Subgroup	Events 7	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Bale 1998	3	26	4	24	100.0%	0.69 [0.17, 2.78]	_
Total (95% CI)		26		24	100.0%	0.69 [0.17, 2.78]	
Total events	3		4				
Heterogeneity: Not app Test for overall effect: 2		= 0.60	0)				0.01 0.1 1 10 100 Favours sterigel Favours intrasite

Figure 730: Protease modulating matrix versus impregnated gauze dressing – proportion of patients completely healed




Figure 731: Protease modulating matrix versus impregnated gauze dressing – proportion of patients with adverse events



Figure 732: Protease modulating matrix versus impregnated gauze dressing – mortality (all-cause)

	- ,											
	Collag	Collagen Impregnated gauze				Peto Odds Ratio		Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	1	Peto, Fi	xed, 95% CI			
Nisi 2005	0	40	0	40		Not estimable						
Total (95% CI)		40		40		Not estimable						
Total events	0		0									
Heterogeneity: Not ap	plicable						0.01	0.1	+	10	100	
Test for overall effect:	Not applic	able					0.01	Favours collagen	Favours in	npreg		

Figure 733: Figure 135. Polyurethane dressing versus different types of dressing – mean time to healing (days) (all stages)




Figure 734: Polyurethane dressing versus different types of dressing – mean time to healing (days) (stage II)




Figure 735: Polyurethane dressing versus different types of dressing – mean time to healing (days) (stage III)




Figure 736: Polyurethane dressing versus different types of dressing – mean difference in PUSH score




Figure 737: Polyurethane dressing versus different types of dressing – proportion of patients with systemic worsening




Figure 738: Polyurethane dressing versus different types of dressing – proportion of patients with localized adverse events




Figure 739: Polyurethane dressing versus different types of dressing – mortality (all-cause)



Figure 740: Alginate dressing versus silver alginate dressing – proportion of patients worsened




Figure 741: Alginate dressing versus silver alginate dressing – mean percentage reduction in ulcer area




Figure 742: Alginate dressing versus silver alginate dressing – absolute cm² decrease in ulcer area




Figure 743: Alginate dressing versus silver alginate dressing – mean rate of healing (cm²/day)




Figure 744: Alginate dressing versus silver alginate dressing – proportion of patients with an infection



Figure 745: Alginate dressing versus silver alginate dressing – mean mASEPSIS index at and of treatment




Figure 746: Alginate dressing versus silver alginate dressing – proportion of patients with poor acceptability and/or tolerability




Figure 747: Alginate dressing versus silver alginate dressing –mortality (all-cause)

	Algina	ate	Silve	er		Peto Odds Ratio		Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
Meaume 2005	0	48	0	51		Not estimable				
Total (95% CI)		48		51		Not estimable				
Total events	0		0							
Heterogeneity: Not ap Test for overall effect:	•	able					0.01 Favo	0.1 ours alginate	1 10 Favours silve	100 er alginate

Figure 748: Alginate dressing versus dextranomer – proportion of patients with > 75% reduction in ulcer area

	Algina	ite	Dextran	omer		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
30.1.1 Dextranomer							
Sayag 1996 Subtotal (95% CI)	15	47 47	6	45 45	100.0% 100.0%	2.39 [1.02, 5.62] 2.39 [1.02, 5.62]	
Total events Heterogeneity; Not ap Test for overall effect:	*	(P = 0.0	6 (5)				
Test for subgroup diff	erences:	Not ap	plicable				0.01 0.1 1 10 100 Favours dextranomer Favours alginate

Figure 749: Alginate dressing versus dextranomer – proportion of patients with > 40% reduction in ulcer area

	Algina	ate	Dextran	omer		Risk Ratio	Risk Ra	atio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed,	95% CI
30.2.2 Dextranomer								
Sayag 1996 Subtotal (95% CI)	35	47 47	19	45 45	100.0% 100.0%	1.76 [1.21, 2.58] 1.76 [1.21, 2.58]		•
Total events Heterogeneity: Not ap Test for overall effect		(P = 0.0	19				ha ala ala	1 1
Test for subgroup diff	erences:	Not ap	plicable				0.1 0.2 0.5 1 Favours dextranomer F	2 5 10 avours alginate

Figure 750: Alginate dressing versus dextranomer – proportion of patients worsened or stagnated




Figure 751: Alginate dressing versus dextranomer – mean rate of healing in patients improved > 40% (cm²/week)




Figure 752: Alginate dressing versus dextranomer – mean rate of healing (cm²/week)




Figure 753: Alginate dressing versus dextranomer – proportion of patients with an infection

	Algina	ate	Dextran	omer		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed	1, 95% CI	
30.6.3 Dextranomer										
Sayag 1996 Subtotal (95% CI)	2	47 47	2	45 45	100.0% 100.0%	0.96 [0.14, 6.51] 0.96 [0.14, 6.51]				
Total events Heterogeneity: Not ap Test for overall effect		(P = 0,9	2 (96)				0.002	0.1 1	10 Favours de	500

Figure 754: Alginate dressing versus dextranomer – proportion of patients with hypergranulation




Figure 755: Alginate dressing versus dextranomer – proportion of patients with skin irritation




Figure 756: Alginate dressing versus dextranomer – proportion of patients with bleeding

	Algina	ate	Dextran	omer		Peto Odds Ratio	Peto Oc	dds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
30.9.2 Dextranomer								
Sayag 1996 Subtotal (95% CI)	0	47 47	3	45 45	100.0% 100.0%	0.12 [0.01, 1.22] 0.12 [0.01, 1.22]		1
Total events Heterogeneity: Not ap Test for overall effect.		(P = 0.0	3 (77)				0.002 0.1	1 10 500
Test for subgroup diff	erences:	Not ap	plicable				Favours dextranomer	Favours alginate

Figure 757: Alginate dressing versus dextranomer – proportion of patients with pain




Figure 758: Alginate dressing versus dextranomer – proportion of patients with pruritus




Figure 759: Alginate dressing versus dextranomer –mortality

	Algina	ate	Dextrand	omer		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Sayag 1996	5	47	6	45	100.0%	0.80 [0.26, 2.43]	-
Total (95% CI)		47		45	100.0%	0.80 [0.26, 2.43]	-
Total events	5		6				
Heterogeneity: Not app Test for overall effect:		P = 0.6	9)				0.01 0.1 1 10 100 Favours alginate Favours dextranomer

Figure 760: Silver dressing versus silver cream – mean percentage reduction in ulcer area

	D	ressing		(Cream			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Chuangsuwanich 2011	36.95	56.13	20	25.06	56.13	20	100.0%	11.89 [-22.90, 46.68]	
Total (95% CI)			20			20	100.0%	11.89 [-22.90, 46.68]	•
Heterogeneity: Not applic Test for overall effect: Z =		= 0.50)							-100 -50 0 50 100 Favours dressing Favours cream

Figure 761: Silver dressing versus silver cream –percentage reduction in PUSH score

	Dre	essin	g	Cr	eam			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Chuangsuwanich 2011	28.15	0	20	34.51	0	20		Not estimable	
Total (95% CI)			20			20		Not estimable	
Heterogeneity: Not applic Test for overall effect: No		ole							-100 -50 0 50 10 Favours cream Favours dressin

Figure 762: Silver dressing versus silver cream – proportion of people with adverse events

	Dressi	ng	Crea	m		Risk Ratio			Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	l		M-H, Fixe	ed, 95% C	1	
Chuangsuwanich 2011	0	20	0	20		Not estimable						
Total (95% CI)		20		20		Not estimable						
Total events	0		0									
Heterogeneity: Not applie Test for overall effect: No		le					0.01 Favou	0 urs (.1 dressing	1 10 Favours	-	100 am

Figure 763: Silver dressing versus silver cream – mortality (all-cause)

	Dressir	ng	Crear	n		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% (CI
Chuangsuwanich 2011	0	20	0	20		Not estimable		
Total (95% CI)		20		20		Not estimable		
Total events	0		0					
Heterogeneity: Not applic Test for overall effect: No		е					0.01 0.1 1 1 1 Favours dressing Favours	10 100 cream

Figure 764: Sugar versus dextranomer – proportion of patients completely healed




Figure 765: Sugar versus dextranomer – proportion of ulcers completely healed

	Suga	ar	Dextran	omer		Peto Odds Ratio	Peto Odd	s Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed	I, 95% CI
32.3.1 Dextranomer								
Parish 1979 Subtotal (95% CI)	0	9	6	14 14	100.0% 100.0%	0.12 [0.02, 0.77] 0.12 [0.02, 0.77]	-	
Total events Heterogeneity: Not ap Test for overall effect;	Not the second	(P = 0.0	6					
						F	0.001 0.1 1	10 1000 avours sugar

Figure 766: Sugar versus dextranomer – proportion of patients improved

	Suga	ar	Dextran	omer		Peto Odds Ratio	Pet	o Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto	Fixed, 95% CI
32.2.1 Dextranomer								
Parish 1979	0	5	7	7	100.0%	0.02 [0.00, 0.21]		-
Subtotal (95% CI)		5		7	100.0%	0.02 [0.00, 0.21]		
Total events	0		7					
Heterogeneity: Not ap	plicable							
Test for overall effect.	Z = 3.32	(P = 0.0)	1009)					
							0.001 0.1	1 10 1000
								mer Favours sugar

Figure 767: Sugar versus dextranomer – proportion of ulcers improved




Figure 768: Sugar versus different types of topical agents – proportion of patients completely healed




Figure 769: Sugar versus different types of topical agents – mean healing index

		Sugar		Diffe	rent age	ents		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95%	CI IV, Fixed, 95% CI
33.2.1 Different type	of topic	al agen	ts						
Rhodes 1979 Subtotal (95% CI)	16.8	39.65	17	-3,8	39.65	21 21	100.0%	20.60 [-4.75, 45.9 20.60 [-4.75, 45.9	
Helerogensity: Not a Test for oversit strect			11)						
									-100 -50 0 50 100
Test for subgroup dif	ferences	: Not an	plicab	le				-1	avours different agents Favours sugar

Figure 770: Honey versus ethoxydiaminoacridine and nitrofurazone – proportion of ulcers completely healed

	Hone	ey	Etho	ку		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
34.1.1 Ethoxydiamin	oacridine	and nit	trofurazo	ne			
Günes 2007 Subtotal (95% CI)	5	25 25	0	25 25	100.0% 100.0%	8.83 [1.42, 54.99] 8.83 [1.42, 54.99]	-
Total events Heterogeneity: Not ap Test for overall effect		(P = 0.0	0				
Test for subgroup dif	ferences:	Not ap	olicable				0.002 0.1 10 500 Favours ethoxy Favours honey

Figure 771: Honey versus ethoxydiaminoacridine and nitrofurazone – mean percentage reduction in ulcer area




Figure 772: Honey versus ethoxydiaminoacridine and nitrofurazone – mean percentage reduction in PUSH score




Figure 773: Honey versus ethoxydiaminoacridine and nitrofurazone – proportion of people with adverse events




Figure 774: Honey versus ethoxydiaminoacridine and nitrofurazone – mortality

	Hone	y	Ethoxydiaminoa	cridine		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Günes 2007	0	15	1	12	100.0%	0.11 [0.00, 5.44]	
Total (95% CI)		15		12	100.0%	0.11 [0.00, 5.44]	
Total events	0		1				
Heterogeneity: Not app Test for overall effect:		P = 0.20	6)				0.01 0.1 1 10 100 Favours honey Favours ethoxy

Figure 775: Platelet gel versus other treatment – proportion of pressure ulcers completely healed

	Favours platel	et gel	Contr	ol		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Scevola 2010	0	8	0	8	100.0%	0.00 [-0.21, 0.21]	•
Total (95% CI)		8		8	100.0%	0.00 [-0.21, 0.21]	
Total events	0		0				
Heterogeneity: Not app	olicable						-100 -50 0 50 100
Test for overall effect: 2	Z = 0.00 (P = 1.00)	0)					Favours platelet gel Favours control

Figure 776: Platelet gel versus other treatment – proportion of ulcers improved

	Platele	t gel	Conti	rol		Risk Ratio		Ris	k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	4	M-H, Fi	xed, 95%	CI	
Scevola 2010	8	8	7	8	100.0%	1.13 [0.81, 1.58]			-		
Total (95% CI)		8		8	100.0%	1.13 [0.81, 1.58]			-		
Total events	8		7								
Heterogeneity: Not as	pplicable						12	0.5	+	1	+
Test for overall effect	Z = 0.74 (P = 0.4	6)				Fal	ours contro	of Favou	rs plate	let gel

Figure 777: Platelet gel versus other treatment – mean percentage reduction in ulcer volume

	Plat	telet g	el	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Scevola 2010	55	22.9	8	17.2	98.1	8	100.0%	37.80 [-32.01, 107.61]	_
Total (95% CI)			8			8	100.0%	37.80 [-32.01, 107.61]	•
Heterogeneity: Not ap Test for overall effect:			0.29)						-200 0 100 200 Favours control Favours platelet gel

Figure 778: Hyaluronic acid versus sodium hyaluronic – mean percentage reduction in ulcer area (stage I)

	D	ressing		5	Sodium			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Felzani 2011	90	21.29	10	70	21.29	10	100.0%	20.00 [1.34, 38.66]	-
Total (95% CI)			10			10	100.0%	20.00 [1.34, 38.66]	•
Heterogeneity: Not as	oplicable	9							-100 -50 0 50 100
Test for overall effect	Z = 2.10	P = 0	04)						Favours sodium Favours dressing

Figure 779: Hyaluronic acid versus sodium hyaluronic – mean percentage reduction in ulcer area (stage II)

	D	ressing		5	Sodium			Mean Difference	D/	lean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	II.	V, Fixed, 95% CI
Felzani 2011	70	26.28	10	40	26.28	10	100.0%	30.00 [6.96, 53.04]		
Total (95% CI)			10			10	100.0%	30.00 [6.96, 53.04]		-
Heterogeneity: Not as	pplicable								-100 -50	50 400
Test for overall effect	Z = 2.55	(P = 0	01)							0 50 100 odium Favours dressing

Figure 780: Hyaluronic acid versus sodium hyaluronic – time to 50% reduction in ulcer diameter (days) (stage I)

	Dr	essing	1	S	odium			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Felzani 2011	9	6.39	10	15	6.39	10	100.0%	-6.00 [-11.60, -0.40]	
Total (95% CI)			10			10	100.0%	-6.00 [-11.60, -0.40]	•
Heterogeneity: Not a Test for overall effect			0.04)						-20 -10 0 10 20 Favours dressing Favours sodium

Figure 781: Hydraluronic acid versus sodium hyaluronic – time to 50% reduction in ulcer diameter (days) (stage II)

	Dr	essing	1	S	odium			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Felzani 2011	9.5	5.85	10	15	5.85	10	100.0%	-5.50 [-10.63, -0.37]	-
Total (95% CI)			10			10	100.0%	-5.50 [-10.63, -0.37]	•
Heterogeneity: Not ap Test for overall effect			0.04)						-20 -10 0 10 20 Favours dressing Favours sodium

Figure 782: Hyaluronic acid versus sodium hyaluronic – time to 50% reduction in ulcer diameter (days) (stage III)

	Dr	essing	1	S	odium			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Felzani 2011	12.9	6.71	7	19.2	6.71	7	100.0%	-6.30 [-13.33, 0.73]	-
Total (95% CI)			7			7	100.0%	-6.30 [-13.33, 0.73]	•
Heterogeneity: Not as	plicable								-20 -10 0 10 20
Test for overall effect	Z= 1.78	(P = ((80.0						Favours dressing Favours sodium

Figure 783: Zinc gauze dressing versus streptokinase-streptodornase – proportion of patients with skin reaction

	Zino	:	Ointm	ent		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Agren 1985	0	14	1	14	100.0%	0.14 [0.00, 6.82]	-
Total (95% CI)		14		14	100.0%	0.14 [0.00, 6.82]	
Total events	0		1				
Heterogeneity: Not as	oplicable						0.001 0.1 1 10 1000
Test for overall effect:	Z=1.00	(P = 0.3)	32)				0.001 0.1 1 10 1000 Favours zinc Favours ointment

Figure 784: Zinc gauze dressing versus streptokinase-streptodornase – proportion of patients with an infection

	Zino		Ointm	ent		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ked, 95% CI	
Agren 1985	0	14	1	14	100.0%	0.14 [0.00, 6.82]	_		1	
Total (95% CI)		14		14	100.0%	0.14 [0.00, 6.82]	-	-		
Total events	0		1							
Heterogeneity: Not ap	plicable						0.001	0.1	1 10	1000
Test for overall effect:	Z = 1.00	(P = 0.3)	32)					w	Favours	

Figure 785: Zinc gauze dressing versus streptokinase-streptodornase – mortality (all-cause)

Zinc			Ointm	ent	•	Peto Odds Ratio		Peto Odds Ratio				
Study or Subgroup	Events				Weight	Peto, Fixed, 95% C	l		ed, 95% CI			
Agren 1985	0	14	0	14		Not estimable						
Total (95% CI)		14		14		Not estimable						
Total events	0		0									
Heterogeneity: Not ap Test for overall effect:	•	able					0.01 Favo	0.1 ours zinc gauze	1 10 Favours str		100 kinase	

Figure 786: Hydrofibre versus resin salve – proportion of patients completely healed




Figure 787: Hydrofibre versus resin salve – proportion of ulcers completely healed

	Hydrof	ibre	Resin s	alve		Risk Ratio		Ris	k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95% (CI	
Sipponen 2008	4	11	17	18	100.0%	0.39 [0.17, 0.85]					
Total (95% CI)		11		18	100.0%	0.39 [0.17, 0.85]		-			
Total events	4		17								
Heterogeneity: Not as	oplicable						0.05	0.2	1	1	20
Test for overall effect	Z = 2.37	P = 0.0	12)				-1	u.z urs resin salv	Favour	s hydro	-

Figure 788: Hydrofibre versus resin salve – proportion of ulcers improved

	Hydrof	ibre	Resin s	alve		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Sipponen 2008	10	11	18	18	100.0%	0.90 [0.72, 1.13]	-
Total (95% CI)		11		18	100.0%	0.90 [0.72, 1.13]	
Total events Heterogeneity: Not ap		(D = 0.1	18				0.5 0.7 1 1.5 2
Test for overall effect	Z= 0.93	P = 0.3	(5)				Favours resin salve Favours hydrofibre

Figure 789: Hydrofibre versus resin salve – proportion of ulcers worsened

	Hydrof	ibre	Resin s	alve		Peto Odds Ratio		Peto Od	ds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fixe	d, 95% CI	
Sipponen 2008	1	11	0	18	100.0%	13.96 [0.25, 792.93]				_
Total (95% CI)		11		18	100.0%	13.96 [0.25, 792.93]		-	-	
Total events	1		0							
Heterogeneity: Not as	pplicable						0.001	01	10	1000
Test for overall effect	Z = 1.28	(P = 0.2)	(0)					s hydrofibre	Favours re	

Figure 790: Hydrofibre versus resin salve – proportion of patients with allergic skin irritation




Figure 791: Hydrofibre versus resin salve – mortality

	Hydrof	ibre	Resin s	alve		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Sipponen 2008	4	16	3	21	100.0%	1.75 [0.45, 6.74]	
Total (95% CI)		16		21	100.0%	1.75 [0.45, 6.74]	
Total events	4		3				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 0.81 (I	P = 0.42	2)				Favours hydrofibre Favours resin salve

Figure 792: Dextranomer versus chlorinated lime solution – Time to healing (defined as granulation and < 25% of original ulcer area) (days)

	Dex	tranom	er	Chlor	inated I	ime		Mean Difference		Me	ean Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV	Fixed, 95%	6 CI	
Nasar 1982	39.3	17.67	6	61.8	13.86	5	100.0%	-22.50 [-41.14, -3.86]					
Total (95% CI)			6			5	100.0%	-22.50 [-41.14, -3.86]		-	-		
Heterogeneity: Not as	plicable								-100	żo.	-	50	100
Test for overall effect.	Z = 2.37	(P = 0.	02)							ours dextran	omer Favo		

Figure 793: Dextranomer versus chlorinated lime solution – mortality

	Dextran	omer	Chlorinate	d lime		Peto Odds Ratio		Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl		Peto, Fix	ed, 95% CI	
Nasar 1982	1	8	0	8	100.0%	7.39 [0.15, 372.38]				—
Total (95% CI)		8		8	100.0%	7.39 [0.15, 372.38]				
Total events	1		0							
Heterogeneity: Not ap Test for overall effect:) = 0 33)					0.01	0.1	 	0 100
rest for overall effect.	Z = 1.00 (F	= 0.32)					Favo	urs dextranomer	Favours chl	orinated lime

Figure 794: Collagen and foam versus foam dressing – proportion of people with pressure ulcers completely healed



Figure 795: Dextranomer versus chlorinated lime solution – mortality

	Dextrand	omer	Chlorinate	d lime		Peto Odds Ratio	Peto Odds Ra	tio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95°	% CI
Nasar 1982	1	8	0	8	100.0%	7.39 [0.15, 372.38]		
Total (95% CI)		8		8	100.0%	7.39 [0.15, 372.38]		
Total events	1		0					
Heterogeneity: Not ap Test for overall effect:		9 = 0.32)					0.01 0.1 1 Favours dextranomer Favo	10 100 urs chlorinated lime

Figure 796: Collagen and foam versus foam dressing – proportion of people with pressure ulcers completely healed

	Collagen and foam			n		Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, F	ixec	I, 95% CI		
Piatkowski, 2012	4	5	5	5	100.0%	0.82 [0.49, 1.38]		_		-		
Total (95% CI)		5		5	100.0%	0.82 [0.49, 1.38]		•				
Total events	4		5									
Heterogeneity: Not ap	•						0.01	0.1	+	1	0	100
Test for overall effect:	Z = 0.75 (P = 0.4)	45)						Favours foar	n I	Favours c	olla	

Figure 797: Collagen and foam versus foam dressing – mortality (all-cause)

	Collagen and	l foam	Foar	n		Peto Odds Ratio		Peto (Odds R	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, F	xed, 9	5% CI	
Piatkowski, 2012	0	5	0	5		Not estimable					
Total (95% CI)		5		5		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:	•					Favou	0.01	0.1 gen and foam	1 Fav	10 rours foam	100

I.2.9 Management of heel pressure ulcers

I.2.9.1 Various interventions for management of heel ulcers

Figure 798: Nimbus system versus Carewave system – proportion of people with pressure ulcers completely healed




Figure 799: Nerve growth factor versus placebo – reduction in ulcer area (mm2)




Figure 800: Hydrocolloid dressing versus collagen – proportion of people with pressure ulcers completely healed

	,						
	Hydrocolloid Collagen		jen		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
4.1.4 Heel ulcers							
Müller 2001	7	11	11	12	100.0%	0.69 [0.43, 1.12]	
Subtotal (95% CI)		11		12	100.0%	0.69 [0.43, 1.12]	
Total events	7		11				
Heterogeneity: Not app	licable						
Test for overall effect: 2	Z = 1.50 (P)	= 0.13)					
Total (95% CI)		11		12	100.0%	0.69 [0.43, 1.12]	
Total events	7		11				
Heterogeneity: Not app	licable						
Test for overall effect: 2	Z = 1.50 (P	= 0.13)					0.2 0.5 1 2 5 Favours collagen Favours hydrocolloid
Test for subgroup differ	rences: No	t applica	able				ravours collageri Favours flydrocolloid

Figure 801: Hydrocolloid dressing versus collagen - mean time to healing of pressure ulcers (weeks)

	Hydrocolloid			Collagen				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% CI		
4.6.2 Heel ulcer											
Müller 2001	14	4.6	11	10	4.6	12	100.0%	4.00 [0.24, 7.76]	- - - - - - - - - 		
Subtotal (95% CI)			11			12	100.0%	4.00 [0.24, 7.76]			
Heterogeneity: Not ap	plicable										
Test for overall effect:	Z = 2.08	(P = 0)	0.04)								
Total (95% CI)			11			12	100.0%	4.00 [0.24, 7.76]			
Heterogeneity: Not ap	plicable								-4 -2 0 2 4		
Test for overall effect: Z = 2.08 (P = 0.04)									Favours hydrocolloid Favours collagen		
Test for subgroup diffe	erences: I	Not ap	plicable	е					1 avours riyurocollolu 1 avours collager		

Figure 802: Ornithine alpha-ketoglutarate versus placebo – rate of complete healing of pressure ulcers at week 6 (cm2/day)

•	Ornithine alpha Placebo						Mean Difference			Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fix			
Meaume, 2009	0.07	0.11	85	0.04	0.08	75	100.0%	0.03 [0.00, 0.06]					
Total (95% CI)			85			75	100.0%	0.03 [0.00, 0.06]					
Heterogeneity: Not ap Test for overall effect:	•	(P = 0.	05)						-100 Fa	-50 avours placeb	0 o Fav	50 rours ornit	100 hine alpha

Figure 803: Ornithine alpha-ketoglutarate versus placebo – mean % reduction in pressure ulcer size

	Ornithine alpha Placebo					0	Mean Difference			Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fix	ed, 95%	CI	
Meaume, 2009	59.5	71.4	85	54	69	75	100.0%	5.50 [-16.28, 27.28]		_			
Total (95% CI)			85			75	100.0%	5.50 [-16.28, 27.28]		_			
Heterogeneity: Not applicable Test for overall effect: $Z = 0.50$ ($P = 0.62$)									-100 Fa	-50	0 Favo	50 urs ornith	100 ine alpha

Figure 804: Ornithine alpha-ketoglutarate versus placebo – mean surface area reduction (cm2)




Figure 805: Ornithine alpha-ketoglutarate versus placebo – all-cause mortality

	Ornithine	Place	bo		Risk Ratio	Risl	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fix	ced, 95% CI		
Meaume, 2009	5	89	3	76	100.0%	1.42 [0.35, 5.76]				
Total (95% CI)		89		76	100.0%	1.42 [0.35, 5.76]	•			
Total events	5		3							
Heterogeneity: Not app	plicable						0.01 0.1	1 10	100	
Test for overall effect:	0.62)				Fa	avours ornithine alpha				